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Feline coronavirus (FCoV) leads to the fatal disease known as feline infectious peritonitis in a small 
proportion of infected cats. Research into FCoV has so far been hindered by our inability to culture 
the most common serotype, Type 1, in vitro. 
This project aimed to establish a reverse genetic system for Type 1 FCoV. Such a system would 
enable a deeper understanding of the role of viral mutations in the pathogenesis of disease and 
could serve as a platform for rational vaccine design. To this end, cDNA infectious clone and replicon 
constructs based on Type 1 FCoV were developed and transcribed. During this project, infectious 
virus or replicon-expressing cells were not recovered following transfection of the constructs into 
mammalian cells, but a foundation was laid for this to be achieved in future. 
Recovery of recombinant Type 1 FCoV would necessitate a cell line capable of supporting this 
serotype’s growth in vitro, so an aim of this project was to identify a cell entry receptor (CER) for 
Type 1 FCoV in order to develop a cell line permissive to infection with the virus. To this end, ‘bait 
proteins’ bearing the spike proteins of Type 1 and 2 FCoV were produced, and Type 2 bait protein 
was able to recognise its CER. Feline intestinal organoid cultures were established, and an 
interaction identified between Type 1 bait protein and heat shock 70 kDa protein 1a (HSPA1A) 
suggested that HSPA1A is a receptor for Type 1 FCoV. 
Finally, a feline IFN- ELISpot assay was used to measure the cellular immune response to peptides 
representing a Type 1 FCoV epitope with and without a substitution. No significant difference in the 
ability of the peptide variants to stimulate a response was identified, but the assay could be used in 





I would like to thank my supervisors, Andrew Davidson and Séverine Tasker, for their wisdom, 
support and patience throughout this process. Special thanks go to the members of the E50 virology 
lab for their help, encouragement and friendship. I would also like to acknowledge Linda Wooldridge 
and Anya Lissina for supervising the ELISpot part of this project and, with others in Linda’s group, 
giving me an excellent introduction into the weird world of postgraduate research. 
Thanks to all the wonderful scientists who contributed their time and expertise to this project, 
including Anja Kipar, Alex Malbon, Michael Behnke, Rhiannon Jenkinson, I’ah Donovan-Banfield, 
Stuart Siddell, Kate Heesom and Christy Waterfall, and to the E floor tech team for their endless 
patience. Thanks to Rayana Kamal and others at the Bristol Animal Rescue Centre, and to all the cats 
who donated blood and tissue samples; without you, this project would not have been possible. 
Last but not least, I dedicate this thesis to my family and other loved ones, human and furry, who 




I declare that the work in this dissertation was carried out in accordance with the requirements of 
the University's Regulations and Code of Practice for Research Degree Programmes and that it has 
not been submitted for any other academic award. Except where indicated by specific reference in 
the text, the work is the candidate's own work. Work done in collaboration with, or with the 
assistance of, others, is indicated as such. Any views expressed in the dissertation are those of the 
author. 
 




Table of Contents 
1 Introduction .................................................................................................................................... 1 
1.1 Coronaviruses ......................................................................................................................... 1 
1.2 Feline coronavirus ................................................................................................................... 1 
1.2.1 Serotypes of FCoV ........................................................................................................... 2 
1.2.2 FCoV genome and structure ........................................................................................... 3 
1.3 FCoV replication cycle ............................................................................................................. 9 
1.3.1 Receptor recognition .................................................................................................... 10 
1.3.2 Cell entry ....................................................................................................................... 11 
1.3.3 Viral RNA replication, transcription and translation ..................................................... 11 
1.3.4 Viral particle assembly and budding ............................................................................. 12 
1.4 Clinical syndromes caused by FCoV ...................................................................................... 13 
1.4.1 FECV .............................................................................................................................. 13 
1.4.2 FIPV ............................................................................................................................... 14 
1.5 Pathogenesis of FIP ............................................................................................................... 17 
1.5.1 The role of viral mutations in development of FIP ....................................................... 17 
1.5.2 The role of the host in development of FIP .................................................................. 18 
1.5.3 The role of the environment in development of FIP .................................................... 20 
1.6 Diagnosis of FIP ..................................................................................................................... 21 
1.6.1 Indirect tests ................................................................................................................. 21 
1.6.2 Direct tests .................................................................................................................... 22 
1.7 Treatment of FIP ................................................................................................................... 23 
1.8 Prevention of FIP ................................................................................................................... 25 
1.8.1 Prevention of FCoV transmission .................................................................................. 25 
1.8.2 Vaccination against FCoV .............................................................................................. 26 
1.8.3 Reducing the risk of FCoV developing into FIP ............................................................. 27 
1.8.4 Breeding FIP-resistant cats............................................................................................ 27 
1.9 In vitro propagation of FCoV ................................................................................................. 28 
v 
 
1.9.1 Identification of coronavirus receptors ........................................................................ 28 
1.9.2 Coronavirus reverse genetic systems ........................................................................... 30 
1.10 Aims of the project................................................................................................................ 32 
2 Materials and methods ................................................................................................................. 34 
2.1 Materials ............................................................................................................................... 34 
2.1.1 Cell culture media ......................................................................................................... 34 
2.1.2 Bacterial culture media ................................................................................................. 34 
2.1.3 Solutions, buffers and detergents ................................................................................. 35 
2.1.4 Antibodies ..................................................................................................................... 36 
2.2 Cell culture methods ............................................................................................................. 38 
2.2.1 Cell lines ........................................................................................................................ 38 
2.2.2 Intestinal epithelial cells ............................................................................................... 38 
2.2.3 Peripheral blood mononuclear and monocyte-derived cells ....................................... 39 
2.2.4 Intestinal organoids ...................................................................................................... 39 
2.3 DNA and RNA techniques ..................................................................................................... 42 
2.3.1 Plasmid design and production ..................................................................................... 42 
2.3.2 Bacterial transformation and subsequent harvesting of plasmid DNA ........................ 43 
2.3.3 PCR ................................................................................................................................ 43 
2.3.4 RT-PCR ........................................................................................................................... 44 
2.3.5 Restriction enzyme digestion ........................................................................................ 44 
2.3.6 Agarose gel electrophoresis .......................................................................................... 44 
2.3.7 DNA gel extraction ........................................................................................................ 44 
2.3.8 Antarctic phosphatase digestion .................................................................................. 45 
2.3.9 NEBuilder HiFi DNA assembly ....................................................................................... 45 
2.3.10 Oligonucleotide ligation ................................................................................................ 45 
2.3.11 T4 DNA ligation ............................................................................................................. 45 
2.3.12 Phenol chloroform extraction and ethanol precipitation ............................................. 46 
2.3.13 DNA Sequencing ............................................................................................................ 46 
vi 
 
2.3.14 RNA transcription .......................................................................................................... 46 
2.3.15 Denaturing agarose gel electrophoresis ....................................................................... 47 
2.3.16 RNA transfection into mammalian cells ........................................................................ 47 
2.3.17 DNA transfection into mammalian cells ....................................................................... 48 
2.4 Protein techniques ................................................................................................................ 49 
2.4.1 ELISpot assay ................................................................................................................. 49 
2.4.2 FCoV antibody titre ....................................................................................................... 49 
2.4.3 Making a whole cell lysate ............................................................................................ 50 
2.4.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) .................... 50 
2.4.5 Coomassie Brilliant Blue staining .................................................................................. 50 
2.4.6 Western blot ................................................................................................................. 50 
2.4.7 Immunoprecipitation .................................................................................................... 51 
2.4.8 Proteomic analysis ........................................................................................................ 52 
2.4.9 Flow cytometry ............................................................................................................. 53 
2.4.10 Immunofluorescence assay........................................................................................... 53 
2.5 Statistical analysis ................................................................................................................. 55 
2.5.1 ELISpot........................................................................................................................... 55 
2.5.2 Proteomic data analysis ................................................................................................ 55 
3 Establishing a reverse genetic system for Type 1 FCoV ................................................................ 56 
3.1 Introduction .......................................................................................................................... 56 
3.1.1 Aims ............................................................................................................................... 58 
3.2 Results ................................................................................................................................... 59 
3.2.1 Design and synthesis of cDNA fragments ..................................................................... 59 
3.2.2 Amplifying fragments .................................................................................................... 61 
3.2.3 Assembling units ........................................................................................................... 63 
3.2.4 Obtaining sequence-perfect units ................................................................................ 67 
3.2.5 Amplifying units ............................................................................................................ 70 
3.2.6 Ligation of units to produce full-length cDNA clones ................................................... 71 
vii 
 
3.2.7 Transcribing full-length constructs ............................................................................... 76 
3.2.8 Transfecting cells with full-length construct RNA ......................................................... 80 
3.2.9 Next generation sequencing ......................................................................................... 83 
3.3 Discussion .............................................................................................................................. 86 
4 Identifying a CER for Type 1 FCoV ................................................................................................. 92 
4.1 Introduction .......................................................................................................................... 92 
4.1.1 Aims ............................................................................................................................... 94 
4.2 Results ................................................................................................................................... 95 
4.2.1 Production and analysis of bait proteins ...................................................................... 95 
4.2.2 Validation of the bait protein method .......................................................................... 98 
4.2.3 Screening cell lines for a Type 1 FCoV CER ................................................................. 103 
4.2.4 Screening feline PBMC for a Type 1 FCoV CER ............................................................ 105 
4.2.5 Establishing feline intestinal organoid cultures .......................................................... 108 
4.2.6 Screening feline intestinal organoids for a Type 1 FCoV CER ..................................... 114 
4.2.7 Proteomic analysis of the proteins precipitated from organoids by bait proteins ..... 117 
4.2.8 Validation of HSPA1A as a CER for Type 1 FCoV ......................................................... 119 
4.3 Discussion ............................................................................................................................ 125 
5 Measuring the immunogenicity of FCoV-derived peptides using ELISpot .................................. 134 
5.1 Introduction ........................................................................................................................ 134 
5.1.1 Aims ............................................................................................................................. 136 
5.2 Results ................................................................................................................................. 137 
5.2.1 Peptides synthesised ................................................................................................... 137 
5.2.2 Obtaining PBMC .......................................................................................................... 138 
5.2.3 Optimisation of ELISpot assay ..................................................................................... 141 
5.2.4 Response of PBMC to peptide pools on ELISpot assay ............................................... 144 
5.3 Discussion ............................................................................................................................ 148 
6 Final perspectives and future work ............................................................................................ 153 
viii 
 
References …………………………………………………………………………………………………………………………………… 157 
Appendix A ………………………………………………………………………………………………………………………………….. 172 
Appendix B ………………………………………………………………………………………………………………………………….. 204 
Appendix C ………………………………………………………………………………………………………………………………….. 205 




List of Figures 
Figure 1.1. Flowchart to show FCoV classification .................................................................................. 2 
Figure 1.2. Schematic diagram of the FCoV genome .............................................................................. 3 
Figure 1.3. Schematic diagram of an FCoV viral particle  ....................................................................... 4 
Figure 1.4. Cryo-electron micrograph of two FCoV particles.................................................................. 5 
Figure 1.5. In silico protein models of the FCoV S protein ...................................................................... 6 
Figure 1.6. A schematic overview of the coronavirus replication cycle ................................................. 9 
Figure 1.7. Schematic to show the transcription and translation of FCoV sgRNAs .............................. 12 
Figure 1.8. Characteristic lesions of feline infectious peritonitis on post mortem examination .......... 15 
Figure 1.9. Clinical signs in cats with FIP ............................................................................................... 16 
Figure 3.1. Schematic to show the fragments and units comprising each full-length construct. ........ 59 
Figure 3.2. Analysis of fragment 1B by agarose gel electrophoresis .................................................... 61 
Figure 3.3. Analysis of all fragments available as plasmids by agarose gel electrophoresis ................ 62 
Figure 3.4. Schematic to illustrate the NEBuilder HiFi DNA assembly method .................................... 63 
Figure 3.5. The oligonucleotide adaptor used to ligate unit 5 into a low copy number vector ........... 64 
Figure 3.6. Schematic to show the assembly of an infectious clone ‘unit’ from three fragments  ...... 65 
Figure 3.7. Analysis of unit 3 by agarose gel electrophoresis ............................................................... 66 
Figure 3.8. Analysis of unit 1 by agarose gel electrophoresis ............................................................... 67 
Figure 3.9. Analysis of unit 2 by agarose gel electrophoresis ............................................................... 68 
Figure 3.10. Analysis of unit 4 by agarose gel electrophoresis ............................................................. 70 
Figure 3.11.  Schematic to show the ligation of units into a full-length construct ............................... 72 
Figure 3.12. Analysis by agarose gel electrophoresis of units to be ligated into full-length constructs
 .............................................................................................................................................................. 73 
Figure 3.13. Analysis of the products of full-length construct ligation ................................................. 74 
Figure 3.14. Comparison of different ligation conditions for replicon ligation .................................... 74 
Figure 3.15. Schematic to show the amplicons obtained by PCR from the three full-length constructs
 .............................................................................................................................................................. 75 
Figure 3.16. Analysis of the PCR amplicons obtained from each full-length construct by agarose gel 
electrophoresis. .................................................................................................................................... 76 
Figure 3.17. Analysis of replicon RNA by agarose gel electrophoresis ................................................. 77 
Figure 3.18. Analysis of replicon RNA by denaturing agarose gel electrophoresis .............................. 77 
Figure 3.19. Analysis of long-range PCR amplicons by agarose gel electrophoresis ............................ 78 
Figure 3.20. Analysis of full-length construct RNA by denaturing agarose gel electrophoresis ........... 79 
x 
 
Figure 3.21. Schematic to illustrate the T2S transfection strategy, plus the results of the transfection
 .............................................................................................................................................................. 81 
Figure 3.22. Analysis of the RT-PCR amplicons obtained from each full-length construct RNA by 
agarose gel electrophoresis. ................................................................................................................. 83 
Figure 3.23. Next generation sequencing results of the three full-length constructs .......................... 85 
Figure 4.1. Analysis of bait protein-encoding plasmids by agarose gel electrophoresis ...................... 95 
Figure 4.2. Examination of transfected cells to determine the impact on transfection efficiency of 
two variables ......................................................................................................................................... 96 
Figure 4.3. Demonstration of the presence of bait protein in transfected cell culture supernatant ... 97 
Figure 4.4. Examination of CrFK cells by immunofluorescence assay for bait protein recognition ..... 98 
Figure 4.5. Examination of CrFK cells by flow cytometry for bait protein recognition ......................... 99 
Figure 4.6. Analysis of the proteins present at different stages of an immunoprecipitation 
experiment with CrFK cells and the bait proteins............................................................................... 100 
Figure 4.7. Analysis by western blot of the concentration of protein in human IgG Fc compared with 
culture supernatant containing the Type 1 and 2 bait proteins ......................................................... 103 
Figure 4.8. Examination of DH82 and FE-A cells by immunofluorescence assay for bait protein 
recognition .......................................................................................................................................... 104 
Figure 4.9. Examination of feline PBMC by immunofluorescence assay for bait protein recognition
 ............................................................................................................................................................ 105 
Figure 4.10. Examination of feline PBMC by flow cytometry for bait protein recognition ................ 106 
Figure 4.11. Examination of feline monocyte-derived cells by immunofluorescence assay for bait 
protein recognition ............................................................................................................................. 107 
Figure 4.12. Schematic to show the process for subculturing organoid cultures .............................. 109 
Figure 4.13. Examination of a large, budding murine intestinal organoid ......................................... 109 
Figure 4.14. The cultivation of feline intestinal organoids from intestinal crypts .............................. 112 
 Figure 4.15. Examination of a typical cystic (A) and budding (B) feline intestinal organoid ............. 113 
Figure 4.16. Examination of a mixed culture containing feline intestinal organoids and spindle cells
 ............................................................................................................................................................ 113 
Figure 4.17. Examination of feline intestinal organoids by immunofluorescence assay by bait protein 
recognition .......................................................................................................................................... 114 
Figure 4.18. Comparing two protocols for examination of single cells from feline intestinal organoids 
by immunofluorescence assay for bait protein recognition ............................................................... 115 
Figure 4.19. Examination of single cells from feline intestinal organoids by immunofluorescence 
assay for bait protein recognition ....................................................................................................... 115 
xi 
 
Figure 4.20. Image of a single feline intestinal organoid cell that is positive for staining with the Type 
1 bait protein, taken to assess the morphology of the cell. ............................................................... 116 
Figure 4.21. Examination of heat shocked CrFK cells by immunofluorescence assay for bait protein 
recognition .......................................................................................................................................... 121 
Figure 4.22. Examination of pHSPA1A-transfected CrFK cells by immunofluorescence assay for 
HSPA1A-FLAG recognition .................................................................................................................. 122 
Figure 4.23. Examination of pHSPA1A-transfected CrFK cells by immunofluorescence assay for Type 1 
bait protein recognition ...................................................................................................................... 123 
Figure 4.24. Analysis by western blot of the proteins immunoprecipitated from pHSPA1A-transfected 
cells by the bait proteins ..................................................................................................................... 124 
Figure 5.1. The FCoV antibody titres and source of the individual cats whose blood samples were 
collected for this study........................................................................................................................ 139 
Figure 5.2. The age groups and sexes of the 51 cats whose PBMC were used in the ELISpot study . 140 
Figure 5.3. The breeds of the 51 cats whose PBMC were used in the ELISpot study ......................... 140 
Figure 5.4. Schematic to illustrate a feline IFN- ELISpot assay .......................................................... 141 
Figure 5.5. Comparison of the feline IFN- ELISpot assay before and after optimisation. ................. 142 
Figure 5.6. Example of a PBMC population that failed to respond to PHA in a feline IFN- ELISpot 
assay .................................................................................................................................................... 142 
Figure 5.7. Results of a feline IFN- ELISpot assay carried out to determine the optimal positive 
control mitogen. ................................................................................................................................. 143 
Figure 5.8. A typical 96 well plate plan for the ELISpot assay ............................................................. 144 
Figure 5.9. The response of feline PBMC to each peptide pool. ........................................................ 146 
Figure 5.10. The response of feline PBMC to each peptide pool, of the cats that showed a response 
above background to at least one peptide pool ................................................................................. 146 
Figure 5.11. The response of feline PBMC to isoleucine or threonine peptides, of the cats that 
showed a response above background to either peptide pool .......................................................... 147 
xii 
 
List of Tables 
Table 1.1. The CERs and attachment factors used by coronaviruses ................................................... 10 
Table 3.1. The cDNA fragments synthesised for construction of recombinant viruses ....................... 60 
Table 3.2. The expected size of the PCR amplicons amplified from the three full-length constructs .. 75 
Table 4.1. The top five proteins immunoprecipitated from CrFK cells by the Type 1 bait protein .... 102 
Table 4.2. The top five proteins immunoprecipitated from CrFK cells by the Type 2 bait protein .... 102 
Table 4.3. Summary of the feline organoids available as frozen cultures from Dr M. Behnke .......... 110 
Table 4.4. The proteins significantly enriched by the Type 1 bait protein from feline intestinal 
organoids across all replicates ............................................................................................................ 118 
Table 4.5. The proteins significantly enriched by the Type 2 bait protein from feline intestinal 
organoids across all replicates ............................................................................................................ 118 
Table 5.1. Sequences of the six overlapping peptides spanning the site of the isoleucine to threonine 





A  Adenosine 
aa  Amino acid 
ADE  Antibody dependent enhancement 
APN  Aminopeptidase N 
ATP  Adenosine 5' triphosphate 
BCoV  Bovine coronavirus 
bp  Base pair 
C  Cytidine 
C  Degrees Celsius 
CCoV  Canine coronavirus 
cDNA  Complementary DNA 
CER  Cell entry receptor 
CO2  Carbon dioxide 
CrFK  Crandell feline kidney cells 
C-terminal Carboxyl-terminal 
Da  Dalton 
DAPI  4', 6-diamidino-2-phenylindole 
dATP  2' deoxyadenosine 5' triphosphate 
dCTP  2' deoxycytidine 5' triphosphate 
dGTP  2' deoxyguanosine 5' triphosphate 
dTTP  2' deoxythymidine 5' triphosphate 
DEPC  Diethyl pyrocarbonate 
dNTP  Deoxyribonucleotide triphosphate (equimolar mix of dATP, dCTP, dGTP and dTTP) 
DMEM  Dulbecco’s modified Eagle media 
DMSO  Dimethyl sulphoxide 
DNA  Deoxyribonucleic acid 
DNAse  Deoxyribonuclease 
E  Envelope (gene/protein) 
E. coli  Escherichia coli 
EDTA  ethylene diamine tetra-acetic acid (disodium salt) 
iii 
 
ELISA  Enzyme-linked immunosorbant assay 
ELISpot  Enzyme-linked immunospot 
ER  Endoplasmic reticulum 
f  Femto 
FACS  Fluorescent antibody cell sorting 
FBS  Foetal bovine serum 
FCoV  Feline coronavirus 
FCWF  Felis catus whole foetus cells 
FECV  Feline enteric coronavirus 
FIP  Feline infectious peritonitis 
FIPV  Feline infectious peritonitis virus 
g  gram 
g  gravitational constant 
G  Guanosine 
GFP  Green fluorescent protein 
GTP  Guanosine 5' triphosphate 
HCl  Hydrochloric acid 
HCoV  Human coronavirus 
HE  Haemagglutinin esterase 
H2O  Water 
HR1  Heptad repeat 1 
HR2  Heptad repeat 2 
HRP  Horseradish peroxidase 
Hsc70  Heat shock cognate 71 kDa protein  
HSP70  Heat shock protein 70 family 
HSPA1A Heat shock 70 kDa protein 1a (a.k.a. Hsp70) 
HuNoV  Human norovirus 
IBV  Infectious bronchitis virus  
ICC  Immunocytochemistry 
IFN  Interferon 
Ig  Immunoglobulin 
iv 
 
IH  Interhelical 
IHC  Immunohistochemistry 
kb  Kilobase  
kbp  Kilobase pair 
kDa  Kilodalton 
l  litre 
LB  Luria Bertani medium 
M  Membrane (gene/protein) 
MAb  Monoclonal antibody 
MEM  Modified Eagles media 
MERS  Middle East respiratory syndrome 
m  Milli 
MHC  Major histocompatibility complex 
MHV  Mouse hepatitis virus 
M  Molar 
mol  Mole 
MOPS  3-[N-morpholino] propane sulphonic acid 
mRNA  Messenger RNA 
N  Nucleocapsid (gene/protein) 
n  Nano 
nsp  Non-structural protein  
nt  Nucleotide 
N-terminal Amino-terminal 
ORF  Open reading frame 
p  Pico 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PBMC  Peripheral blood mononuclear cells 
PCR  Polymerase chain reaction 
PEDV  Porcine epidemic diarrhoea virus 
PFU  Plaque forming unit 
v 
 
PHA  Phytohaemagglutinin 
PMA  Phorbol 12-myristate 13-acetate 
Poly(A)  Polyadenylated 
pp1a  Polyprotein 1a 
pp1ab  Polyprotein 1ab 
RNA  Ribonucleic acid 
rpm  Revolutions per minute 
RT  Reverse transcription 
RTC  Replicase-transcriptase complex 
RT-PCR  Reverse transcription polymerase chain reaction 
S  Spike (gene/protein) 
SARS  Severe acute respiratory syndrome 
SDS  Sodium dodecyl sulphate 
sgRNA  Subgenomic RNA 
sgmRNA Subgenomic messenger RNA 
SGTA  Small glutamine-rich tetratricopeptide repeat-containing protein alpha 
ssRNA  Single stranded RNA 
T  Thymine 
Taq  Heat-stable DNA polymerase isolated from Thermus aquaticus 
TBE  Tris borate EDTA 
TGEV  Transmissible gastroenteritis virus  
Th1   T helper 1 
TMT  Tandem mass tag 
Tris  Tris (hydroxymethyl) methylamine 
U  Uracil 
UTR  Untranslated region 
UV  Ultraviolet 
µ  Micro 
v/v  Volume per volume 
WFE  Whole feline embryo cells 





The Coronavirinae are a sub-family of viruses belonging to the family Coronaviridae and order 
Nidovirales. They are spherical to pleomorphic, enveloped, positive sense ssRNA viruses with non-
segmented genomes of around 30,000 nucleotides (Siddell, 1995). Coronaviruses exhibit a high rate 
of mutation during RNA replication and therefore exist as quasispecies, or clusters of genetically 
diverse populations. This genetic diversity, along with a readiness to recombine with other strains, 
promotes pathogenesis and cross-species transmission (Denison et al., 2011). It has been 
hypothesised that the sudden emergence of feline coronavirus-related disease in the late 1950s 
occurred as a result of a jump into cats from another species (Pedersen, 2009).  
Coronaviruses can be found in virtually every species of mammal and bird and usually infect the 
intestinal and/or respiratory tracts (Pedersen, 2014b). Coronaviruses were not considered important 
pathogens of humans until the emergence in 2002 of severe acute respiratory syndrome coronavirus 
(SARS-CoV): a coronavirus outbreak that was introduced into the human population, most likely 
from bats, and resulted in the deaths of around 10% of those infected (Yip et al., 2009). Middle East 
respiratory syndrome coronavirus (MERS-CoV), a coronavirus thought to have originated from bats 
but spilt over into the human population via dromedary camels as an intermediate host, 
subsequently caused a SARS-like disease outbreak with a 60% mortality rate (de Groot et al., 2013, 
Alagaili et al., 2014). Coronaviruses are also clinically and economically important pathogens of a 
range of domestic species including pigs, chickens, dogs and cats. 
1.2 Feline coronavirus 
The feline coronavirus (FCoV) sub-species belongs to the Alphacoronavirus 1 species (Figure 1.1) 
alongside canine coronavirus (CCoV) and porcine transmissible gastroenteritis virus (TGEV). 
Present in most cat populations worldwide, FCoV is a pathogen of domestic, feral and some wild cats 
(Brown et al., 2009). In most cases, infection with FCoV results in intestinal disease with mild to no 
clinical signs, but in 5 to 12% of infected cats a fatal syndrome known as feline infectious peritonitis 




Figure 1.1. Flowchart to show FCoV classification. HCoV: human coronavirus, PEDV: porcine epidemic diarrhoea virus; adapted from Kipar 
and Meli (2014). 
1.2.1 Serotypes of FCoV 
Two FCoV serotypes are recognised: Type 1, which represents the vast majority of field strains 
(Benetka et al., 2004, Addie et al., 2003, Li et al., 2018), and Type 2, which came about through 
homologous recombination between Type 1 and CCoV. The spike (S) gene is the most significant 
region of variation between the two serotypes of FCoV; the Type 2 FCoV S gene has a homology of 
around 91% with that of CCoV, compared to 46% with that of Type 1 FCoV (Jaimes and Whittaker, 
2018). Different strains of Type 2 FCoV appear to have arisen through independent recombination 
events and, depending on the strain in question, further regions originating from CCoV may include 
the open reading frame (ORF)1b, 3a-c, envelope (E) and membrane (M) genes (Herrewegh et al., 
1998).  
Distinction between the FCoV serotypes is made using reverse transcription polymerase chain 
reaction (RT-PCR) to detect characteristic differences in the viral S gene (Addie et al., 2003), or by 
testing antibodies raised in the infected cat for their ability to detect each serotype (Kummrow et al., 
2005, Shiba et al., 2007). Using these methods, studies looking at the relative prevalances of the two 
FCoV serotypes in Europe and Asia have found that Type 2 FCoV represents 2-11% of natural 
infections (Addie et al., 2003, Kummrow et al., 2005, Li et al., 2018, Lin et al., 2009, Hohdatsu et al., 
1992, Duarte et al., 2009, Shiba et al., 2007). 
The S gene encodes the S protein, which mediates host cell entry. Type 2 FCoV uses the cell entry 
receptor (CER) feline aminopeptidase N (fAPN) (Belouzard et al., 2012): a 150 kDa cell surface 
glycoprotein commonly expressed in progenitor cells of the granulocyte-monocyte lineage as well as 
respiratory and intestinal epithelial cells (Hohdatsu et al., 1998). The CER for Type 1 FCoV is 
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unknown (Dye et al., 2007, Hohdatsu et al., 1998). Both Type 1 and 2 FCoV are capable of causing FIP 
(Benetka et al., 2004). Two Asian studies found that Type 2 FCoV was overrepresented in cats with 
FIP (Hohdatsu et al., 1992, Lin et al., 2009), whereas a study conducted in Europe found the converse 
(Kummrow et al., 2005). 
1.2.2 FCoV genome and structure 
1.2.2.1 FCoV genome 
The FCoV genome (Figure 1.2) comprises two open reading frames (ORF1a and ORF 1b) that 
encompass around two thirds of the genome and encode 16 non-structural proteins mainly involved 
in viral RNA synthesis, and nine open reading frames that encode four structural proteins (S, E, M 
and nucleocapsid (N); Figure 1.3) and five group-specific accessory proteins (3a, 3b, 3c, 7a and 7b) 
(Kipar and Meli, 2014). 
There is an untranslated region at the 5 end of the coronavirus genome comprising a 65-100 
nucleotide leader sequence (Pasternak et al., 2006) followed by a region that is involved in RNA 
replication (Raman and Brian, 2005), then a transcription regulating sequence (TRS) that is also 
found preceding each structural and accessory gene and is involved in discontinuous transcription of 
subgenomic viral RNAs (Dufour et al., 2011). A second untranslated region at the 3 end of the 
genome is thought to act as a switch regulating viral RNA synthesis (Goebel et al., 2004). 
Figure 1.2. Schematic diagram of the FCoV genome. The ~29 kb genome consists of 11 open reading frames (ORFs) encoding 16 non-
structural proteins (ORF1a-b), four structural proteins (spike (S), envelope (E), membrane (M), nucleocapsid (N)) and five group-specific 




Figure 1.3. Schematic diagram of an FCoV viral particle. The four structural proteins (S: spike, E: envelope, M: membrane, N: 
nucleocapsid) are displayed. A closer look at the S protein reveals its two functional domains (S1 and S2) and, within S2, the fusion peptide 
(FP), heptad repeat 1 (HR1) and heptad repeat 2 (HR2) regions. Adapted from Kipar and Meli (2014) and Fields et al. (2013). 
1.2.2.2 S protein 
The S protein is a 180-220 kDa transmembrane protein that mediates host cell entry. It is highly 
glycosylated and assembles as trimers on the viral particle surface (Jaimes and Whittaker, 2018), 
giving the virus its characteristic ‘crown-like’ appearance (Figure 1.4). The S protein consists of three 
domains, from N-terminus to C-terminus: a large external domain, a transmembrane domain and a 
short cytoplasmic domain (Fields et al., 2013). Alternatively, the S protein can be divided into S1, 
which contains the receptor binding domain and is responsible for binding to the target receptor, 
and S2. S1 comprises an C-terminal domain which binds proteins and a N-terminal domain which is 
generally responsible for binding carbohydrates (Li, 2016). S2 contains all the features of a class I 
fusion protein, including a fusion peptide which enables fusion of the virus envelope with the host 
cell membrane, and two heptad repeats (HR1 and HR2), separated by a stretch of ~140 amino acids 
called the interhelical (IH) region, which form coiled coils that participate in the fusion process 
(Bosch et al., 2003, Jaimes and Whittaker, 2018, Belouzard et al., 2012). The S2 region of both FCoV 
serotypes contains a cleavage site (S2), while a cleavage site at the border of S1 and S2 is only 
present in Type 1 FCoV (Jaimes and Whittaker, 2018). Through mediating receptor binding and 












Figure 1.4. Cryo-electron micrograph of two FCoV particles (marked with white asterisks). This image illustrates the spherical shape and 
distinctive S protein projections (one of which is indicated by a white arrow) of the viral particles, giving a ‘crown-like’ appearance. 
Reproduced with permission from Neuman et al. (2011). 
The cryo-electron microscopy structure of the FCoV S protein has not been reported, but Wu et al. 
(2009) used this method to solve the structure of the S protein of another Alphacoronavirus, human 
coronavirus (HCoV) NL63, complexed with its CER, angiotensin-converting enzyme 2 (ACE2). The 
study found that the HCoV NL63 receptor binding domain consisted of a novel -sandwich core 
structure comprising two layers of -sheets, which presented three receptor binding motifs to bind 
ACE2 (Wu et al., 2009). The receptor binding domain of porcine respiratory coronavirus, an 
Alphacoronavirus closely related to TGEV that uses porcine APN as its CER, has a very similar core 
structure to HCoV NL63 but different receptor binding motifs, which account for the difference in 
receptor usage between the two viruses (Li, 2015). Based on the structure of the HCoV NL63 S 
protein, Jaimes and Whittaker (2018) used in silico protein modelling to predict the structure of 
three strains of FCoV: Type 1 FCoV Black, Type 2 FCoV 79-1146 and Type 2 FCoV 79-1683 (Figure 
1.5). The models corroborated the features that had already been identified for other coronavirus S 
proteins and revealed a conserved organisation for Alphacoronavirus S proteins.  
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Figure 1.5. In silico protein models of the FCoV S protein. The models are based on the cryo-electron microscopy structure of HCoV NL63 
(RCSB PDB # 5SZS). Three strains of FCoV are shown, representing the two serotypes. The S1 domain is shown in salmon, the S2 domain is 
shown in grey and the fusion peptide is shown in lime green. All three S proteins contain an S2 cleavage site, but only the Type 1 FCoV 
contains an S1/S2 cleavage site. Reproduced with permission from Jaimes and Whittaker (2018). 
1.2.2.3 E protein 
The E protein is an 8-12 kDa type III membrane protein, present in the envelope of the viral particle, 
that has a hydrophilic amino terminus of 7-12 amino acids, a hydrophobic transmembrane domain 
of 25 amino acids and a hydrophilic carboxyl terminus of 39-77 amino acids. The E protein is 
localised to the endoplasmic reticulum and intermediate compartment; a complex situated between 
the endoplasmic reticulum and Golgi apparatus. As well as having ion channel activity, the E protein 
is known to play a role in virus maturation, assembly, budding and interaction with the host cell 
(Schoeman and Fielding, 2019). 
1.2.2.4 M protein 
The 25-30 kDa M protein is the most abundant structural protein in the virus (Fields et al., 2013). It is 
an N-linked glycosylated class III protein of approximately 230 amino acids, randomly distributed 
throughout the envelope of the viral particle and comprising a short ectodomain, three 
transmembrane domains and an extensive endodomain (Jaimes and Whittaker, 2018). The M 
protein interacts with itself and the other viral structural proteins, and is the main driver of the virus 
budding process (Alsaadi and Jones, 2019). With the N protein, the M protein forms the structural 
core of the virion (McBride et al., 2014). 
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1.2.2.5 N protein 
The N protein is a 50 kDa protein that binds and protects viral RNA, forming the viral helical 
nucleocapsid and enabling transcription. It comprises an N-terminal domain, a C-terminal domain 
and an intrinsically disordered central region, which all bind RNA but through different mechanisms. 
The N protein is localised to the nucleolus and cytoplasm of the host cell (McBride et al., 2014). 
Phosphorylation of the N protein may be responsible for its bias towards binding viral rather than 
non-viral RNA (Jaimes and Whittaker, 2018). The N protein plays an important role in viral RNA 
replication and transcription by tethering RNA to the replicase-transcriptase complex (RTC; section 
1.2.2.6), and as such is required for efficient viral RNA synthesis (Almazan et al., 2004, Hurst et al., 
2010). 
1.2.2.6 Non-structural proteins 
The coronavirus RTC is encoded by ORF1a and ORF1b. A heptanucleotide ‘slippery’ sequence and an 
RNA pseudoknot sit between these ORFs (Namy et al., 2006). In most cases, the ribosome unwinds 
the pseudoknot and ORF1a is translated into polyprotein 1a (pp1a). However, in some cases the 
ribosome is blocked by the pseudoknot and becomes stuck on the slippery sequence, which causes 
the ribosome to shift back by one nucleotide and continue translation using a different reading 
frame. This results in the longer pp1ab. The two polyproteins are processed into 11 and 16 active 
subunits respectively by viral-encoded proteases (Fehr and Perlman, 2015). These subunits, also 
known as ‘nsp’s, are responsible for replication of the viral genome and generation of template 
RNAs for transcription of the structural and accessory proteins (Jaimes and Whittaker, 2018).  
The functions of the nsps are approximately as follows: nsp1-2 interfere with host defences, nsp3-6 
contain factors for the formation of viral replicative organelles and proteinases for the processing of 
the viral polyproteins, nsp7-11 are involved with viral RNA synthesis through primer-synthesis and 
interaction with downstream RNA synthesis factors, and nsp12-16 contain enzyme activities 
necessary for RNA replication, capping and proofreading (Neuman et al., 2014). 
1.2.2.7 Accessory proteins 
The role of the viral accessory proteins is not completely understood. ORF3a-c are well conserved 
within the Alphacoronavirus 1 species. ORF3a and ORF3b encode proteins that are localised in the 
nucleus and cytoplasm, and the mitochondrion and nucleolus respectively, and whose functions are 
unknown (Meszaros et al., 2018). The predicted sequence of ORF3c suggests that it encodes a 
membrane-residing protein with a similar structure to M protein (Kipar and Meli, 2014).  
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ORF7a encodes a small membrane protein that acts as an interferon-alpha (IFN-α) antagonist 
(Dedeurwaerder et al., 2014). ORF7b, present only in FCoV and very closely related viruses, encodes 
a soluble glycoprotein that resides in the lumen of the endoplasmic reticulum (Vennema et al., 1992) 
and is released into the extracellular space. It is thought that the secreted 7b protein could act as a 
modulator of the host immune response (Rottier, 1999), and deletions of ORF7b readily occur in 




1.3 FCoV replication cycle 
Figure 1.6 gives an overview of the entire coronavirus replication cycle, then each step is discussed 
in more detail in sections 1.3.1-4. 
Figure 1.6. A schematic overview of the coronavirus replication cycle. Adapted from Jaimes and Whittaker (2018). 
1: The virion recognises and attaches to its receptor(s) on the host cell surface via the S protein. 
2: The virion is endocytosed. 
3: The membrane of the virion fuses with the membrane of the endosome and the viral RNA is released into the cell’s cytoplasm. 
4: The viral positive-sense (+) genomic RNA (gRNA) undergoes replication to produce negative-sense (-) gRNA, which acts as a template for 
new copies of the viral genome. The gRNA also undergoes transcription to produce a nested set of negative-sense subgenomic RNAs 
(sgRNAs), which act as templates for positive-sense messenger sgRNAs (sgmRNAs) from which the structural (S, E, M and N) and accessory 
(not shown) proteins of the virus are translated. 
5: Following maturation in the endoplasmic reticulum (not shown), the structural and accessory proteins, along with newly synthesised 
copies of the viral genome, assemble in the intermediate compartment. 
6: The assembled virions bud from the intermediate compartment and are transported to the cell surface in secretory vesicles, where they 
are released through fusion of the plasma membrane with the vesicle. 
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1.3.1 Receptor recognition 
The initial step of viral replication is the binding of the viral particle to the plasma membrane of the 
target cell, which is mediated by the S1 domain of the S protein. The coronavirus S1 domain can be 
further divided into a C-terminal domain and an N-terminal domain. The C-terminal domain binds 
protein receptors and the N-terminal domain binds carbohydrate receptors, except in the case of 
mouse hepatitis virus (MHV) where the N-terminal domain binds a protein receptor (Li, 2015). 
Based on the CERs of Type 2 FCoV and other Alphacoronaviruses it is likely that Type 1 FCoV uses a 
protein receptor. However, the possibility that, like the Betacoronavirus HCoV-OC43 (Szczepanski et 
al., 2019), Type 1 FCoV utilises a carbohydrate as its CER cannot be ruled out. Additionally many 
Beta- and Gammacoronaviruses use carbohydrate attachment factors (Li, 2015); receptors that allow 
the virus to bind to host cell membrane but do not mediate viral entry into the cell (Jolly and 
Sattentau, 2013). See Table 1 for a summary of the receptors used by different coronaviruses. 
A C-type lectin, dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN), has been shown to 
play a role in infection of monocytes by Type 2 FCoV and the culture-adapted Type 1 FCoV Black, but 
is considered more likely to function as an attachment factor than a CER (Regan and Whittaker, 
2008, Van Hamme et al., 2011).  
Table 1.1. The CERs and attachment factors used by coronaviruses. Where a CER or attachment factor has not been identified, the cell 
has been left blank. The receptors shown in bold are carbohydrates, while the remainder are proteins. PEDV: porcine epidemic diarrhoea 
virus, BCoV: bovine coronavirus, IBV: avian infectious bronchitis virus. Adapted from Jaimes and Whittaker (2018), with the source of 
additional information cited as appropriate. 
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1.3.2 Cell entry 
Following receptor binding, the virus must fuse with a cell membrane in order to gain entry to the 
cell. This can occur either directly at the cell surface or in the endosomal compartment following 
endocytosis (Belouzard et al., 2012). Coronaviruses in general can use either mechanism, but FCoV 
has been demonstrated to use the endocytic pathway in vitro (Van Hamme et al., 2007). Once 
endocytosed, it is thought that the Type 2 FCoV S protein is primed for membrane fusion through 
cleavage by the cysteine protease cathepsin and a drop in endosomal pH (Regan et al., 2008). Less is 
known about the mechanism of entry for Type 1 FCoV, but a functional S protein furin or heparan 
sulfate cleavage site at the boundary of S1 and S2 identified in some strains suggests that Type 1 
FCoV S protein likely undergoes cleavage prior to fusion (Licitra et al., 2013, de Haan et al., 2008). S 
protein cleavage is thought to activate the fusion function of the S2 subunit (Burkard et al., 2014), 
allowing it to fuse with the endosomal membrane and the viral RNA to be released into the 
cytoplasm of the host cell (Pedersen, 2014b). 
Anti-coronavirus antibodies have been demonstrated to facilitate uptake of virus into macrophages 
via Fc receptors in vitro, bypassing the requirement for receptor binding (Takano et al., 2008a). 
Additionally, transcriptional profiling of peritoneal cells showed upregulation of Fc receptor genes in 
cats with FCoV-related disease (Watanabe et al., 2018), suggesting that this mechanism may also 
occur in vivo. Increased uptake of virus by macrophages is thought to manifest clinically in antibody 
dependent enhancement of disease, whereby cats immunised against FCoV prior to experimental 
infection show decreased survival rates and times post-infection (Takano et al., 2008b, Klepfer et al., 
1995, Vennema et al., 1990, Balint et al., 2014). 
1.3.3 Viral RNA replication, transcription and translation 
ORF1a and ORF1b are immediately translated following virus uncoating, which results in the 
production of pp1a and pp1ab. These polyproteins are cleaved into nsp1-16, many of which go on to 
form the RTC (Fehr and Perlman, 2015). The RTC recognises cis-acting elements at the 5 and 3 
untranslated regions of the viral genome and copies the genome either continuously for replication, 
or discontinuously for transcription (Sawicki et al., 2007). In the case of replication, the full-length 
negative-sense RNA generated is used as a template for making positive-sense copies of the 
genome. The N protein participates in viral RNA synthesis by tethering the RNA to the RTC (Hurst et 
al., 2010). 
Discontinuous transcription generates a nested set of seven negative-sense subgenomic RNAs 
(sgRNAs) which act as templates for positive-sense subgenomic mRNAs (sgmRNAs), from which the 
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structural and accessory proteins of the virus are translated (Figure 1.7). Transcription proceeds 
from the 3 end of the genome and, when a TRS is reached, either continues or stops and jumps to 
the leader sequence. In this way each sgRNA contains a common leader sequence derived from the 
5 end of the viral genome (Sola et al., 2015, Sawicki et al., 2007). This strand switching capability of 
the RNA-dependent RNA polymerase is what allows coronaviruses to undergo homologous 
recombination (Fehr and Perlman, 2015). 
Figure 1.7. Schematic to show the transcription and translation of FCoV sgRNAs. The viral genome is transcribed discontinuously from 
the 3 end to produce a set of seven nested negative-sense sgRNAs (not shown), which act as templates for the positive-sense sgmRNAs. 
The full-length genome (sgmRNA 1) acts as the first sgmRNA, from which pp1a and pp1ab are translated. The structural (S, E, M, N) and 
accessory (3a-c, 7a-b) proteins are translated from the subsequent sgmRNAs. L: leader sequence. Adapted from Sawicki et al. (2007). 
1.3.4 Viral particle assembly and budding 
The viral structural proteins mature in the endoplasmic reticulum and are transported through the 
secretory pathway into the intermediate compartment, which is the site of coronavirus assembly. 
The M protein recruits a region of membrane for viral particle assembly and guides other structural 
proteins to the site, while the N protein binds to the newly synthesised copies of the viral genome to 
form the nucleocapsid (Neuman et al., 2011). The assembled virions bud from the intermediate 
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compartment and are transported in secretory vesicles to the cell surface and released through 
endosome-plasma membrane fusion (Rottier, 1999, Jaimes and Whittaker, 2018). 
1.4 Clinical syndromes caused by FCoV 
FCoV infection causes two distinct disease types in cats: a transient to persistent enteric disease that 
usually involves mild clinical signs if any, and a near invariably fatal systemic disease known as FIP. 
The virus pathotype that results in the former clinical presentation is referred to as ‘feline enteric 
coronavirus’ (FECV), while the pathotype that results in the latter is referred to as ‘FIP virus’ (FIPV) 
(Pedersen, 2009). It is thought that, in most cases, a cat will initially become infected with FECV, 
then the virus will mutate within that cat to FIPV (Pedersen, 2014b). Both Type 1 and 2 FCoV can be 
either FECV or FIPV (Benetka et al., 2004). 
1.4.1 FECV 
FECV is present in most cat populations and extremely contagious, with a seroprevalence of 4 to 
24% in single cat households. This figure rises to between 26 and 87% in multi-cat environments 
(Drechsler et al., 2011), and FCoV was found to be by far the most common faecal pathogen among 
cats living in a shelter in the USA (Sabshin et al., 2012). This demonstrates the ubiquity of FCoV, 
especially amongst cats living in large groups such as those in shelters or catteries. Typical clinical 
signs of FECV include diarrhoea and inappetence, though many infected cats will have no signs at all 
(Pedersen et al., 2008). A very small minority of cats die from FECV-associated enteritis (Kipar et al., 
1998b). Transmission of FECV occurs via the faecal-oral route (Meli et al., 2004), and the virus infects 
the mature epithelial cells of the small and large intestine (Kipar et al., 1998b). 
Following infection, cats start shedding FECV in their faeces within a week and continue to shed for 
up to 11 months. They then either clear the virus and cease shedding (though remain susceptible to 
reinfection with the same or a different strain) or continue to shed persistently, possibly for life. 
Persistent infection does not appear to predispose a cat to development of FIP (Pedersen et al., 
2008, Addie et al., 2003, Addie and Jarrett, 2001). Approximately 3% of cats are naturally resistant to 
infection with FECV (Addie and Jarrett, 2001). 
It was previously thought that, unlike FIPV, FECV is confined to the gut and unable to infect 
monocytes and macrophages (Pedersen, 1987). However, it has been demonstrated through 
detection of FCoV in the blood of clinically healthy cats that FECV can infect monocytes and spread 
from the gut via monocyte-associated viraemia (Kipar et al., 1999a, Gunn-Moore et al., 1998, Meli et 
al., 2004, Desmarets et al., 2016). It was demonstrated in one case that FECV can infect monocytes 
even without an initial period of intestinal replication (Desmarets et al., 2016). Gunn-Moore et al. 
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(1998) found that 80% of FCoV-infected cats without FIP in endemic households had FCoV RNA in 
circulating monocytes. However, the viral load in cats without FIP is significantly lower than those 
with FIP (Kipar et al., 2006), perhaps indicating that it is not systemic infection but the ability of the 
virus to replicate to high levels in monocytes that is the key event leading to FIP. This has been 
demonstrated in feline monocytes infected in vitro with FCoV, whereby FIPV can replicate 
sustainably and to a much higher level than FECV in this cell type (Dewerchin et al., 2005). Once 
systemic, the virus can reside within macrophages in extra-intestinal sites including the abdominal 
organs, lymphoid tissues and brain, still without resulting in any clinical signs. The virus can persist in 
these sites long after viraemia has cleared. The major site of FECV persistence in the gut is the colon 
(Kipar et al., 2010). 
FCoV-infected cats that do not go on to develop FIP demonstrate a strong immune response to the 
virus, including rising antibody titre, circulating immune complexes, and follicular and T cell 
hyperplasia in the lymph nodes, thymus and spleen (Kipar et al., 1999a). These tissues contain FCoV-
specific plasma cells, indicating a specific response to FCoV rather than a general response to 
inflammation (Kipar et al., 1998a). 
1.4.2 FIPV 
In 5 to 12% of FCoV-infected cats, FIP develops (Addie and Jarrett, 1992, Addie et al., 1995). This is a 
usually fatal systemic disease caused by FIPV, which in most cases is thought to be a pathogenic 
mutant of FECV that has arisen within the individual cat (Pedersen, 2014b). Though the ability to 
infect monocytes and macrophages is not unique to FIPV, the level to which it replicates in these 
cells sets it apart from FECV (Dewerchin et al., 2005); substantial replication of FIPV in monocytes 
results in their activation and precipitates the development of FIP (Kipar and Meli, 2014). When cats 
are experimentally infected with FIPV, clinical signs of FIP emerge from around 10 days post 
infection (de Groot-Mijnes et al., 2005). This does not reflect the natural situation, where the 
incubation period is usually weeks to months (Addie et al., 1995). 
Unlike FECV, FIPV is not usually transmitted horizontally. This is because FIPV is rarely shed in the 
faeces and, when it is, it is not infectious to other cats (Pedersen et al., 2012). Despite this, FIP 
outbreaks have been reported in multi-cat environments. Host and environmental factors are likely 
important factors in these outbreaks, but horizontal transmission of FIPV (or at least FCoV with an 
increased tendency to mutate into FIPV) is also thought to play a part (Drechsler et al., 2011, Kipar 
and Meli, 2014).  
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1.4.2.1 Characteristic lesions of FIP 
It was previously thought that the characteristic pyogranulomatous perivascular lesions of FIP 
(Figure 1.8) are the result of immune complex formation and deposition in vessels (Olsen, 1993). 
However, circulating immune complexes have been found in cats infected with FCoV that do not go 
on to develop FIP (Kipar et al., 1999a). More recent evidence demonstrates that the lesions of 
naturally infected cats are monocyte mediated. Activated, FIPV-infected monocytes produce 
cytokines and adhesion molecules that allow them to interact with activated endothelial cells and 
extravasate (Acar et al., 2016, Olyslaegers et al., 2013). The activated monocytes also produce 
enzymes that dissolve the vascular basement membrane (Kipar et al., 2005) and neutrophil survival 
factors that attract neutrophils to the lesions and give them their pyogranulomatous character 
(Takano et al., 2009). Lesions are typically restricted to veins, likely due to selective responsiveness 
of the endothelium (Kipar et al., 2005). 
Figure 1.8. Characteristic lesions of feline infectious peritonitis on post mortem examination. A perivascular pyogranuloma on the small 
intestinal serosa of a cat with FIP is indicated with a white arrow. Image courtesy of The Feline Centre, Langford Vets, University of Bristol. 
1.4.2.2 Clinical signs of FIP 
Most clinical signs of FIP are related to the pyogranulomatous perivascular lesions that characterise 
the disease. As a result, they can vary depending on which organs are affected. Commonly involved 
sites are the serosa, kidneys, mesenteric lymph nodes, brain, eyes, liver, spleen and lungs (Kipar and 
Meli, 2014), leading to clinical signs including ascites (Figure 1.9A), dyspnoea, uveitis (Figure 1.9B), 
ataxia and seizures (Pedersen, 2014a, Riemer et al., 2015). Papular cutaneous lesions have also been 
described less commonly as a feature of FIP (Declercq et al., 2008, Redford and Al-Dissi, 2019, Osumi 
et al., 2018). More general findings include persistent pyrexia that is refractory to antibiotics, 
lethargy, anorexia, icterus and weight loss (Addie et al., 2009) 
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Figure 1.9. Clinical signs in cats with FIP. Image A shows a cat with ascites: accumulation of abdominal fluid due to serosal inflammation. 
Image B shows a cat with uveitis: inflammation of the eye resulting from pyogranulomatous lesions in the vessels of the region. Images 
courtesy of The Feline Centre, Langford Vets, University of Bristol. 
A distinction is often made between ‘wet’ and ‘dry’ FIP. The former presentation involves serosal 
inflammation and effusions and is associated with a survival time of days to weeks. The latter 
involves solid parenchymatous lesions in organs and is associated with a survival time of weeks to 
months (Addie, 2012, Pedersen, 2014a). However, it is more realistic to consider these two 
presentations the extremes of a spectrum, with most cases sitting somewhere in the middle. This is 
confirmed by post mortem examination of cats with FIP, which usually reveals a combination of 
effusion and solid lesions (Kipar and Meli, 2014). A form of FIP where lesions appear to be largely 
restricted to the intestine and/or mesenteric lymph nodes, often leading to a palpable abdominal 
mass and signs related to intestinal dysfunction (Harvey et al., 1996, Kipar et al., 1999b), could be 
interpreted as an extreme type of dry FIP. 
The prognosis of FIP is extremely poor, with a median survival time from diagnosis of just nine days 




1.5 Pathogenesis of FIP 
1.5.1 The role of viral mutations in development of FIP 
The ‘internal mutation’ theory of FIP pathogenesis is commonly accepted, whereby the host 
becomes infected with FECV and the virus acquires mutations within the individual to become FIPV 
(Pedersen, 2014b). Various viral mutations have been identified that correlate with pathotype, but 
to date none that definitively distinguish FIPV from FECV have been found. Differences have been 
noted between FECVs and FIPVs in the M and ORF7a-b genes (Brown et al., 2009, Kennedy et al., 
2001, Herrewegh et al., 1995, Borschensky and Reinacher, 2014), but two regions of particular 
interest are ORF3c and S. 
The ORF3c gene was found to be intact in all FCoVs derived from the faeces of healthy cats 
(presumed to be FECVs) but remained intact in only a small proportion of FCoVs derived from the 
tissues of cats with FIP (presumed to be FIPVs) (Pedersen et al., 2012, Chang et al., 2010, Bank-Wolf 
et al., 2014, Borschensky and Reinacher, 2014, Hora et al., 2016, Vennema et al., 1998). This could 
be interpreted as ORF3c mutations conferring virulence to FCoV, but Chang et al. (2010) argued that 
3c is only necessary for enteric replication and, once systemic, there is no longer selection pressure 
on the virus for the gene to remain intact. This was confirmed when FIPVs with intact ORF3c genes 
were characterised (Pedersen et al., 2012). 
Mutations in the S gene have been associated with FCoVs derived from the tissues of cats with FIP 
but not those derived from the faeces of healthy cats, particularly in the putative S2 fusion peptide 
(Chang et al., 2012, Lewis et al., 2015, Bank-Wolf et al., 2014), the HR1 region (Bank-Wolf et al., 
2014, Lewis et al., 2015) and the cleavage site between S1 and S2 (Licitra et al., 2013). However, the 
majority of FCoVs in the tissues of healthy cats with systemic FCoV also carry the S2 fusion peptide 
mutations, suggesting that these mutations are associated with a switch in tropism and systemic 
spread rather than virulence (Barker et al., 2017, Porter et al., 2014). The relevance of the HR1 
mutations to virus pathotype are unknown, though it has been demonstrated that they sit within a 
major T cell epitope for Type 1 FCoV (Satoh et al., 2011a) so may alter the immune response of the 
host to the virus. The mutations in the cleavage site between S1 and S2 have been demonstrated to 
alter the protease activation requirements of the virus (Licitra et al., 2013), offering a possible 
explanation for the increased ability of FIPVs to replicate in monocytes and macrophages. 
By constructing chimeric viruses bearing regions of the S gene from either an FECV or FIPV, Rottier et 
al. (2005) demonstrated that the S2 region dictates macrophage tropism. To investigate this further, 
Shirato et al. (2018) mapped the exact mutations in the Type 2 FIPV S gene that confer its ability to 
replicate effectively in ex vivo feline macrophages. The S genes of FECVs and FIPVs were compared, 
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and the non-synonymous mutations consistently found in FIPVs only were engineered into a 
recombinant FECV, using reverse genetics, to observe their effect on virus phenotype. The authors 
found that efficient replication in macrophages could be pinpointed to five cooperative mutations in 
the FCoV S2 region. Though these mutations are not identical to those that have previously been 
identified through comparing the sequences of FECVs and FIPVs, one mutation sits within the S2 
fusion peptide and another lies within the HR1 region. 
Though viral mutations that enable efficient replication in monocytes and macrophages are 
undoubtedly necessary for the development of FIP, no mutation or set of mutations is unique to 
FIPV or sufficient to cause FIP in all cats. When challenged with the same dose of genetically 
identical FIPV, some cats succumb while others are able to overcome the infection (de Groot-Mijnes 
et al., 2005, Pedersen et al., 2014, Mustaffa-Kamal et al., 2019). This demonstrates the importance 
of host factors in conferring resistance and susceptibility to FIP. 
1.5.2 The role of the host in development of FIP 
Cats with FIP are typically under two years of age, though cats of any age can be affected and a 
smaller peak is observed in cats older than 10 years (Riemer et al., 2015, Addie and Jarrett, 1992, 
Addie et al., 1995, Pesteanu-Somogyi et al., 2006). A longitudinal study of cats naturally infected 
with FCoV found that the risk of developing FIP decreased over time (Addie et al., 1995). This 
phenomenon could be explained by the development of immunological resistance to FIP but would 
also be observed if some cats were intrinsically susceptible to FIP and succumbed quickly, leaving 
those that were intrinsically resistant behind. 
Males are slightly more susceptible to FIP than females (Riemer et al., 2015, Rohrbach et al., 2001, 
Norris et al., 2005), and some studies have found that unneutered males are overrepresented 
compared to their neutered and female counterparts (Rohrbach et al., 2001, Pesteanu-Somogyi et 
al., 2006). However, cats from breeding households are more likely to be unneutered, and it is 
known that FCoV is more prevalent in multi-cat environments such as breeding households and 
shelters.  
Pedigree cats are more likely to have FIP than non-pedigree cats (Norris et al., 2005, Pesteanu-
Somogyi et al., 2006, Rohrbach et al., 2001), though again cats from breeding households are more 
likely to be pedigree so may be overrepresented. The two major studies into the incidence of FIP in 
individual breeds disagree over which are susceptible and which are resistant (Pesteanu-Somogyi et 
al., 2006, Norris et al., 2005). Pedersen (2009) argues that perhaps the bloodlines within a breed are 
more relevant than the breeds themselves. However, an attempt to breed FIP-resistant cats through 
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positive genetic selection led to an increase in susceptibility, suggesting that genetic diversity is 
more important than selection of particular traits (Pedersen et al., 2016). 
Based on the idea that gut microbiota may influence the immune response to viral disease, a pilot 
study identified differences in the intestinal microbial communities between cats with FIP, healthy 
FCoV-infected cats and cats without FCoV. However, the authors were unable to draw any 
conclusions about the relevance of these differences (Meazzi et al., 2019). 
1.5.2.1 Immune Response to FCoV 
It is generally accepted that the pathology associated with FIP arises due to an interplay between the 
virus and the host’s immune system, with the immune response of the individual guiding disease 
outcome (Pedersen, 2014b). A study following a cohort of cats experimentally infected with FIPV 
found that antibody titre rises at a similar rate and magnitude in all cats, regardless of clinical course 
or outcome (de Groot-Mijnes et al., 2005), demonstrating that a humoral response to FIPV infection 
takes place but is not protective. This is also evidenced by the presence of B cells with anti-FCoV 
antibodies in the lymphoid tissues of both cats with FIP and those that overcame the infection (Kipar 
et al., 1999a) and the high antibody titres often found in cats with naturally occurring FIP (Hartmann 
et al., 2003). Cornelissen et al. (2009) demonstrated that FIPV-infected macrophages do not undergo 
antibody-dependent, complement-mediated lysis, suggesting that the usual protective function of 
antibodies is somehow subverted in FIP. 
Antibody dependent enhancement (ADE) has been documented in experimentally infected cats 
whereby passive or active immunisation, particularly against the FIPV S protein, actually decreases 
survival rate and survival time post-infection (Takano et al., 2008b, Klepfer et al., 1995, Vennema et 
al., 1990, Balint et al., 2014, Takano et al., 2019b). A similar effect has been demonstrated in vitro, 
whereby presence of anti-FIPV antibodies increased uptake of FIPV via the macrophage Fc receptor 
(Corapi et al., 1992, Olsen et al., 1992). However, Addie et al. (1995) found that ADE of disease did 
not occur in naturally infected cats, and that repeated exposure to FCoV did not increase the risk of 
developing FIP. In cats naturally infected with FCoV, those that cleared the virus had a significantly 
higher anti-S to anti-M antibody ratio compared with those that shed persistently or succumbed to 
FIP (Gonon et al., 1999), suggesting that a humoral immune response to the S protein could be 
protective in at least some situations.  
The cellular immune response to FCoV infection seems to be more closely correlated with course 
and outcome of disease. Following experimental infection with FIPV, all cats initially became T cell 
depleted. Those cats that succumbed to FIP remained T cell depleted, whereas those that overcame 
the challenge experienced a strong resurgence in T cell numbers (de Groot-Mijnes et al., 2005, 
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Mustaffa-Kamal et al., 2019). This reflects the clinical situation, where lymphopenia is a common 
haematological finding in cats with FIP (Riemer et al., 2015). Studies looking at the lymphoid tissues 
of cats with FIP and those of FCoV-infected cats without FIP found that the former group had 
lymphoid depletion and thymic atrophy, compared to the lymphoid hyperplasia seen in the latter 
group (Kipar et al., 1999a, Kipar et al., 2001). This suggests that a robust cellular immune response 
may have contained the infection and prevented FIP from developing. In vitro studies have 
demonstrated that T cells, and in particular natural killer cells, from cats with FIP are not only 
depleted, but are also less functional (Vermeulen et al., 2013, Satoh et al., 2011b). Takano et al. 
(2007) argue that production of tumour necrosis factor alpha (TNF-α) by infected macrophages is 
responsible for induction of T cell apoptosis, and indeed TNF-α was found to be elevated in the 
blood (Kiss et al., 2004) and mediastinal lymph node (Malbon et al., 2019) of cats with FIP. 
It was previously thought that wet FIP arose when a strong humoral immune response to FCoV 
infection led to increased uptake of virus into macrophages and immune complex-mediated 
vasculitis, while dry FIP resulted from a mixed humoral and cellular immune response. The 
contribution of antibodies to the pathogenesis of the disease cannot be completely ruled out, but it 
is now understood that lesions in all forms of FIP are primarily mediated by monocytes (Kipar and 
Meli, 2014). 
1.5.3 The role of the environment in development of FIP 
It is known that FIP  frequently occurs in multi-cat environments such as catteries and shelters 
(Addie et al., 2009), with the risk for FIP increasing with the number of cats kept together (Kass, 
1995), the overall frequency of FCoV shedding and the proportion of cats chronically shedding FCoV 
(Foley et al., 1997). It is unclear whether the rate of FIP is actually increased in these populations, or 
whether the increased incidence of FIP simply reflects increased prevalence of FCoV. However, 
stress (Addie et al., 2009), high viral load (Addie and Jarrett, 1992) and co-infections (Foley et al., 
1997) are risk factors for development of FIP from FCoV infection, and these factors are likely to be 
present where many cats are kept together (Drechsler et al., 2011). 
Stress is an important factor in the development of FIP in all FCoV-infected cats, not just those in 
multi-cat environments. In a retrospective study of 231 cats with confirmed FIP, Riemer et al. (2015) 
found that a specific stressful event such as adoption, surgery or vaccination preceded diagnosis in 




1.6 Diagnosis of FIP 
The vague and varied clinical signs of FIP can make it a challenging disease to diagnose, particularly 
when an effusion is not present. The clinician will often use a combination of signalment (the cat’s 
age, sex and breed), history, physical examination findings and multiple indirect and direct tests to 
come to a diagnosis of FIP. Direct detection of FCoV in tissue or effusion macrophages using 
immunostaining methods is sufficient for a definitive diagnosis of FIP (section 1.6.2.1), but this is not 
always possible. 
1.6.1 Indirect tests 
Indirect tests aim to detect changes associated with FIP rather than the virus itself. 
1.6.1.1 Haematology and biochemistry 
Certain findings on routine haematology and biochemistry are typical of FIP. These are a mild to 
moderate non-regenerative anaemia, microcytosis, lymphopenia, neutrophilia with or without left 
shift, hyperbilirubinaemia, hyperglobulinaemia, hypoalbuminaemia and an albumin to globulin ratio 
of less than 0.8 (Addie et al., 2009, Riemer et al., 2015). However, it is important to note that these 
findings are neither pathognomonic for FIP nor present in all cats with FIP. Serum levels of the acute 
phase protein alpha-1 acid glycoprotein (AGP) greater than 1.5 mg/ml are suggestive of FIP, 
particularly when other criteria fit the diagnosis, but can be elevated with other inflammatory 
conditions (Duthie et al., 1997, Paltrinieri et al., 2007, Giori et al., 2011, Stranieri et al., 2018).  
1.6.1.2 Effusion analysis 
The presence of a characteristic effusion, usually in the thorax or abdomen, is highly suggestive of 
FIP (Pedersen, 2014a). A typical FIP effusion is yellow, clear and viscous with a high protein content 
(>35 g/l) and low cellularity (<5 x 109 nucleated cells/l). The cells are predominantly macrophages 
and neutrophils (Tasker, 2018). Albumin, globulin and AGP can also be measured in effusion fluid, 
with an albumin to globulin ratio of less than 0.4 and an AGP of greater than 1.55 mg/ml being highly 
consistent with FIP (Tasker, 2018, Hazuchova et al., 2016). Immunostaining can be used to look for 
FCoV in the effusion fluid macrophages (section 1.6.2.1). 
1.6.1.3 Histopathology 
Samples of tissues affected by FIP lesions can be collected by biopsy ante mortem or on post mortem 
examination. Presence of characteristic histopathological changes are considered reliable for 
diagnosis of FIP (Tasker, 2018), but immunostaining can be used in addition to look for FCoV in tissue 
macrophages (section 1.6.2.1). 
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1.6.2 Direct tests 
Direct tests aim to demonstrate the presence of FCoV in clinical samples. 
1.6.2.1 Immunostaining 
Immunocytochemistry (ICC), used to detect FCoV in macrophages found in effusion fluid (Felten et 
al., 2016, Litster et al., 2013), cerebrospinal fluid (Ives et al., 2013) and aqueous humour (Felten et 
al., 2017b), was historically considered to be very specific, but two studies found positive results in 
samples from cats without FIP (Litster et al., 2013, Felten et al., 2016). Tasker (2018) argued that the 
false positive results in these studies were likely due to the methodology used or suboptimal storage 
of cytology slides, suggesting that the specificity of ICC is high if the test is carried out properly. False 
negative results can occur with ICC due to low cellularity of samples and the inability of the method 
to detect cells with a low virus burden (Tasker, 2018). Detection of FCoV by immunohistochemistry 
(IHC) in surgical biopsies or tissue samples obtained at post mortem examination has a very high 
positive predictive value and is considered the gold-standard test for diagnosis of FIP (Kipar and 
Meli, 2014), but obtaining a biopsy can be challenging due to its invasive nature. 
1.6.2.2 Polymerase chain reaction (PCR) 
RT-PCR can detect FCoV RNA in various clinical samples. Since FCoV spreads systemically in cats 
without FIP, its detection in sites beyond the gut is not necessarily indicative of FIP. However, FCoV 
RNA is more commonly found and at higher levels in tissues from cats with FIP compared to those 
without (Porter et al., 2014, Barker et al., 2017, Stranieri et al., 2018). The use of RT-PCR on blood 
samples is limited due to a low specificity and sensitivity for FIP (Meli et al., 2004, Felten et al., 2015, 
Pedersen et al., 2015, Doenges et al., 2016b), but the test has a very high specificity and reasonable 
sensitivity when used with effusion fluid and mediastinal lymph node fine needle aspirates from cats 
with FIP-consistent signs (Longstaff et al., 2015, Doenges et al., 2016b, Dunbar et al., 2018), and 
cerebrospinal fluid from cats with neurological FIP-consistent signs (Doenges et al., 2016a).  
RT-PCR and sequencing have been used in combination to attempt to differentiate FECV from FIPV, 
based on mutations in the S2 fusion peptide thought to be associated with the latter. The inclusion 
of a sequencing step was found to slightly increase specificity in some cases compared to RT-PCR 
alone, but none of the studies demonstrated a definitive distinction between FECV and FIPV (Sangl 
et al., 2018, Felten et al., 2015, Longstaff et al., 2015, Felten et al., 2017a, Barker et al., 2017). This is 
unsurprising given that the mutations analysed are not unique to FIPV and rather indicate systemic 




Detection of anti-FCoV antibodies in the serum cannot be used to diagnose FIP because positive 
titres are frequently found in healthy FCoV-infected cats and negative results are possible in cats 
with FIP (Sparkes et al., 1991, Hartmann et al., 2003). However, a very high anti-FCoV antibody titre 
was found to correlate with FIP (Foley et al., 1997). Measurement of anti-FCoV antibodies in effusion 
fluid and cerebrospinal fluid is not recommended because neither test is specific for FIP (Hartmann 
et al., 2003, Boettcher et al., 2007, Soma et al., 2018). 
1.7 Treatment of FIP 
Corticosteroids are widely used to suppress the inflammation associated with FIP and increase 
survival time, but there are no controlled studies proving their efficacy. Other immunosuppressive 
drugs that have been suggested include chlorambucil, cyclophosphamide and salicylic acid, though 
evidence to prove their benefit is lacking (Addie et al., 2009). There is anecdotal evidence for the 
benefit of the methylxanthine derivatives propentofylline and pentoxyfylline, which are thought to 
ameliorate vasculitis through inhibition of pro-inflammatory cytokines. However, a placebo-
controlled double-blind trial investigating the efficacy of propentofylline in 23 cats with naturally 
occurring FIP found no effect of the drug on survival time or quality of life (Fischer et al., 2011).  
Ozagrel hydrochloride is a thromboxane synthetase inhibitor that is hypothesised to treat vasculitis 
through inhibition of platelet aggregation. Watari et al. (1998) describe its successful use in two cats 
with naturally occurring FIP, though it is difficult to draw any conclusions from such a small case 
series where the diagnosis of FIP was not confirmed by IHC. Chloroquine inhibits viral replication in 
vitro and has been used to treat immune-mediated inflammatory conditions. A placebo-controlled 
trial carried out in nine cats experimentally infected with FIPV showed an improved clinical score and 
a non-significant increase in survival time in the treatment groups compared to control group, but 
this was accompanied by an increase in liver enzyme alanine aminotransferase suggestive of toxicity 
(Takano et al., 2013). The antiviral compound ribavirin has been shown to prevent FCoV replication 
in vitro, but kittens treated with the drug had shorter survival times and more severe clinical signs 
than the control group (Weiss et al., 1993).  
Ishida et al. (2004) reported a complete or partial remission of FIP in eight out of 12 cats treated 
with feline interferon-omega (IFN-ω) and corticosteroid. However, the study was uncontrolled and 
the diagnosis unconfirmed by IHC in those cats that survived. A more recent placebo-controlled 
double-blind trial carried out in 37 cats showed no benefit of IFN-ω, though the treatment group did 
include one long-term survivor (Ritz et al., 2007). A study involving 74 experimentally infected cats 
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showed a modest increase in lifespan with human IFN-α treatment (Weiss et al., 1990), but no 
benefit to survival was demonstrated and the treatment is untested in naturally infected cats. 
Following a report of the remission of dry FIP in two out of three cats treated with polyprenyl 
immunostimulant (PI) (Legendre and Bartges, 2009), there has been a lot of interest in this agent 
and related immunostimulatory substances. A follow up study saw 60 cats with naturally occurring, 
dry FIP treated with PI. The survival times of cats treated with PI were measured from the start of 
treatment and compared to survival times reported in the literature for cats with dry FIP. An 
improvement in survival was identified, with four long-term survivors living for over 300 days. 
Additionally, treating veterinarians reported a subjective improvement in the wellbeing of many of 
the cats (Legendre et al., 2017). Though these results sound promising, they must be interpreted 
cautiously since neither study included a control group and definitive diagnosis of FIP with 
histopathology and immunostaining was not a requirement for inclusion in the studies. 
A placebo-controlled study of six experimentally infected cats showed development of FIP in all cats 
in the control group compared to one of three undergoing treatment with anti-feline TNF-α 
monocloncal antibody (Doki et al., 2016). The same group have demonstrated the efficacy of FCoV-
derived peptides in preventing FCoV infection in vitro, based on a current treatment for human 
immunodeficiency virus in which the peptides are hypothesised to inhibit infection through virus and 
receptor binding (Doki et al., 2015). Other compounds that were efficacious in preventing and/or 
treating FCoV infection in vitro include Inonotus obliquus polysaccharide (Tian et al., 2016), 
itraconazole (Takano et al., 2019a), diphyllin (Hu et al., 2017), ciclosporin A (Tanaka et al., 2013) and 
micro RNAs targeted against FCoV (Anis et al., 2016). However, none of these treatments have been 
tested in vivo. 
Kim et al. (2016) demonstrated the safety of the coronavirus 3C-like protease inhibitor ‘GC376’ in 
four healthy cats and showed that its presence in cell culture did not induce FIPV strain 79-1146 to 
evolve to overcome the inhibitory effects of the drug at 20 passages. The group went on to test the 
efficacy of GC376 in eight cats experimentally infected with a field strain (m3c-2) of Type 1 FCoV. 
Treatment was given at two different stages of disease representing early and late FIP, but in both 
stages the authors deemed the FIP terminal without intervention. Clinical signs and laboratory 
parameters consistent with FIP were reversed in six out of eight cats, and they remained healthy for 
the eight-month monitoring period. Interestingly, the two cats that were euthanised had severe 
clinical signs that, on post mortem examination, were attributed to severe pancreatitis and not FIP 
lesions. The authors were unable to explain why the cats had pancreatitis. A further study in 20 cats 
with naturally occurring FIP demonstrated long-term survival in seven cats treated with GC376. Six of 
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the seven survivors had developed acute, wet FIP and were less than 5 months old at presentation. 
The seventh survivor was an adult cat with only mediastinal lymph node involvement. Of the cats 
who succumbed to FIP despite GC376 treatment, 11 initially presented with dry FIP and all but three 
were older than 5 months. These results suggest that GC376 may be an effective treatment in very 
young cats with acute, wet FIP. Despite none of the cats in the study initially presenting with 
neurological signs, eight of the 13 cats who succumbed to FIP had marked neurological disease at 
time of death. This suggests that the drug may be selecting for neurotropic viral mutations 
(Pedersen et al., 2017).  
The nucleoside analogue ‘GS-441524’ was demonstrated to be effective at suppressing FIPV in cell 
culture, so, following a pharmacokinetic study, was tested as a treatment for FIP in 10 
experimentally infected cats. Treatment reversed the signs of FIP in all 10 cats, and they remained 
healthy for the eight-month study follow up period (Murphy et al., 2018). Thirty-one naturally 
infected cats were then treated for FIP with GS-441524, and, of these, 25 cats recovered completely 
and remained healthy for the duration of the study (at least nine months follow up) or, in the case of 
one cat, died of an unrelated cause (Pedersen et al., 2019). GS-441524, possibly used in conjunction 
with GC376 or other antiviral drugs, presents an exciting novel therapeutic option for FIP. 
1.8 Prevention of FIP 
Prevention of FIP can be approached in two ways: prevention of FCoV transmission or prevention of 
the development of FIP from FCoV infection. The former is more applicable to multi-cat 
environments, while the latter is relevant to any FCoV-infected cat. 
1.8.1 Prevention of FCoV transmission 
FCoV, being such a common and contagious virus, is endemic in almost all breeding facilities, 
boarding catteries and shelters (Hartmann, 2005). The likelihood of FIP being present in a cattery 
was shown to increase with the size of the cattery (Kass, 1995), but it is unclear whether this is 
independent of there simply being a higher prevalence of FCoV. Though not appropriate for 
diagnosis of FIP, serum antibody titre and faecal RT-PCR are useful in multi-cat environments to 
check FCoV status, identify persistently infected individuals serving as a source of infection for other 
cats and monitor the impact of any changes implemented. Specific strategies to eradicate FCoV from 
such environments include quarantining cats that are shedding high levels of FCoV in faeces and 
early weaning and isolation of kittens (Addie et al., 2004, Addie et al., 2009, Drechsler et al., 2011), 
though these strategies can be impractical to implement.  
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Addie et al. (2019) looked at the role of cat litter in preventing the transmission of FCoV. The authors 
recommend the use of a non-tracking, Fuller’s earth-based litter based on its ability to prevent the 
virus from infecting cells in vitro, and possibly reduce viral transmission when used in a breeding 
household. As FCoV can survive for up to seven weeks in the environment and is spread via the 
faecal oral route, proper disinfection of litter boxes and all potentially contaminated surfaces is 
recommended to reduce transmission between individuals (Drechsler et al., 2011). 
1.8.2 Vaccination against FCoV 
Historically the aim of vaccination has not been to prevent the cat from becoming infected when 
challenged with FCoV, but rather to induce a state of premonition immunity that allows the cat to 
contain FCoV and prevent FIP from developing (Pedersen, 2009). 
Only one FCoV vaccine is in production, and it is commercially available only in the USA and some 
European countries: an intranasally-administered, temperature-sensitive FCoV mutant developed by 
passaging Type 2 FIPV strain DF2 in cell culture at 31 C followed by ultraviolet irradiation 
(Christianson et al., 1989). Its efficacy is controversial, with experimental and field studies reporting 
protection in 0 to 78% of cats (Olsen, 1993). The vaccine does not protect cats less than 16 weeks of 
age and is thought to be ineffective in individuals that have previously been exposed to FCoV (Addie 
et al., 2009, Drechsler et al., 2011), restricting the number of cats suitable for vaccination.  
Two studies have vaccinated cats with a recombinant vaccinia virus expressing the Type 2 FCoV S 
protein, but in both cases ADE resulted in decreased survival rate and time in vaccinated compared 
to unvaccinated cats when challenged with FIPV (Vennema et al., 1990, Klepfer et al., 1995). 
Similarly, Balint et al. (2014) found that a recombinant FCoV vaccine based on the Type 2 FIPV strain 
DF2 strain, generated via reverse genetics, induced ADE of disease in British Shorthair cats. 
Interestingly, the vaccine provided complete protection against an FIPV challenge to specific 
pathogen free cats, illustrating the importance of host factors in determining disease course. A DNA 
vaccine containing the FCoV M and N genes did not confer protection against an FIPV challenge and, 
when administered with a cytokine-encoding plasmid, again resulted in ADE of disease (Glansbeek et 
al., 2002). 
Through reverse genetics, Haijema et al. (2004) generated FIPVs, based on Type 2 strain 79-1146, in 
which ORF3a-c, ORF7a-b or both accessory gene clusters were deleted. These recombinant FIPVs 
replicated well in cell culture and all displayed an attenuated phenotype in vivo, inducing a humoral 
immune response but not producing clinical signs of disease. The study found that FIPV without 
ORF3a-c and FIPV without OFR7a-b provided protection against an FIPV challenge in 90% of cats 
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without any sign of ADE, whereas FIPV where both accessory gene clusters were deleted provided 
no protection and in fact appeared to speed up the progression of disease compared to the control 
group. The authors speculated that this could reflect the latter construct’s inability to induce cellular 
immunity. The performance of the vaccine in a non-experimental situation remains to be tested. 
1.8.3 Reducing the risk of FCoV developing into FIP 
In order to reduce the risk of FIP developing in a FCoV-infected individual, Addie et al. (2009) 
recommend minimising the number of cats in a household, keeping well-adapted sub-groups of no 
more than three cats, maintaining hygiene standards, allowing outdoor access and providing 
multiple litter trays that are cleaned regularly and kept away from food bowls. These measures aim 
to reduce stress, viral load and co-infections, all of which are known to contribute to FIP 
pathogenesis (Drechsler et al., 2011). Since a specific stressful event such as adoption or surgery is 
known to precipitate FIP in many cases (Riemer et al., 2015), it is logical to avoid such events in 
FCoV-infected cats wherever practically possible. 
1.8.4 Breeding FIP-resistant cats 
Hartmann (2005) recommends cessation of breeding from cats that produce two or more litters in 
which kittens develop FIP, based on the notion that susceptibility to FIP has a genetic basis. Recent 
studies have identified candidate genes that could contribute towards this susceptibility (Golovko et 
al., 2013, Pedersen et al., 2014, Wang et al., 2014), but the importance of individual genes in the 
complex pathogenesis of FIP has been called into question (Pedersen et al., 2016). On retrospective 
analysis of 145 cats seen at a referral hospital, Hsieh and Chueh (2014) identified a single nucleotide 
polymorphism (SNP) in the feline interferon-gamma (IFN-) gene where 20% of cats with the 
heterozygous genotype had FIP compared to 48% of homozygotes. This led to the development of a 
genetic test, now offered commercially, for ‘FIP resistance’. Unsurprisingly, doubt has been cast on 
the validity of this test because of its apparent attribution of FIP resistance to a single gene that is 
not even strongly associated with FIP. Kedward-Dixon et al. (2019) found no association between 
genotype and FIP status for SNPs in the IFN-, TNF-α and DC-SIGN genes. 
Attempts to selectively breed FIP-resistant cats found that survival following an FIPV challenge was 
actually decreased by positive selection (Pedersen et al., 2008, Pedersen et al., 2016). The authors 
hypothesise that this effect resulted from a loss of genetic diversity, which is in agreement with the 
finding that pedigree cats, who may exhibit decreased genetic diversity compared to non-pedigree 




1.9 In vitro propagation of FCoV 
The FCoV strain Black, first isolated and identified as a Type 1 FCoV in the 1970s, was successfully 
grown in cell culture following animal passage and has since been maintained in vitro in the Felis 
catus whole fetus (FCWF) cell line (Tekes et al., 2008). Regan et al. (2010) also describe infecting ex 
vivo feline dendritic cells, a feline-derived lung cell line named ‘AKD’ and Crandell feline kidney 
(CrFK) cells engineered to overexpress DC-SIGN with the Black strain. However, the strain is so 
adapted to cell culture that it can no longer be said to represent Type 1 FCoV found in the field 
(Tekes et al., 2012, Pedersen, 2009). A novel approach from Desmarets et al. (2013) involved 
developing an immortalised feline intestinal epithelial cell line to propagate Type 1 FCoV strains 
‘UCD’ and ‘UG-FH8’, which were originally obtained from clinical material and have since been 
passaged through live cats. The group were able to grow these viruses in cell culture, but titres 
obtained from this method were very low (around 102-103 PFU/ml). 
The majority of in vitro work has been carried out on Type 2 FCoV as it can easily be propagated in 
cell lines expressing fAPN on their surface (Pedersen, 2014b), such as CrFK cells (Miguel et al., 2002, 
Dewerchin et al., 2005, Harun et al., 2013). Conversely, a robust system for propagating field strains 
of Type 1 FCoV has not yet been developed (Pedersen, 2014b), likely due to the absence of cell lines 
that this virus can infect. This is compounded by a lack of knowledge about a Type 1 FCoV CER; this 
information would help to guide the search for a suitable cell line or would enable the development 
of a cell line stably expressing a Type 1 FCoV CER. By creating a chimeric virus comprising a Type 1 
FCoV backbone with a Type 2 FCoV spike, Tekes et al. (2010) demonstrated that the differences 
observed between the serotypes in vitro in receptor usage, cell tropism and replication kinetics is 
solely down to the S protein. This suggests that a cell line such as CrFK engineered to express a Type 
1 FCoV CER would likely support growth of this virus. 
1.9.1 Identification of coronavirus receptors 
The first coronavirus CER to be identified was that of mouse hepatitis virus (MHV). Williams et al. 
(1991) demonstrated that MHV bound to a glycoprotein in liver and intestinal brush border 
preparations, and that the sequence of the glycoprotein had a high homology with the human 
carcinoembryonic antigen family of proteins. Based on this evidence, Dveksler et al. (1991) reverse 
transcribed and PCR amplified the gene encoding murine carcinoembryonic antigen-related 
adhesion molecule 1 (mCEACAM1) from mouse RNA and expressed it in MHV-resistant cells, 
rendering them susceptible to infection with MHV and demonstrating that mCEACAM1 is a 
functional CER for MHV. 
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Porcine APN (pAPN) was first identified as a CER for TGEV when monoclonal antibodies were raised 
against cells susceptible to infection with TGEV, and an antibody that was able to block infection was 
taken forward. The protein that was precipitated from an intestinal brush border preparation by this 
monoclonal antibody was sequenced and identified as pAPN. Finally, pAPN was expressed in TGEV-
resistant cells and shown to render them permissive to infection with TGEV (Delmas et al., 1992). 
Similarly, human APN (hAPN) was identified as a CER for human coronavirus 229E (HCoV-229E) by 
demonstrating that previously uninfectable cells became infectable with HCoV-229E when 
engineered to express hAPN (Yeager et al., 1992). 
Based on the identification of APN as a CER for other Alphacoronaviruses, the role of fAPN in FCoV 
infection was explored. Stable expression of fAPN in FCoV-resistant mouse and hamster cell lines 
rendered them permissive to infection with Type 2 FCoV, demonstrating that fAPN is a functional 
receptor for this virus. Interestingly, fAPN was also shown to serve as a receptor for TGEV, HCoV-
229E and CCoV (Tresnan et al., 1996). Benbacer et al. (1997) then ascertained that APN is a CER for 
Type 2 but not Type 1 FCoV by expressing APN in FCoV-resistant cells and rendering them infectable 
by Type 2 FCoV only. Hohdatsu et al. (1998) confirmed this result by demonstrating that a 
monoclonal antibody raised against FCWF cells precipitated fAPN from an intestinal brush border 
preparation and blocked infection of FCWF by Type 2 but not Type 1 FCoV. However, FCWF cells do 
not normally support propagation of Type 1 FCoV so the virus used in this study must not represent 
a field strain. To definitively show that fAPN is not a CER for Type 1 FCoV, Dye et al. (2007) produced 
viral pseudotypes bearing the Type 1 FCoV spike protein and demonstrated that these constructs 
failed to recognise fAPN on three cell lines. 
Most recently, a CER for MERS-CoV was identified by Raj et al. (2013) using the ‘bait protein’ 
method. This method utilised a chimeric protein comprising the S1 domain of the MERS-CoV spike 
protein and the Fc region of human IgG. This chimeric bait protein was incubated with a lysate of 
cells susceptible to infection, and the protein it precipitated was identified as dipeptidyl peptidase 4 
(DPP4) using mass spectrometry. To demonstrate the functional relevance of DPP4 as a CER for 
MERS-CoV, experiments were then carried out to show that anti-DPP4 antibodies block infection of 
susceptible cells, and expression of DPP4 in previously MERS-CoV-resistant cells renders them 
permissive to infection. Since the start of this project, Zhang et al. (2017) have utilised a similar 
method to identify an interaction in chicken lung, kidney and proventriculus tissues between the 
avian infectious bronchitis virus (IBV) S1 protein and heat shock protein 70 (Hsp70), suggesting that 
the latter functions as part of the receptor complex for the virus. 
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1.9.2 Coronavirus reverse genetic systems 
Reverse genetics is the name given to an approach whereby the function of a genetic mutation is 
elucidated by engineering that mutation into a genome, in vitro, and observing the effect of the 
mutation on the organism’s phenotype. This is distinct from classical genetics, whereby a mutant 
phenotype is observed before the mutation underlying it is uncovered (Griffiths, 2000). Reverse 
genetic systems not only permit the study of targeted genetic changes in viral genomes, but also 
serve as powerful platforms for vaccine development through directed attenuation and targeted 
modifications (Stobart and Moore, 2014).  
The first coronavirus reverse genetic systems relied on targeted genetic recombination, where the 
tendency of coronaviruses to swap genetic material was exploited by introducing a synthetic donor 
RNA and recipient virus into the same cell and allowing them to naturally recombine (Cavanagh, 
2008). More recently, coronavirus reverse genetic systems have utilised the generation of full-length 
recombinant viruses, also known as ‘infectious clones’. For a time it was unclear whether it would be 
technically feasible to build infectious clones of such large viruses, but three methods have shown 
their construction to be possible: in vitro ligation, bacterial artificial chromosome (BAC) systems and 
vaccinia virus vectors (Almazan et al., 2014).  
For in vitro ligation, full-length cDNA is assembled from a panel of contiguous fragments spanning 
the viral genome. The fragments are generated either by RT-PCR from virus or synthesised de novo. 
Sequences are introduced to incorporate a T7 RNA polymerase promotor at the 5 end and a poly(A) 
tail at the 3 end of the construct. Older methods used silent mutations to insert restriction sites and 
avoid T7 transcription termination signals, but this has been overcome using Type IIS restriction 
enzymes. Type IIS enzymes recognise asymmetrical sites and cleave 1-4 nucleotides away from the 
recognition sequences, leaving overhangs that can only anneal with complementary DNA generated 
at an identical site. If fragments are designed so that the recognition sequence is cleaved from the 
fragment, the exact viral sequence is left behind resulting in seamless, directional cloning. The main 
advantage of in vitro ligation is that it is relatively simple and fast, and that cDNA fragments 
incorporating mutations of interest can easily be interchanged. Additionally, constructs generated 
through in vitro ligation can later be cloned into BAC and vaccinia systems if the correct flanking 
sequences are present (Almazan et al., 2014). This method, originally pioneered by Yount et al. 
(2000) to create a TGEV infectious clone, has been used to produce many recombinant 
coronaviruses but not FCoV. 
In a BAC system, viral genome fragments are assembled into a very low copy number synthetic 
plasmid which is maintained in bacterial cells. The advantages of this system are stable maintenance 
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of large DNA fragments and unlimited production of the cDNA clone. Additionally, features such as a 
CMV promoter or a synthetic poly(A) tail can be engineered into the plasmid, allowing recovery of 
infectious virus without an in vitro transcription step (Almazan et al., 2014). This system has been 
successfully used to build infectious clones of coronaviruses including a Type 2 FIPV (Balint et al., 
2012). 
In a vaccinia virus system, coronavirus cDNA fragments are assembled in vitro then ligated into 
vaccinia virus DNA. The ligation reaction is transfected into mammalian cells and recombinant 
vaccinia viruses containing the coronavirus cDNA are rescued. Purified vaccinia virus DNA is cleaved 
so that the coronavirus cDNA insert drops out, and the insert is transcribed in vitro. The advantages 
of this system are similar to those of the BAC system: the cDNA clone is maintained stably and can 
be produced infinitely through infection of cells with the recombinant vaccinia virus. Additionally, 
vaccinia virus-mediated homologous recombination can be used to easily introduce modifications 
into the coronavirus genome. However, generation of recombinant vaccinia viruses is time-
consuming because it involves all the work of in vitro ligation with additional steps to ligate the 
construct into vaccinia virus then remove it again for transcription (Almazan et al., 2014). Since the 
start of this project, the vaccinia virus method has been utilised by Ehmann et al. (2018) to build the 
first Type 1 FCoV infectious clone representing a field strain of the virus. 
Development of a cell line supporting the in vitro propagation of field strains of Type 1 FCoV would 
be an important component of a Type 1 FCoV reverse genetic system, as it would enable in vitro 
recovery of recombinant viruses.  
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1.10 Aims of the project 
Despite recent progress in the field of treatment, most cases of FIP are fatal and cause a great deal 
of suffering, not only to the affected cat but to those who care for that cat. A better understanding 
of how FIP develops from FCoV, and particularly biologically relevant field strains of Type 1 FCoV, will 
be indispensable for the rational design of vaccines, treatments and prevention strategies. 
That is why the overall aim of this project is to establish a reverse genetic system based on a field 
strain of Type 1 FCoV. Such a system would allow the effect of a given mutation on the phenotype of 
the virus to be elucidated, providing insight into FIP pathogenesis. In order to achieve that overall 
aim, the specific aims of this project are: 
1. To develop cDNA infectious clones corresponding to full-length Type 1 FCoV, chimeric Type 1 
FCoV with a Type 2 S gene and sub-genomic replicons, and to test the ability of the clones to 
replicate in cell culture. 
2. To identify a CER for Type 1 FCoV, for the purpose of developing a cell line that can support 
in vitro propagation of the virus, 
3. To explore the use of the feline IFN- ELISpot assay in measuring T cell response to viral 
epitopes, for the purpose of identifying mutations that may be of use for engineering 
attenuated recombinant viruses. 
In this project, cDNA infectious clones will form the basis of the reverse genetic system. A specific 
aim of this project is therefore to develop cDNA infectious clones corresponding to full-length Type 
1 FCoV, chimeric Type 1 FCoV with a Type 2 S gene and sub-genomic replicons, and to test the 
ability of the clones to replicate in cell culture. At the commencement of this project there was no 
report of a reverse genetic system based on a field strain of Type 1 FCoV in the literature, so its 
development would have been novel. Ehmann et al. (2018) have since published a report detailing 
their establishment of such a system, and this will be discussed further in chapters 3 and 6.  
A major limitation with the study by Ehmann et al. (2018), and something that has long impeded 
FCoV research, is absence of a cell line in which Type 1 FCoV can be propagated. The authors had no 
choice but to use their recombinant Type 1 FCoV to directly infect live cats, when an in vitro 
characterisation stage may have been more informative. Desmarets et al. (2013) developed an 
immortalised feline intestinal epithelial cell line in which Type 1 FCoV can be grown, but this cell line 
is unavailable to other researchers. A way to rescue recombinant virus in vitro would certainly be 
important to this project, since we plan to use the reverse genetic system to explore the effect of 
viral mutations on viral phenotype in vitro. 
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A specific aim of this project is therefore to identify a CER for Type 1 FCoV. Knowledge of a CER that 
Type 1 FCoV uses would allow this receptor to be stably expressed in a feline cell line. Such a cell line 
should support propagation of this serotype, and therefore enable rescue of recombinant Type 1 
FCoV and its characterisation in vitro. 
An important potential use of the reverse genetic platform is the rational design and production of a 
vaccine against FIP. Reverse genetics has been used to generate candidate vaccines against FIP but 
these have been based on Type 2 FIPVs (Haijema et al., 2004, Balint et al., 2014) so their biological 
relevance is questionable. An effective vaccine against FIP would likely have to mimic natural FIP 
resistance, where a cat becomes infected with a relatively avirulent strain of Type 1 FCoV then is 
able to contain that infection and prevent it from developing into FIP. The factors that contribute to 
this disease outcome are not entirely understood, but a robust cellular immune response is thought 
to play an important part (Pedersen, 2014b). 
Based on this idea, another specific aim of this project is to explore the use of the feline IFN- 
ELISpot assay in measuring T cell response to viral epitopes. Within this project, a feline ELISpot 
assay that measures the production of IFN- will be optimised and used to analyse the effect of a 
specific FCoV mutation in a known T cell epitope. T cells will be stimulated by exposing peripheral 
blood mononuclear cells (PBMC) to peptides with and without the mutation. IFN- ELISpot 
represents a tool for identifying the FCoV epitopes that are best able to elicit a cellular immune 
response, and with this knowledge any candidate vaccines generated by the reverse genetic 




2 Materials and methods 
2.1 Materials 
2.1.1 Cell culture media 
Cell line medium Dulbecco’s modified Eagle medium (DMEM) with high 
glucose, GlutaMAX supplement and pyruvate (Thermo-
Fisher, Massachusetts, USA), supplemented with 1% (v/v) 
penicillin-streptomycin (10,000 U/ml; Thermo-Fisher), 100 
µM non-essential amino acids (Sigma-Aldrich, Gillingham, 
UK) and 10% (v/v) heat-inactivated fetal bovine serum (FBS; 
Thermo-Fisher) 
Epithelial cell medium DMEM/Nutrient F-12 Ham, supplemented with 2 mM L-
glutamine (Thermo-Fisher), 1% (v/v) penicillin-streptomycin, 
one HCM SingleQuots growth supplement pack (Lonza, 
Basel, Switzerland) and 5% (v/v) heat-inactivated FBS 
PBMC medium RPMI 1640 (Lonza), supplemented with 2 mM L-glutamine, 
1% (v/v) penicillin-streptomycin and 10% (v/v) heat-
inactivated FBS 
Primary culture medium Advanced DMEM/F12 (Thermo-Fisher) supplemented with 2 
mM L-glutamine, 1% (v/v) penicillin-streptomycin and 20% 
(v/v) heat-inactivated FBS 
2.1.2 Bacterial culture media 
Super optimal broth with catabolite repression (SOC) medium 20.0 g/l tryptone, 5.0 g/l yeast 
extract, 0.5 g/l NaCl, 5.0 g/l MgSO4, 
0.2 g/l KCl, 2.03 g/l MgCl2 and 3.6 
g/l glucose 
Luria broth (LB) agar plates 10 g/l tryptone, 5 g/l yeast extract, 
10 g/l NaCl and 15 g/l agar 
LB medium  10 g/l tryptone, 5 g/l yeast extract 
and 10 g/l NaCl 
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2.1.3 Solutions, buffers and detergents 
Phosphate buffered saline (PBS) 138 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM 
KH2PO4 
Tris-borate-EDTA (TBE)   89 mM Tris base, 89 mM boric acid, 2 mM EDTA 
Tris-acetate-EDTA (TAE)   40 mM Tris base, 20 mM acetic acid, 1 mM EDTA 
Annealing buffer   50mM Tris-HCl pH 8.0, 100 mM NaCl, 1mM EDTA 
SDS-PAGE sample buffer; 2x 7 ml 0.5 M Tris-HCl pH6.8, 3 ml Glycerol, 1.2 g SDS, 1.2 mg 
Bromophenol blue, made up to 30 ml with deionised water 
Coomassie Blue staining solution 0.575 g Coomassie Brilliant Blue R-250, 200 ml methanol, 50 
ml glacial acetic acid, made up to 250 ml with deionised 
water 
Destaining solution 100 ml methanol, 50 ml glacial acetic acid, 350 ml deionised 
water 
Transfer buffer 100 ml methanol, 12.5 g Tris base, 5.63 g glycine, made up 
to 500 ml with deionised water 
Cell surface lysis buffer 5 ml PBS containing 1 cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail tablet (Roche, Basel, Switzerland) and 
0.3% (w/v) n-Dodecyl ß-D-maltopyranoside (Thermo-Fisher) 
Whole cell lysis buffer 20 mM Tris HCl pH 8, 137 mM NaCl, 1% (v/v) Triton X-100, 2 
mM EDTA with 1 cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail per 5 ml 
Elution buffer 70% (v/v) water, 5% (v/v) β-mercaptoethanol, 25% (v/v) 4x 





Antibody Manufacturer and 
catalogue number 
Application Concentration 
Rabbit anti-human IgG 
Fc antibody 
Thermo-Fisher; 31142 Primary antibody in 
western blot 




California, USA;  
PI-1000 
Secondary antibody in 
western blot 





Secondary antibody in 
western blot 





Primary antibody in 
western blot  
Primary antibody in 
immunofluorescence 
1 in 2000 
 
1 in 100 





Secondary antibody in 
flow cytometry 
Secondary antibody in 
immunofluorescence 
1 in 100 to 1 in 1000 
 
1 in 1000 
 
Mouse anti-FLAG Sigma-Aldrich; F1804 Primary antibody in 
western blot  
Primary antibody in 
immunofluorescence 
1 in 1000 
 
1 in 500 
Goat anti-human IgG 
DyLight 488-
conjugated antibody 
Abcam; ab97003 Secondary antibody in 
immunofluorescence 




Santa Cruz, Dallas 
USA; sc-65653 
Primary antibody in 
immunofluorescence 
1 in 100 





Secondary antibody in 
immunofluorescence 
1 in 700 
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Secondary antibody in 
immunofluorescence 
1 in 1000 





Secondary antibody in 
immunofluorescence 




2.2 Cell culture methods 
2.2.1 Cell lines 
Cell lines used were human embryonic kidney 293T (HEK293T; CRL-3216, American Type Culture 
Collection, Virginia, USA), Crandell feline kidney (CrFK; CCL-94, American Type Culture Collection), 
DH82 (CRL-10389, American Type Culture Collection), feline embryo-A (FE-A) (Jarrett et al., 1973), 
baby hamster kidney (BHK-21; CCL-10, American Type Culture Collection) and L-WRN (CRL-3276, 
American Type Culture Collection) cells. Cells were were grown at 37 °C in a humidified incubator 
with 5% CO2 on cell culture plates or flasks. Cells were passaged when approximately 90% confluent 
by washing once with phosphate buffered saline without calcium and magnesium (PBS; Thermo-
Fisher), detaching from the flask with 0.05% (v/v) trypsin-EDTA in PBS (Thermo-Fisher), adding cell 
line medium and harvesting the cells by centrifugation at 300 x g for 3 minutes. The cell pellet was 
resuspended in cell line medium and an aliquot was used to seed a new culture vessel. 
2.2.2 Intestinal epithelial cells 
Gut samples were obtained from cats euthanased for clinical reasons not related to this study. 
Ethical approval was awarded and owner consent obtained for post-mortem examination and 
collection of tissue samples for research (University of Bristol veterinary investigation number 
VIN/14/013) and the use of these samples in cell culture (University of Bristol veterinary 
investigation number VIN/16/033). As soon as possible after euthanasia, approximately 1 cm lengths 
of jejunum, ileum and colon were removed and placed in cold, neat histidine tryptophan 
ketoglutarate (Pharmapal Ltd, Elstree, UK) on ice. Visible fat and connective tissue was removed 
from the intestine, it was opened longitudinally, then it was washed three times in PBS containing 
1% (v/v) penicillin-streptomycin (10,000 U/ml; Thermo-Fisher) and 1 µg/ml amphotericin-B (Sigma-
Aldrich).  
The epithelial cells were isolated from intestinal tissue as described by Desmarets et al. (2013) with 
some modifications, whereby the tissue was digested with 0.4 mg/ml collagenase (Thermo-Fisher) 
and 1.2 mg/ml dispase (Sigma-Aldrich) for 1 hour with a refreshment of medium in the middle of the 
incubation time. The digested intestinal mucosa was scraped with a sterile scalpel blade into warm 
DMEM (Thermo-Fisher) supplemented with 1.2 mg/ml dispase for 10 minutes with constant 
pipetting. The resulting cell suspension was passed through a 70 µm cell strainer and centrifuged at 
500 x g for 10 minutes. The cell pellet was resuspended in epithelial cell medium and grown at 37 °C 
in a humidified incubator with 5% CO2 on cell culture plates or flasks. 
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2.2.3 Peripheral blood mononuclear and monocyte-derived cells 
Feline whole blood, from which PBMC were isolated, was obtained as surplus from routine 
venepuncture of cats undergoing diagnostic testing for an unrelated condition, or post mortem from 
cats euthanased for clinical reasons not related to this study. Ethical approval was awarded and 
owner consent obtained for collection of surplus material from patients (University of Bristol 
veterinary investigation number VIN/14/020), for post mortem examination and collection of tissue 
samples for research (University of Bristol veterinary investigation number VIN/14/013) and the use 
of these samples in cell culture (University of Bristol veterinary investigation number VIN/16/033). 
Approximately 1 ml of blood was collected into tubes containing EDTA (whichever used normally by 
the veterinary practice in which the blood was being taken), stored at room temperature and 
processed as soon as practically possible after collection (usually within two days). 
After removing the plasma, blood was resuspended in 6 ml PBMC medium. This was carefully 
layered onto 6 ml of Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) in a second 15 ml Falcon tube, 
using a Pasteur pipette, before centrifugation at 1,000 x g for 20 minutes with the brake off. A 
Pasteur pipette was then used to aspirate the buffy coat and transfer it to a third 15 ml Falcon tube. 
The buffy coat was topped up to 14 ml with PBMC medium before gentle inversion and 
centrifugation at 700 x g for 10 minutes. The supernatant was discarded, and the pellet resuspended 
in 5 ml PBMC medium. 
The resulting PBMC were either used in an ELISpot assay (section 2.4.1), applied to a glass slide by 
cytocentrifugation at 1,000 rpm for 5 minutes using a Cytospin 4 (Thermo-Fisher) for use in an 
immunofluorescence assay (section 2.4.10) or cultured to obtain monocyte-derived macrophages. 
For the latter, 5-6 x 105 live (as determined by mixing an equal volume of cell suspension and trypan 
blue, transferring into a counting chamber and counting only cells that did not take up the stain) 
PBMC in 1 ml PBMC medium were seeded into each well of a 24 well plate containing a glass 
coverslip. After 24 hours, the cells were gently washed twice with warm medium to remove non-
adherent cells. The resulting cell population was cultured in PBMC medium for a further 4 days to 
obtain monocyte-derived macrophages. 
2.2.4 Intestinal organoids 
2.2.4.1 Making conditioned medium 
Conditioned medium was made by following the ‘small scale preparation’ protocol of Miyoshi and 
Stappenbeck (2013). L-WRN cells were grown in cell line medium at 37 °C in a humidified incubator 
with 5% CO2 in cell culture flasks, in the presence of 500 µg/ml G418 (Thermo-Fisher) and 500 µg/ml 
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hygromycin B (Thermo-Fisher). Cells were passaged when confluent by washing once with PBS, 
detaching from the flask with 0.05% (v/v) trypsin-EDTA in PBS, adding cell line medium and using 
aliquots of the cell suspension to seed new flasks. Cells were grown in cell line medium at 37 °C in a 
humidified incubator with 5% CO2 (without G418 and hygromycin) until overconfluent, then the cell 
line medium was replaced with primary culture medium. The medium was collected and replaced 
every 24 hours, centrifuged at 2000 x g for 5 minutes to remove cells, pooled and diluted with an 
equal volume of primary culture medium. The resulting conditioned medium was stored in aliquots 
at -20 C and kept for two weeks once thawed. 
2.2.4.2 Isolating feline intestinal crypts 
Gut samples were obtained from cats euthanased for clinical reasons not related to this study. 
Ethical approval was awarded and owner consent obtained for post-mortem examination and 
collection of tissue samples for research (University of Bristol veterinary investigation number 
VIN/14/013) and the use of these samples in cell culture (University of Bristol veterinary 
investigation number VIN/16/033).  
As soon as possible after euthanasia, an approximately 1 cm length of ileum was removed and 
placed in PBS on ice. The tissue was trimmed to remove connective tissue and fat, then opened 
longitudinally. The lumen was washed with cold PBS, then the whole piece of tissue was shaken 
vigorously in a tube containing cold PBS. The tissue was cut into approximately 1 cm3 pieces and 
washed again with cold PBS. The tissue was placed in cell line medium, then the luminal surface was 
gently scraped with a sterile scalpel blade to remove villi. The tissue pieces were minced using 
scissors, then incubated in 2 mg/ml collagenase (Thermo-Fisher) in cell line medium for 90 minutes 
with frequent agitation. The resulting digest was passed through a 70 µm cell strainer (Thermo-
Fisher) and the filtrate centrifuged at 50 x g for 5 minutes. The pelleted cells (including crypt cells) 
were washed twice in cell line medium, resuspended in Matrigel matrix (growth factor reduced, 
phenol red free; catalogue number 356234; Corning, New York, USA) and pipetted on to a cell 
culture plate. The Matrigel domes were set at 37 °C for at least 5 minutes then submerged in 
conditioned medium supplemented with 10 µM Y-27632 (Enzo Life Sciences, Exeter, UK), 10 µM SB-
43154 (Stemcell, Vancouver, Canada) and 10 mM nicotinamide (Sigma-Aldrich). 
2.2.4.3 Growing and passaging intestinal organoids 
Murine intestinal organoids (a gift from Dr Rhiannon Jenkinson, University of Bristol) were cultured 
at 37 °C in a humidified incubator with 5% CO2 in 48-well plates and passaged every 7 days. They 
were liberated from Matrigel matrix by adding 1 ml ice cold PBS, then mechanically dissociated by 
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pipetting vigorously and passing through a 27 G needle. The organoids were transferred to 5 ml ice 
cold PBS and centrifuged at 150 x g for 10 minutes at 4°C. 
Feline intestinal organoids (isolated in-house as described in section 2.2.4.2 or a gift from Dr Michael 
Behnke, University of Louisiana, USA) were cultured at 37 °C in a humidified incubator with 5% CO2 
in 24-well plates and passaged every 3-7 days. They were liberated from Matrigel matrix by adding 
200 µl 0.125% (v/v) trypsin-EDTA in PBS and suspending the matrix by pipetting with a 1,000 µl 
pipette, then incubated at 37 °C for 5 minutes. 500 µl cell line medium were added and the 
organoids were transferred to 5 ml cell line medium and centrifuged at 200 x g for 5 minutes. 
In both cases, the supernatant was taken off except for 200 µl, and the organoids were resuspended 
and transferred to a 1.5 ml microcentrifuge tube. Muramyl dipeptide (Bio-Techne, Abingdon, UK) 
was added to a final concentration of 10 µg/ml and this was incubated at room temperature for 10 
minutes. 1 ml cell line medium was added, and the organoid suspension was centrifuged at 200 x g 
for 5 minutes. The supernatant was taken off and the organoids were resuspended in Matrigel 
matrix. 20 µl domes were pipetted on to a new plate, and these were set at 37 °C for at least 5 
minutes. 350-500 µl medium were added per well. For feline organoids the medium was conditioned 
medium supplemented with 10 µM Y-27632, 10 µM SB-43154 and 10 mM nicotinamide. For murine 
organoids the medium was conditioned medium supplemented with 10 µM Y-27632 and 10 µM SB-
43154, IntestiCult Organoid Growth Medium Human (Stemcell) or IntestiCult Organoid Growth 




2.3 DNA and RNA techniques 
2.3.1 Plasmid design and production 
2.3.1.1 Bait protein plasmids 
Quirke (2016), a previous Master of Research student in the laboratory, cloned DNA inserts encoding 
Type 1 and Type 2 bait proteins (~3,100 bp) into the mammalian expression vector pCAGGS 
(GenBank accession number LT727518.1). The bait protein DNA inserts, designed by Professor Stuart 
Siddell (University of Bristol), encode the S1 domain of Type 1 FCoV 80F strain (GenBank accession 
number KP143511.1) or Type 2 FCoV 79-1146 (GenBank accession number DQ010921.1) fused to the 
Fc region of human IgG. The S1 domains were codon optimized for translation in human cells, 
putative splice donor and receptor sites were removed and restriction enzyme cloning site 
sequences were added onto each end. Bait protein coding sequences are in Appendix A 
Used as a positive control for transfection, pmaxGFP (Lonza) is a 3,486 bp vector containing a green 
fluorescent protein gene under the control of a cytomegalovirus promoter. 
2.3.1.2 Infectious clone plasmids 
cDNA fragments comprising the Type 1 FCoV 80F strain, Type 2 FCoV 79-1146 strain S gene, green 
fluorescent protein/puromycin (GFP puro) resistance coding sequence and Renilla luciferase coding 
sequence were designed using EMBOSS Sixpack and Microsoft Word software. Fragment sequences 
were submitted to Twist Bioscience (San Francisco, USA) for synthesis and cloning into the 2,221 bp 
vector pTwist 31 pMB1-Amp-UCS1.2. Fragment sequences are in Appendix A. 
Some unstable or potentially toxic sequences were cloned into the low copy number vector pWSK29 
(GenBank accession number AF016889.1). 
Additional oligonucleotides were designed using Microsoft Word and NEBCutter V2.0 software (New 
England BioLabs (NEB), Massachusetts, USA), and were synthesised by Eurofins Genomics 
(Ebersberg, Germany). The oligonucleotide sequences are in Appendix A. 
2.3.1.3 HSPA1A plasmid 
A translated BLAST (NCBI, Bethesda, USA) search was carried out based on the amino acid sequence 
of the feline HSPA1A protein (Uniprot accession number A0A337RXE8_FELCA), which identified 
LOC105260573 as the encoding gene. The coding sequence was identified using ExPASy translate 
tool (Swiss Institute of Bioinformatics, Lausanne, Switzerland), edited to incorporate a 3xFLAG tag 
and restriction endonuclease sites (Not I and Eco RI) using Microsoft Word and checked for 
restriction endonuclease sites using NEBCutter V2.0 software. 
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The HSPA1A construct was cloned into the pEX-A258 vector by Eurofins Genomics, then subcloned 
into the mammalian expression vector pcDV4 (Hannemann et al., 2013). 
2.3.2 Bacterial transformation and subsequent harvesting of plasmid DNA 
Alpha select chemically competent cells (Bioline, London, UK) or 5-alpha competent Escherichia coli 
(NEB) were incubated with 5 ng of plasmid DNA on ice for 30 minutes. The cells were then heat 
shocked at 42 C for 30 seconds before another incubation on ice for 2 minutes. 950 µl SOC medium 
was added and the cells incubated at 37 °C for 1 hour with shaking (220 rpm) in an orbital shaker, 
then the resulting bacterial suspension was spread on LB agar plates containing 100 μg/ml ampicillin 
(Sigma-Aldrich) and incubated at 28-37 °C until colonies reached the desired size. 
Colonies were picked and inoculated into LB medium containing 100 μg/ml ampicillin before 
incubation at 28-37°C with shaking (220 rpm) in an orbital shaker. Plasmid DNA was extracted from 2 
ml, 50 ml and 200 ml of bacterial culture using a GeneJET Plasmid Miniprep, GeneJET Plasmid 
Midiprep or PureLink HiPure Plasmid Filter Maxiprep Kit (Thermo-Fisher) respectively, following the 
manufacturer’s instructions. When dealing with low copy number plasmids, double the volume of 
bacterial culture was processed. 
2.3.3 PCR 
10 ng of DNA to be amplified by PCR were incubated with 10 µl OneTaq standard reaction buffer (5x; 
NEB), 200 µM deoxyribonucleotide triphosphates (dNTPs), 0.2 µM each of forward and reverse 
primer and 2.5 units OneTaq DNA polymerase (NEB) in a total volume of 50 µl.  
When a DNA fragment >5,000 bp was to be amplified, 10 ng of DNA were incubated with 10 µl 
Phusion HF buffer (5x; NEB), 200 µM dNTPs, 0.5 µM each of forward and reverse primer and 1 unit 
Phusion DNA polymerase (NEB) in a total volume of 50 µl. 
For long-range PCR, 10 ng of DNA were incubated with 25 µl GoTaq Long PCR Master Mix (2x; 
Promega, Madison, USA) and 0.5 µM each of forward and reverse primer in a total volume of 50 µl. 
In all cases, the volume was brought up to 50 µl with deionised water, and a PCR programme with 
step lengths and times appropriate to the primers and enzymes was carried out in a GS1 
thermocycler (G-Storm, Somerset, UK). See Appendix B for the thermocycler programmes used. 
A proportion of the resulting DNA was analysed by electrophoresis through a 0.7-1.0% TBE or a 0.4% 
TAE agarose gel (section 2.3.6). The remaining DNA was purified using a GeneJet PCR Purification Kit 
(Thermo-Fisher) following the manufacturer’s instructions, or by phenol chloroform extraction and 
ethanol precipitation (section 2.3.12). 
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PCR primers were chosen manually and checked using Multiple Primer Analyzer software (Thermo-
Fisher). For a list of PCR primers, see Appendix A. 
2.3.4 RT-PCR 
RNA was reverse transcribed and amplified by PCR in a one-step RT-PCR reaction. 10-50 ng of RNA 
was incubated with 25 µl Platinum™ SuperFi™ RT-PCR Master Mix (2x; Thermo-Fisher), 10 µM each 
of forward and reverse primer and 0.5 µl SuperScript™ IV RT Mix (Thermo-Fisher). The volume was 
brought up to 50 µl with deionised water and, following an incubation for 10 minutes at 50 C, a PCR 
programme with step lengths and times appropriate to the primers and enzymes (Appendix B) was 
carried out in a GS1 thermocycler. 
2.3.5 Restriction enzyme digestion 
Appropriate restriction enzymes (NEB) were used to digest DNA in a total volume of 15-50 µl for 1-2 
hours in the buffer and at the temperature specified by the manufacturer.  
The resulting products were analysed by electrophoresis through a 0.7-1.0% TBE agarose gel (section 
2.3.6). 
2.3.6 Agarose gel electrophoresis 
Samples containing DNA were diluted with nuclease-free water and 6x gel loading dye (NEB) in an 
appropriate volume, and electrophoresed through a 0.7-1.0% TBE agarose gel (0.7-1.0% (w/v) 
UltraPure agarose (Thermo-Fisher) in TBE) at 100 V for 40 minutes, or a 0.4% TAE agarose gel (0.4% 
(w/v) agarose in TAE) at 15 V for 24 hours. Electrophoresis was performed in 1x TBE or TAE buffer. 
Both the gel and buffer contained 0.5 μg/ml ethidium bromide (Sigma-Aldrich). 
Following electrophoresis, the gel was imaged on a UVP BioDoc-ITTM System Ultraviolet 
transilluminator (UVP, California, USA) to estimate the size of the DNA fragment(s) compared to a 
GeneRuler™ 1 kb Plus (Thermo-Fisher) or λ DNA-Mono Cut Mix (NEB) DNA Ladder.  
2.3.7 DNA gel extraction 
DNA that had undergone restriction digestion and agarose gel electrophoresis was visualised briefly 
using the UVP BioDoc-ITTM System Ultraviolet or Dark Reader (Clare Chemical Research, Colorado, 
USA) transilluminator, and the band corresponding to the desired product was excised from the gel. 
DNA was extracted from the gel slice using a GeneJET Gel Extraction Kit (Thermo-Fisher) following 
the manufacturer’s instructions.  
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2.3.8 Antarctic phosphatase digestion 
Approximately 3 µg DNA digested by restriction enzyme was incubated with 15 units Antarctic 
Phosphatase (NEB) and 6 µl Antarctic Phosphatase buffer (10x; NEB). The volume was brought up to 
60 µl with deionised water and incubated at 37 °C for a further 30 minutes. 
The product was purified using a GeneJet PCR Purification Kit (Thermo-Fisher) following the 
manufacturer’s instructions. 
2.3.9 NEBuilder HiFi DNA assembly 
DNA fragments with 25 bp overlapping regions were ligated together using the NEBuilder HiFi DNA 
assembly protocol as described by the manufacturer (NEB). Briefly, fragments were incubated 
together in a 1:2 vector:insert molar ratio, in a maximum volume of 10 µl and a maximum molarity 
of 0.2 pmols. To this, 10 µl NEBuilder HiFi DNA Assembly Master Mix was added and the volume was 
brought up to 20 µl with deionised water. The mixture was incubated at 50 °C for 1 hour. 2 µl of the 
reaction mixture was used to transform chemically competent bacterial cells, following the 
procedure described in section 2.3.2. 
2.3.10 Oligonucleotide ligation 
Oligonucleotides were diluted to 40 ng/µl in annealing buffer and incubated as complementary pairs 
at 95 °C for 5 minutes. The reaction was cooled gradually to room temperature over 45 minutes to 
allow oligonucleotide annealing. 
2.3.11 T4 DNA ligation 
2.3.11.1 Ligating inserts into vectors 
DNA fragments that had undergone restriction digestion or oligonucleotide ligation to form 
complementary oligonucleotide pairs with cohesive ends were incubated together in a 1:3 to 1:6 
vector:insert molar ratio, with 2 µl T4 DNA ligase buffer (10x; NEB) and 1 µl T4 DNA ligase (NEB). The 
volume was brought up to 20 µl with deionised water. This was incubated at room temperature for 1 
hour before enzyme inactivation at 65 °C for 10 minutes. 
2.3.11.2 Ligating full-length infectious clones 
DNA ‘units’ collectively comprising full-length infectious clones were incubated together in an 
equimolar ratio and approximately 5.5 µg total DNA, with 20 µl T4 DNA ligase buffer and 20 µl T4 




A proportion of the ligation reaction was analysed by electrophoresis through a 0.4% TAE agarose 
gel. The remainder of the ligation reaction was purified by phenol chloroform extraction and ethanol 
precipitation (section 2.3.12) and used as a template for transcription.  
2.3.12 Phenol chloroform extraction and ethanol precipitation 
One volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to one volume of a DNA 
containing solution and this was shaken by hand for 2 minutes before centrifugation at 13,000 × g 
for 5 minutes. The upper aqueous phase was removed and set aside, one volume of deionised water 
was added to the original sample and this was shaken by hand for 2 minutes before centrifugation at 
13,000 × g for 5 minutes. The upper aqueous phase was again removed and set aside. 
DNA was precipitated from the aqueous phase by adding a 0.1 volume of 3 M sodium acetate (pH 
5.2) followed by 2.5 volumes of 100% ethanol. The solution was incubated at -20 °C for at least 30 
minutes and the precipitate collected by centrifugation at 13,000 x g at 4 °C for 20 minutes. The 
pellet was washed with 70% ethanol, collected again by centrifugation and finally dried and 
resuspended in nuclease-free water. 
2.3.13 DNA Sequencing 
2.3.13.1 Sanger sequencing 
DNA was submitted to Eurofins Genomics for Sanger sequencing. Sequencing data was compiled and 
analysed in BioEdit version 7.0.5.3 software. For a list of sequencing primers, see Appendix A. 
2.3.13.2 Next generation sequencing 
cDNA amplicons generated by RT-PCR were pooled in an equimolar fashion and submitted to the 
Genomics Facility, University of Bristol, for next-generation sequencing. Samples were prepared for 
sequencing using a TruSeq Nano DNA Library Preparation kit (Illumina, California, USA) and were 
sequenced using a MiSeq Version 2 2x250bp Nano platform (Illumina). 
Reads were aligned against a reference genome using Bowtie2 software accessed through the 
Galaxy online bioinformatics suite. Alignments were visualised using Integrative Genomics Viewer 
(IGV) software.  
2.3.14 RNA transcription 
Transcription of RNA from DNA template was carried out using a mMessage mMachine T7 kit 
(Thermo-Fisher) following the protocol specified by the manufacturer with minor modifications. 
Briefly, 0.1-10 µg template DNA was incubated with 10 µl NTP/CAP (2x), 2 µl reaction buffer (10x), 2 
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µl enzyme mix and, when transcribing full-length infectious clones, 3 µl GTP (final cap analog:GTP 
ratio of 1:1). The volume was brought up to 20 µl with nuclease-free water. This was incubated at 37 
°C for 2 hours. 1 µl of TURBO DNase was added and this was incubated at 37 °C for 15 minutes. 
The resulting RNA was purified by lithium chloride precipitation as specified by the kit manufacturer 
and was analysed for yield and purity on a NanoDrop 1000 spectrophotometer (Thermo-Fisher). 
2.3.15 Denaturing agarose gel electrophoresis 
5 ml 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (10x; Thermo-Fisher), 9 ml 37% 
formaldehyde (Sigma-Aldrich) and 25 µg ethidium bromide were added to 0.5 g agarose dissolved in 
36 ml nuclease-free water. This gel was poured and set in a tray, then assembled in an 
electrophoresis tank submerged in 1x MOPS buffer containing 50 µg ethidium bromide per 100 ml of 
buffer. 
RNA samples were prepared by adding one volume of NorthernMax Formaldehyde Load Dye 
(Thermo-Fisher) and incubating at 70 °C for 10 minutes. Ethidium bromide was added directly to the 
samples to a final concentration of 10 µg/ml, and the samples were run through the gel at 100 V 
until the bromophenol blue marker had migrated two thirds of the gel’s length. The gel was 
destained in nuclease-free water overnight before RNA bands were visualised using a UVP BioDoc-
ITTM System Ultraviolet transilluminator. 
2.3.16 RNA transfection into mammalian cells 
Cells were grown in cell culture plates in cell line medium at 37 °C and 5% CO2 for ~24 hours (cells at 
60-90% confluency). The RNA transfection mixture was prepared using the TransMessenger 
Transfection Reagent kit (Qiagen, Venlo, the Netherlands) as specified by the manufacturer, using an 
RNA:TransMessenger Transfection Reagent ratio of 1:4. Medium was removed from the cells, they 
were washed once with PBS and the transfection mixture was added dropwise. This was incubated 
at 37 °C and 5% CO2 for 3 hours, then the transfection mixture was removed. The cells were washed 
once with PBS and an appropriate volume of cell line medium was added back into the wells. 
Following transfection with the replicon construct, BHK or CrFK cells were recovered for 24 hours 
before being transferred to a 25 cm2 cell culture flask. After another 24 hours, 1.5 µg/ml or 5 µg/ml 
puromycin (Sigma-Aldrich) was added to the medium to select for successfully transfected BHK and 
CrFK cells respectively. 
Following transfection with the infectious clone construct, the culture supernatant was harvested 
after 2 days and either stored at -80 °C for analysis or passaged on to CrFK cells (passage 1). The 
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cells, which had been grown on glass coverslips, underwent an immunofluorescence assay (section 
2.4.10). After 5 days, the passage 1 culture supernatant was harvested and either stored at -80 °C for 
analysis or passaged on to CrFK cells (passage 2). After 5 days, the passage 2 culture supernatant was 
harvested and stored at -80 °C for analysis. 
2.3.17 DNA transfection into mammalian cells 
For bait protein production, HEK293T cells were seeded in 6-well plates at 3 x 105 cells in 2.5 ml cell 
line medium per well. For pHSPA1A transfection, CrFK cells were seeded in either 6-well plates at 1 x 
105 cells in 2.5 ml cell line medium per well, or 24-well plates containing glass coverslips at 2 x 104 
cells in 1 ml cell line medium per well. 
After culturing at 37 °C and 5% CO2 for ~24 hours (cells at 60-90% confluency), the cell line medium 
was removed and the transfection mixture (10 µl Lipofectamine 2000 (Thermo-Fisher) and 4 µg 
sterile plasmid DNA per transfection reaction for 6-well plates or 2 µl Lipofectamine 2000 and 0.5 µg 
sterile plasmid DNA per transfection reaction for 24-well plates, prepared in Opti-MEM Reduced 
Serum Medium (Thermo-Fisher) according to the manufacturer’s instructions) was added dropwise. 
This was incubated at 37 °C and 5% CO2 for 3 hours. The transfection mixture was then carefully 
removed and 2.5 ml Pro293A-CDM (Lonza) was added per well for bait protein production, and 2.5 
ml (6-well plate) or 1 ml (24-well plate) cell line medium per well for pHSPA1A transfection. 
For bait protein production, cells were incubated for 72 hours following transfection before 
examination by light and fluorescence microscopy and harvesting of the culture supernatants. 
Culture supernatants were centrifuged at 2,000 x g for 10 minutes to pellet any detached cells. The 
supernatant was transferred to a fresh sterile tube and stored at 4 °C. 
For pHSPA1A transfection, cells were incubated for 24 or 48 hours following transfection before 
being taken forward into an immunoprecipitation (section 2.4.7.2) or immunofluorescence (section 
2.4.10) assay.  
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2.4 Protein techniques 
2.4.1 ELISpot assay 
Synthetic peptides (Pepscan, Lelystad, the Netherlands) were reconstituted to a stock concentration 
of 20 mM in dimethylsulfoxide (DMSO), then diluted to a working concentration of 1 mM in PBMC 
medium. 
The assay was conducted using the Feline IFN-γ ELISpot Development and ELISpot Blue Colour 
Modules (Strep-AP and BCIP-NBT; R&D Systems, Abingdon, UK). Antibodies were reconstituted as 
per the manufacturer’s instructions. 
96-well MultiScreen-IP clear styrene sterile plates (Merck, Darmstadt, Germany) were coated with 
capture antibody. After blocking the plate with PBMC medium, extracted PBMCs were divided 
evenly across the appropriate wells and cultured for 24 hours (37 °C, 5% CO2) with either a positive 
control (concanavalin A type IV-S; Sigma-Aldrich), negative control (PBMC medium only) or peptide 
mix. The plate was then incubated overnight at 4 °C with the detection antibody. The plate was 
developed with Streptavidin-AP, followed by an incubation with BCIP/NBT Chromogen protected 
from light. Finally, the underdrain was removed and the plate washed thoroughly under tap water 
before drying completely. Washing was carried out between all steps using PBS and/or deionised 
water depending on the step. 
Plates were photographed by an ELISpot Reader classic machine (Autoimmun Diagnostika, 
Strassberg, Germany) and spots counted by eye. Only medium and large spots with a fuzzy border 
were considered to be genuine spots. Number of spot forming cells (SFC) above background per 106 
cells was calculated by subtracting mean spots under negative control conditions from mean spots 
under each peptide condition, then multiplying by 106/number of cells per well. Negative values (i.e. 
more spots in background than peptide wells) were displayed as zero. Individual spots were not 
counted in the positive control wells; instead a subjective assessment was made by comparison with 
the corresponding negative control. 
2.4.2 FCoV antibody titre 
Around 1 ml of whole feline blood was collected into tubes containing EDTA (whichever used 
normally by the veterinary practice in which the blood was being taken), stored at room 
temperature and processed as soon as practically possible after collection (usually within two days). 
Plasma, removed from the whole blood sample after allowing the blood cells to settle by gravity, 
was submitted to Veterinary Diagnostic Services, University of Glasgow, where an indirect 
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immunofluorescent antibody test was used to measure FCoV antibody titre. The antigen used in the 
test was Type 2 FCoV grown in FE-A cells. 
2.4.3 Making a whole cell lysate 
Cells grown in a cell culture flask were washed twice with cold PBS before addition of 500 µl 2x SDS-
PAGE sample buffer. The cells were scraped into the sample buffer using a sterile cell scraper, 
transferred to a microcentrifuge tube and incubated at 95 °C for 5 minutes. The resulting lysate was 
chilled on ice then passed through a 25 G needle 10 times. 
2.4.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
35 µl sample was incubated with 12.5 µl NuPAGE LDS Sample Buffer (Thermo-Fisher) and 2.5 µl β-
mercaptoethanol at 70 °C for 10 minutes. A pre-cast NuPAGE 4-12% Bis-Tris mini gel (Thermo-Fisher) 
was assembled in an XCell SureLock Mini-Cell tank (Thermo-Fisher) in NuPAGE MOPS SDS running 
buffer (20x; Thermo-Fisher) as described by the manufacturer. 25 µl of protein sample was loaded 
into each well alongside 10 µl SeeBlue Plus2 Pre-stained Protein Standard (Thermo-Fisher). The gel 
was run at 200 V until the dye front reached the end of the gel (40-50 minutes). 
2.4.5 Coomassie Brilliant Blue staining 
Proteins separated by SDS-PAGE were visualised by soaking the gel in Coomassie Blue staining 
solution for at least 2 hours. The gel was then transferred to a destaining solution until the 
background was fully destained. Destaining solution was refreshed if necessary. 
2.4.6 Western blot 
Proteins separated by SDS-PAGE were transferred on to an Amersham Hybond polyvinylidene 
fluoride (PVDF) blotting membrane (GE Life Sciences, Pennsylvania, USA). A piece of membrane and 
2 pieces of extra thick blot paper (Bio-Rad) were cut to the size of the gel. The extra thick blot paper 
and gel were soaked in transfer buffer whilst the membrane was first soaked in methanol and then 
soaked in transfer buffer. The transfer was carried out using a Trans-Blot Semi-Dry Transfer Cell (Bio-
Rad, California, USA) run at 15 V for 50 minutes. The membrane containing transferred proteins was 
incubated with 5% (w/v) skimmed milk in PBS with 0.1% (v/v) Tween 20 (PBST) for 1 hour to block, 
then washed once in PBST. The membrane was incubated with primary antibody overnight at 4 °C. 
The membrane was then washed four times for 5 minutes per wash in PBST and incubated with 
secondary antibody for 1 hour. The membrane was washed four times for 5 minutes per wash in 
PBST and a chemiluminescent substrate (Amersham ECL Western Blotting Detection Reagent; GE 
Healthcare Life Sciences, Buckinghamshire, UK) was applied for 1 minute. A piece of Amersham 
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Hyperfilm x-ray film (GE Life Sciences) was exposed to the membrane for 5-30 seconds before the 
film was developed and fixed using a medical film processor (Photon Surgical Systems, Gloucester, 
UK). 
2.4.7 Immunoprecipitation 
2.4.7.1 Immunoprecipitation for proteomic analysis 
CrFK cells were grown in cell line medium to 70-90% confluency in T225 flasks. Medium was poured 
off and the cell sheet was washed twice with PBS. The cells were scraped into cold PBS and 
centrifuged at 800 x g at 4 °C for 5 minutes.  
Organoids embedded in Matrigel matrix were resuspended and transferred to cold PBS before 
centrifugation at 800 x g at 4 °C for 5 minutes. The supernatant was removed and the organoids 
were resuspended in cold PBS before centrifugation at 800 x g at 4 °C for 5 minutes. 
In both cases, the supernatant was removed and the cells were resuspended in 1.5-3 ml cold cell 
surface lysis buffer. This was incubated on ice for 15 minutes with frequent agitation, before 
centrifugation at 14,000 x g at 4 °C for 10 minutes. The resulting lysate was divided into three 
aliquots and incubated with an equal volume of bait protein, plus extra n-Dodecyl ß-D-
maltopyranoside to make a 0.6% (w/v) solution, at room temperature for 1 hour with mixing. 
The resin from NAb Protein A Plus Spin Columns (Thermo-Fisher) was washed twice with PBS. 
Lysate-bait protein was incubated with the resin at 4 °C, with mixing, overnight, then the resin was 
put back on the columns. The resin was washed three times with PBS, then resuspended in 200 µl 
PBS prior to storage at -70 °C and analysis by the Proteomics Facility, University of Bristol.  
At each stage, a 35 µl aliquot was taken for denaturation and analysis by SDS-PAGE and Coomassie 
Brilliant Blue staining (section 2.4.5) or western blotting (section 2.4.6). 
2.4.7.2 Immunoprecipitation with pHSPA1A-transfected CrFK cells 
pHSPA1A-transfected CrFK cells were grown in 6-well plates (section 2.3.17). Medium was poured 
off and the cell sheet was washed once with cold PBS. The cells were scraped into cold whole cell 
lysis buffer and incubated on ice for 30 minutes with frequent agitation, before centrifugation at 
14,000 x g at 4 °C for 10 minutes. 
An aliquot of the resulting lysate was taken for denaturation (14 parts lysate incubated with 1 part β-
mercaptoethanol and 5 parts 4x SDS-PAGE sample buffer at 70°C for 10 minutes) and analysis by 
SDS-PAGE and western blotting (section 2.4.6). The remainder was divided into three aliquots and 
incubated with an equal volume of bait protein at room temperature for 1 hour with mixing. 
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The resin from NAb Protein A Plus Spin Columns (Thermo-Fisher) was washed twice with PBS. 
Lysate-bait protein was incubated with the resin at 4 °C, with mixing, overnight. The resin was 
washed three times with PBS, then proteins were eluted from the resin in elution buffer at 70°C for 
10 minutes. Following centrifugation for 1 minute at 5000 x g, the supernatant was taken forward 
for analysis by SDS-PAGE and western blotting (section 2.4.6). 
2.4.8 Proteomic analysis 
2.4.8.1 TMT labelling 
Pull-down samples were reduced (10 mM TCEP 55 °C, 1 hour), alkylated (18.75 mM iodoacetamide, 
room temperature, 30 minutes) and digested on the beads with trypsin (2.5 µg trypsin; 37 °C, 
overnight), then labelled with Tandem Mass Tag (TMT) six- or ten-plex reagents according to the 
manufacturer’s protocol (Thermo-Fisher) and the labelled samples pooled. 
The pooled sample was evaporated to dryness, resuspended in 5% (v/v) formic acid and then 
desalted using a SepPak cartridge according to the manufacturer’s instructions (Waters, Milford, 
Massachusetts, USA). Eluate from the SepPak cartridge was again evaporated to dryness and 
resuspended in 1% (v/v) formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion 
Tribrid Mass Spectrometer (Thermo-Fisher). 
2.4.8.2 Nano-LC Mass Spectrometry 
The pooled TMT-labelled sample was fractionated using an Ultimate 3000 nano-LC system in line 
with an Orbitrap Fusion Tribrid mass spectrometer (Thermo-Fisher).  In brief, peptides in 1% (v/v) 
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 
washing with 0.5% (v/v) acetonitrile, 0.1% (v/v) formic acid peptides were resolved on a 250 mm by 
75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo-Fisher) over a 150 minute 
organic gradient, using six gradient segments (5-9% solvent B over 2 minutes, 9-25% solvent B over 
94 minutes, 25-60% solvent B over 23 minutes, 60-90% solvent B over 5 minutes, held at 90% 
solvent B for 5 minutes and then reduced to 1% solvent B over 2 minutes) with a flow rate of 300 nl 
min−1.  Solvent A was 0.1% (v/v) formic acid and Solvent B was aqueous 80% (v/v) acetonitrile in 
0.1% (v/v) formic acid. Peptides were ionized by nano-electrospray ionization at 2.0 kV using a 
stainless-steel emitter with an internal diameter of 30 μm (Thermo-Fisher) and a capillary 
temperature of 275 °C.  
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 
3.0 software (Thermo-Fisher) and operated in data-dependent acquisition mode using an SPS-MS3 
workflow. FTMS1 spectra were collected at a resolution of 120,000, with an automatic gain control 
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(AGC) target of 200,000 and a max injection time of 50 milliseconds. Precursors were filtered with an 
intensity threshold of 5,000, according to charge state (to include charge states 2-7) and with 
monoisotopic peak detection set to peptide. Previously interrogated precursors were excluded using 
a dynamic window (60 s +/-10 ppm). The MS2 precursors were isolated with a quadrupole mass filter 
set to a width of 1.2 m/z. ITMS2 spectra were collected with an AGC target of 10,000, max injection 
time of 70 milliseconds and CID collision energy of 35%. 
For FTMS3 analysis, the Orbitrap was operated at 30,000 (three-plex) or 50,000 (nine-plex) 
resolution with an AGC target of 50,000 and a max injection time of 105 milliseconds. Precursors 
were fragmented by high energy collision dissociation (HCD) at a normalised collision energy of 55% 
(three-plex) or 60% (nine-plex) to ensure maximal TMT reporter ion yield. Synchronous Precursor 
Selection (SPS) was enabled to include up to 5 MS2 fragment ions in the FTMS3 scan. 
2.4.9 Flow cytometry 
CrFK cells were grown in cell line medium to 70-90% confluency in T75 flasks prior to detachment 
with ACCUTASE™ Cell detachment solution (Stemcell) as per the manufacturer’s instructions and 
prepared at 200,000 live cells in 1 ml FACS buffer (2% (v/v) FBS in PBS). PBMC were prepared from 
fresh or frozen at ≥ 2 x 105 live cells in 1 ml FACS buffer, depending on how many cells were available 
from that individual. Each sample was centrifuged at 300 x g for 3 minutes, the supernatant was 
poured off and the cells resuspended in 100 µl culture supernatant containing bait protein (1 in 2 
dilution), human IgG Fc fragment (1 in 500 dilution; Merck) or FACS buffer. This was incubated for 20 
minutes at room temperature. 1 ml FACS buffer was added to each sample and, after mixing, all 
were centrifuged at 300 x g for 3 minutes. The supernatant was poured off and the cells 
resuspended in 100 µl primary antibody for 15 minutes at room temperature. 1 ml FACS buffer was 
added to each sample and, after mixing, all were centrifuged at 300 x g for 3 minutes. The 
supernatant was poured off and the cells were resuspended in 100 µl FACS buffer and stored on ice 
prior to analysis by the Flow Cytometry Facility, University of Bristol, using an LSR II (BD Biosciences, 
San Jose, California) flow cytometer. 
Data analysis was carried out using FlowJo software v10.3. 
2.4.10 Immunofluorescence assay 
Cell lines were cultured on glass coverslips until 70-100% confluent and PBMC were applied to glass 
slides by cytocentrifugation. Samples were fixed for 5 minutes using cold 4% (v/v) paraformaldehyde 
in PBS, permeabilized for 5 minutes using 0.1% (v/v) Triton X-100 in PBS then blocked for 1 hour 
using 10% (v/v) FBS in PBS. The fixed cells were incubated with culture supernatant containing bait 
54 
 
protein (1 in 2 dilution in 10% (v/v) FBS in PBS), human IgG Fc fragment (1 in 500 dilution in 10% 
(v/v) FBS in PBS) or primary antibody for 1 hour at room temperature or overnight at 4 °C. 
Organoids embedded in Matrigel matrix were washed twice with PBS then suspended in PBS. The 
organoids were vigorously pipetted and passed through a 27 G needle before being transferred to 
microcentrifuge tubes and centrifuged at 200 x g for 5 minutes. The supernatant was removed and 
the organoids were resuspended in conditioned medium, then an equal volume of bait protein (1 in 
2 final dilution in 10% (v/v) FBS in PBS) or human IgG Fc fragment (1 in 500 final dilution in 10% (v/v) 
FBS in PBS) was added. This was incubated at 4 °C for 1 hour with frequent agitation. Following 
centrifugation at 200 x g for 5 minutes and resuspension in PBS, the organoids were applied to glass 
slides by cytocentrifugation. Samples were fixed for 5 minutes using cold 4% (v/v) paraformaldehyde 
in PBS, permeabilized for 5 minutes using 0.1% (v/v) Triton X-100 (Sigma-Aldrich) in PBS then 
blocked for 1 hour using 10% (v/v) FBS in PBS. 
In all cases, cells were then incubated with secondary antibody for 1 hour at room temperature. The 
cells were washed with PBS before and after all steps. The coverslips were mounted cell side down 
on glass microscope slides, or glass coverslips were applied to the cytocentrifugation cell spots, using 
VECTASHIELD Antifade Mounting Medium (Vector Laboratories) and clear nail varnish to seal the 
edges.  
Slides were viewed and images taken in the Wolfson Bioimaging Facility, University of Bristol, using a 
Leica DM I6000 inverted epifluorescence microscope, a Leica SP5 confocal laser scanning microscope 
and Leica LAS-X acquisition software (Leica Microsystems, Milton Keynes, UK). Images were analysed 




2.5 Statistical analysis 
In all cases, statistical significance was assigned at a level of p<0.05. All p values are given to three 
significant figures. 
2.5.1 ELISpot 
ELISpot data were compiled into a spreadsheet (Excel 2013, Microsoft) and exported into R Studio, 
running R statistical package v. 3.2.2. Bar and pie charts were generated in Excel, while all other 
graphs were produced in R. A Fisher’s exact test was used to determine the significance of the 
difference in seroprevalence between ‘Breeder’ and ‘Non-breeder’ cats. The ELISpot data were 
evaluated for normal distribution using a histogram, q-q plot and Shapiro-Wilk test. A Kruskal-Wallis 
and/or Mann-Whitney test was used to determine the significance of any differences observed 
between peptide conditions on ELISpot. A Spearman’s rank-order correlation coefficient was used to 
determine the significance of the relationship between plasma antibody titre and response to 
peptides.  
2.5.2 Proteomic data analysis 
The raw data files were processed and quantified using Proteome Discoverer software v2.1 (Thermo-
Fisher) and searched against the UniProt Felis catus database using the SEQUEST algorithm.  Peptide 
precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at 0.6 Da. Search criteria 
included oxidation of methionine (+15.9949) as a variable modification and carbamidomethylation 
of cysteine (+57.0214) and the addition of the TMT mass tag (+229.163) to peptide N-termini and 
lysine as fixed modifications. Searches were performed with full tryptic digestion and a maximum of 
one (three-plex) or two (nine-plex) missed cleavages were allowed. The reverse database search 
option was enabled, and all data was filtered to satisfy false discovery rate (FDR) of 5%.   
Data was filtered to exclude known contaminants. The raw abundances were log2 transformed, then 
sorted based on the fold change in their abundance compared with the negative control 
immunoprecipitation. A paired t-test was carried out to determine whether a given protein was 
significantly enriched across all replicates of the proteomics experiment. 
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3 Establishing a reverse genetic system for Type 1 FCoV 
3.1 Introduction 
This chapter will describe the construction of full-length recombinant viruses based on a field strain 
of Type 1 FCoV, which represents a step towards establishing a reverse genetic system for Type 1 
FCoV. 
The first FCoV reverse genetic system used targeted recombination to establish a Type 2 FCoV strain 
79-1146 mutant, incorporating the MHV S protein ectodomain in an intermediate step that allowed 
recombinant viruses to be selected for (Haijema et al., 2003). Though an important breakthrough in 
FCoV reverse genetics that was used to generate candidate FCoV vaccine strains (Haijema et al., 
2004), targeted recombination requires the recombinant virus to grow in cells, therefore does not 
allow study of lethal mutations or viruses that cannot be propagated in cell culture. Since selection 
of recombinant viruses is usually based on cell tropism, targeted recombination systems do not 
easily allow manipulation of the genome 5 to the S gene (Almazan et al., 2014). 
A Type 1 FCoV reverse genetic system was first developed by Tekes et al. (2008) by cloning a cDNA 
copy of the FCoV strain ‘Black’ genome into a vaccinia virus vector. Using this system, the accessory 
gene cluster ORF3a-c was replaced with reporter genes, resulting in a recombinant virus that 
replicated as efficiently as the parental virus in FCWF cells. This reverse genetic system has been 
used to develop and characterise a recombinant Type 2 FCoV based on the strain ‘79-1146’ and a 
chimeric virus based on Type 1 FCoV ‘Black’ but bearing the Type 2 FCoV ‘79-1146’ S gene (Tekes et 
al., 2010, Tekes et al., 2012, Thiel et al., 2014). Though these studies have vastly increased our 
understanding of the importance of the S gene in tropism and pathogenesis, they are limited in that 
‘Black’ is highly laboratory-adapted and cannot be said to represent field strains of Type 1 FCoV 
(Pedersen, 2009). At the start of this project, the ‘Black’ system was the only Type 1 FCoV reverse 
genetic system that had been reported. It was therefore apparent that a reverse genetic system 
based on a field strain of Type 1 FCoV would be an invaluable tool in FCoV research, as it would 
allow the effect of viral mutations on the viral phenotype to be investigated using a clinically 
relevant strain. A reverse genetic system based on a field strain of Type 1 FCoV has since been 
established by another group (Ehmann et al., 2018), and this will be discussed further in the 
discussion section of this chapter (section 3.3). 
Due to their large RNA genomes, it was thought for a time that building full-length infectious cDNA 
clones of coronaviruses may not be possible. However, three strategies have enabled the 
development of coronavirus full-length infectious clones: vaccinia virus vectors, BACs and in vitro 
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ligation (Almazan et al., 2014). The method used for building infectious clones in this project will be 
in vitro ligation, but sequences flanking the genome will be incorporated to allow the cDNA clone to 
be ligated into a vaccinia virus vector if necessary. The infectious clones in this project are based on 
the Type 1 FCoV 80F strain, which was isolated from the faeces of a naturally infected cat without 
FIP (Lewis et al., 2015). This strain was chosen because it represents a typical non-virulent Type 1 
FCoV field strain, therefore is clinically relevant. As well as a Type 1 FCoV 80F infectious clone (‘T1’), 
a construct will be synthesised with a Type 1 FCoV 80F backbone but a Type 2 S gene (‘T2S’). Such 
chimeric viruses have been shown to infect cells otherwise uninfectable by Type 1 FCoV and display 
similar in vitro growth kinetics to the Type 2 FCoV from which the spike gene was taken (Tekes et al., 
2010). Until a cell type in which T1 can be propagated is available to us, T2S would be a valuable 
construct for demonstrating the viability of the reverse genetic system and exploring non-spike 
mutations in the FCoV genome.  
Since the N protein is required for efficient viral RNA synthesis, co-transfecting cells with full-length 
construct and FCoV N gene RNA has been shown to promote infectivity of the infectious clones 
(Yount et al., 2000). It is thought that the N protein promotes infectivity by interacting directly with 
elements of the RTC (Baric et al., 1988, Stohlman et al., 1988, Hurst et al., 2010). An alternative to 
co-transfecting with N gene transcripts is to transfect infectious clone RNA into cells stably 
expressing N protein (Tekes et al., 2008), but the former method was utilised in this project because 
this is the method utilised by other groups using in vitro ligation.  
In addition to the two infectious clones T1 and T2S, this project aimed to synthesise an FCoV 
replicon; something which has not been done previously. Replicons are self-replicating viral 
genomes from which some or all of the structural genes have been deleted and, in some cases, 
reporter genes have been added (Zimmer, 2010). Replicons contain all the genetic material 
necessary for viral RNA synthesis, but they cannot produce infectious progeny. In this way, replicons 
provide a safe way of studying the non-structural components of pathogenic viruses. Additionally, 
stable cell lines containing non-cytopathic replicons have also been produced, which provide a fast 
and simple way of analysing the effect of viral infection on the host cell and screening antiviral drugs 
(Almazan et al., 2014). The same TGEV replicon construct was cytopathic in some cell lines but non-
cytopathic in others (Almazan et al., 2004), so selection of a suitable cell line is an important 
consideration in this project. 
The first coronavirus replicon-like construct comprised the 5 proximal ~20 kb of the HCoV 229E 
genome (encompassing the 5 UTR and ORF1a-b gene), a GFP coding sequence, the 3 UTR of the 
HCoV 229E genome and a synthetic poly-A tail. A small proportion of cells transfected with this 
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construct expressed GFP, and RNA extracted from these cells showed the typical organisation of a 
coronavirus subgenomic mRNA. These results demonstrated that the coronavirus replicase proteins 
suffice for subgenomic mRNA synthesis and translation, but did not show that the construct had 
replicated (Thiel et al., 2001). Almazan et al. (2004), in establishing a replicon for TGEV, found that 
the N gene was the only structural gene necessary for viral genome replication. The TGEV replicon 
construct included an ORF7 accessory gene, but other studies have shown that the accessory genes 
are not necessary for virus replication in cell culture (Haijema et al., 2004). 
In this project, only the S and M genes were deleted from the replicon construct. This is because, 
although not necessary for viral genome replication, the E and accessory genes do not appear to be 
deleterious to the host cells (Ortego et al., 2002) and their inclusion enhances virus replication in 
some scenarios (Dedeurwaerder et al., 2013). Additionally, a puromycin selection marker and two 
reporter genes, GFP and Renilla luciferase, were included in order to select for cells containing the 
replicon and facilitate downstream analyses respectively. 
3.1.1 Aims 
The aims of this part of the project were to: 
• Develop full-length cDNA constructs representing Type 1 FCoV (T1), Type 1 FCoV with a T2 
spike gene (T2S) and an FCoV replicon using an in vitro ligation method 
• Produce full-length in vitro RNA transcripts from these constructs 
• Transfect mammalian cells with the full-length in vitro RNA transcripts in order to recover 






3.2.1 Design and synthesis of cDNA fragments 
Twenty-five cDNA fragments spanning the Type 1 FCoV strain 80F genome, the Type 2 FCoV strain 
79-1146 S gene, a GFP puro resistance coding sequence and a Renilla luciferase coding sequence 
were designed. In various combinations, these fragments comprise three full-length constructs: Type 
1 FCoV 80F (‘T1’), Type 1 FCoV 80F backbone with a Type 2 FCoV 79-1146 spike gene (‘T2S’) and a 
Type 1 FCoV 80F with the S and M genes replaced with the GFP puro and Renilla luciferase coding 
sequences (‘replicon’). All constructs were designed to incorporate a T7 promoter at the 5’ end of 
the viral cDNA clone to enable them to function as templates for in vitro transcription of RNA. The 3’ 
end of all constructs incorporated a poly-A tail and hepatitis delta virus (HDV) ribozyme to aid RNA 
processing in the host cell, but these were separated by a unique restriction endonuclease site to 
give the option of not using the ribozyme. To construct cDNA clones corresponding to the full-length 
genomes, a two-step strategy was used. In the first step, sets of three fragments were assembled 
using a commercially available NEBuilder HiFi DNA Assembly kit into ‘units’ (described in detail in 
section 3.2.3), before being ligated into full-length constructs in the second step (Figure 3.1).  
Figure 3.1. Schematic to show the fragments and units comprising each full-length construct. Fragments are shown as white boxes. Each 
set of three fragments – ‘A’, B’ and ‘C’ – were assembled into a unit, except for 5AR which constituted unit 5R alone. The units were then 
ligated, in various combinations, into three full-length constructs: T1, T2S and replicon (Rep). The genome shown at the top of the figure is 
that of Type 1 FCoV strain 80F, on which the constructs are based. Units representing 80F are shown in light blue, the unit representing 
the Type 2 FCoV strain 79-1146 S gene is shown in yellow, a GFP puro coding sequence is shown in green, and Renilla luciferase coding 
sequence is shown in bright blue. A closer view of the 3’ end of the replicon reveals a poly-A tail and HDV ribozyme, shown in grey, after 
the 3’ UTR, separated by a unique restriction endonuclease site. This is the same for all constructs. 
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The cDNA fragment sequences were submitted to Twist Bioscience for synthesis and cloning into the 
2,221 bp pTwist 31 pMB1-Amp-UCS1.2 (pTwist) vector. Twenty-one of the 25 cDNA fragments 
arrived as plasmids. The remainder could not be amplified in bacterial culture so arrived as synthetic 
DNA fragments. Table 3.1 summarises the cDNA fragments and Appendix A shows the full 
sequences. 
Table 3.1. The cDNA fragments synthesised for construction of recombinant viruses. Twenty-five fragments were synthesised in total, 
and of these 21 arrived as plasmids. Four could not be cloned into plasmids so arrived as synthetic DNA fragments. The ‘unit’ and 





3.2.2 Amplifying fragments 
Bacteria (E. coli) were transformed with all 21 plasmids to amplify the plasmids for downstream 
applications. Following transformation, at least three bacterial colonies were selected per plasmid 
construct and the bacteria were cultured. Plasmid DNA was then extracted using a miniprep or 
midiprep procedure, and a restriction digest was carried out to check the size of the digestion 
products.  
For fragment 1B, a construct of the correct size was identified and taken forward for assembly of 
unit 1 (1B8; Figure 3.2). However, following multiple failed attempts to ligate unit 1, plasmid 1B8 was 
Sanger sequenced and found to be aberrant in that the sequence was not what was expected. 
Eventually a fragment 1B with the correct sequence was obtained by PCR amplification of the 
fragment from the plasmid provided by Twist Bioscience, using primers that sit within the pTwist 
vector (Twist For and Twist Rev; Appendix A). The difficulties experienced during the construction of 
unit 1 are described in detail in section 3.2.3.1. Amplified plasmid DNA of the correct size was 
obtained easily for the other fragments available as plasmids (Figure 3.3), though 2A and 4B showed 
a degree of instability in bacterial culture with multiple colonies screened before a construct of the 
correct size was identified.  
Fragments were liberated from their plasmids or flanking sequences through restriction digestion. 
The digestion products were separated by agarose gel electrophoresis and DNA bands of the correct 
size were excised from the gel and extracted. 
Those fragments not available as plasmids were not amplified prior to downstream applications. 
Figure 3.2. Analysis of fragment 1B by agarose gel electrophoresis.  Six clones containing fragment 1B (1B5-10) were amplified in 
bacterial culture, then the plasmid DNA was extracted and digested with appropriate restriction enzymes to liberate the fragments from 
their plasmids. The digestion products (D) were run alongside an aliquot of undigested plasmid (U) on a 1% agarose gel at 100 V for 40 
minutes. The DNA bands were visualised under a UV transilluminator. The positions of relevant DNA mass markers are shown in bp. 
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Figure 3.3. Analysis of all fragments available as plasmids by agarose gel electrophoresis. Two to three clones containing fragments 1A, 1C, 2A, 2B, 2C, 3A, 3B, 3C, 4A, 4B, 4C, 5B, 5C, 6A, 6B, 5AR, 6AR, 6BR, 5BT2 
and 5CT2 were amplified in bacterial culture, then the plasmid DNA was extracted and digested with appropriate restriction enzymes to liberate the fragments from their plasmids. The digestion products (D) were 
run alongside an aliquot of undigested plasmid (U) on a 1% agarose gel at 100 V for 40 minutes. The DNA bands were visualised under a UV transilluminator. The positions of relevant DNA mass markers are shown in 




3.2.3 Assembling units 
In the first step of full-length cDNA clone production, units were assembled from their constituent 
fragments using the NEBuilder HiFi DNA assembly method. Fragments were designed to overlap by 
25 bp, which enables an exonuclease to chew back the 5’ ends of DNA strands, allowing the 
complementary 3’ overhangs of overlapping sections to match and form a seamless join (Figure 3.4). 
Figure 3.4. Schematic to illustrate the NEBuilder HiFi DNA assembly method.  
1: Two DNA fragments (shown as double-stranded light blue bars) are designed to overlap by 25 bp. Overlapping sequences are shown in 
yellow or purple, depending on which DNA strand is being considered. 
2: A 5’ exonuclease chews back the 5’ ends of DNA strands, revealing the complementary sequences on the 3’ ends. 
3: The complementary sequences match and anneal. 




The unit assembly strategy utilised in this project used restriction digestion to linearise the plasmid 
containing the ‘A’ fragment and liberate the ‘B’ and ‘C’ fragments from their plasmids. The ‘B’ and ‘C’ 
fragments were then assembled into the plasmid containing the ‘A’ fragment by NEBuilder HiFi DNA 
assembly. This resulted in a pTwist vector containing a complete unit (Figure 3.6A). This strategy was 
used to assemble units 1, 2, 3, 4, 6 and 6R.  
Since ‘A’ fragments were not available as plasmids for units 5 and 5T2 and the ‘A’ fragments were 
obviously not stable in a high copy number plasmid vector, a different assembly strategy was 
adopted. Oligonucleotide adaptors (Appendix A) overlapping with the 5’ and 3’ ends of these units 
were designed and synthesised. Figure 3.5 shows an example of an adaptor used in this approach. 
The adaptors were designed with restriction endonuclease sites at each end that would allow them 
to be ligated into the multiple cloning site of the very low copy number vector pWSK29. The 
adaptors also incorporated a restriction endonuclease site in the middle via which the vector could 
be linearised, revealing ends complementary to the ends of the unit. The ‘A’, ‘B’ and ‘C’ fragments, 
liberated from the respective plasmids, were then assembled into the introduced adaptor sequence 
in the linearised pWSK29 vector by NEBuilder HiFi DNA assembly (Figure 3.6B). 
Figure 3.5. The oligonucleotide adaptor used to ligate unit 5 into a low copy number vector. The adaptor was flanked by restriction 
endonuclease sites (SalI and NotI) that would allow it to be ligated into low copy number vector pWSK29 via the vector’s multiple cloning 
site. In the middle of the adaptor, a BamHI restriction endonuclease site allowed the adaptor-containing vector to be linearised, revealing 
ends complementary to the 5’ and 3’ ends of unit 5 that could be used for NEBuilder HiFi DNA assembly. 





Figure 3.6. Schematic to show the assembly of an infectious clone ‘unit’ from three fragments. Fragments are shown as blue bars. 
Overlapping regions are shown are smaller yellow, green or red bars within the fragments. Blue lines indicate vectors. Heavy black arrows 
indicate restriction endonuclease sites. Units 1, 2, 3, 4, 6 and 6R were ligated using method A, whereas units 5 and 5T2 utilised method B. 
A1: Fragments ‘B’ and ‘C’ are liberated from their plasmids using SalI, and the plasmid containing fragment ‘A’ is linearised using XmaI. 
A2: Note that both ends of fragment ‘A’ remain attached to the vector. 
A3: NEBuilder HiFi DNA assembly is used to seamlessly assemble the fragments together via their overlapping regions. 
A4: The three fragments are assembled into a single unit, residing within the vector that originally contained just fragment ‘A’. 
B1: Fragments ‘B’ and ‘C’ are liberated from their plasmids using SalI. Fragment ‘A’ is not digested. 
B2: pWSK29 is digested with BamHI, which cleaves the adaptor revealing two regions that overlap with either end of the unit. 
B3: NEBuilder HiFi DNA assembly is used to seamlessly assemble the fragments together and into pWSK29 via their overlapping regions. 
B4: The three fragments are assembled into a single unit, residing within pWSK29. 
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After unit assembly using the NEBuilder HiFi DNA assembly protocol, bacteria were transformed with 
the resulting unit-containing plasmids. At least three bacterial colonies were selected per construct 
and the bacteria were cultured. Plasmid DNA was extracted using a miniprep or midiprep procedure 
and the DNA underwent restriction digestion and agarose gel electrophoresis to check the size of the 
digestion products. An example is shown in Figure 3.7, where Cl5 is the correct clone of unit 3. A 
clone of the correct size was identified fairly rapidly for all units except unit 1. 
Figure 3.7. Analysis of unit 3 by agarose gel electrophoresis.  Six clones (Cl1-6) of unit 3 were amplified in bacterial culture, then the 
plasmid DNA was extracted and digested with appropriate restriction enzymes to give a particular digestion pattern. The digestion 
products (D) were run alongside an aliquot of undigested plasmid (U) on a 0.7% agarose gel at 100 V for 40 minutes. The DNA bands were 
visualised under a UV transilluminator. The positions of relevant DNA mass markers are shown in bp. 
3.2.3.1 Unit 1 assembly. 
Despite selecting and culturing over 20 bacterial colonies for unit 1, a plasmid clone of the correct 
size was not identified. Many of the clones had different restriction digestion patterns and sizes to 
one another (Figure 3.8A), suggesting instability of the unit in bacterial culture. Culturing the 
bacteria at 28 C was therefore attempted to increase plasmid stability, but this still did not yield 
clones of the correct size. It was then decided to use the same strategy utilised for units 5 and 5T2, 
where an oligonucleotide adaptor was designed, synthesised and ligated into pWSK29 (Figure 3.5B). 
Following another NEBuilder HiFi DNA assembly reaction to ligate fragments 1A, 1B and 1C into the 
modified pWSK29 plasmid, bacteria were transformed with the ligation reaction mix and over 20 
colonies were selected for bacterial culture. Again, none of the plasmid clones were of the correct 
size, despite culturing the bacteria at 28 C. An attempt was made to PCR amplify the unit from both 
ligation reactions, but an amplicon of the correct size was not obtained (data not shown). 
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Due to the difficulty experienced obtaining a correct clone of fragment 1B, it was suspected that this 
fragment may be causing an issue. Clones 8-10 of fragment 1B, which all appeared to be the correct 
size, were PCR amplified and Sanger sequenced. The sequence of 1B8, the clone that was being used 
for the unit 1 ligation, was found to be completely aberrant in that it was not what was expected. 
The sequences of 1B9 and 1B10 were correct, except for a single nucleotide insertion that would 
shift the reading frame and render them unusable. A sequence-perfect clone of fragment 1B was 
finally obtained through PCR amplification of the fragment from the plasmid provided by Twist 
Bioscience, using Twist For and Twist Rev primers (Appendix A). Unit 1 assembly was repeated with 
this new fragment, using the original strategy of ligating 1B and 1C into the pTwist vector containing 
1A. Following bacterial transformation and culture, a single clone of the correct size (Cl51) was 
identified (Figure 3.8B). 
Figure 3.8. Analysis of unit 1 by agarose gel electrophoresis. Clones of unit 1 were amplified in bacterial culture, then the plasmid DNA 
was extracted and digested with appropriate restriction enzymes to give a particular digestion pattern. The digestion products (D) were 
run alongside an aliquot of undigested plasmid (U) on a 0.7% agarose gel at 100 V for 40 minutes. The DNA bands were visualised under a 
UV transilluminator. The positions of relevant DNA mass markers are shown in bp. 
A: Four incorrect clones (Cl1-4), illustrating the heterogeneity of the clones. 
B: A clone of the correct size (Cl51) was finally identified. 
3.2.4 Obtaining sequence-perfect units 
When a clone of the correct size was identified for a unit, plasmid DNA was submitted for Sanger 
sequencing following amplification by larger scale bacterial culture or PCR if necessary. See Appendix 
A for a full list of sequencing primers used in this project. All units were found to have the correct 
sequence except for units 1, 2 and 4. 
Despite the effort that went in to producing a sequence-perfect fragment 1B, following amplification 
in bacterial culture, unit 1 was found to have three single nucleotide substitutions (T>C at unit 1 
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position 1796, T>C at unit 1 position 2225, A>G at unit 1 position 2487) within the fragment 1B 
region. The first two mutations are synonymous so would not be expected to influence the structure 
or function of the final infectious clone into which the unit would be incorporated, but the latter 
mutation results in an amino acid substitution of valine for isoleucine that would be situated in pp1a 
and pp1ab following translation of ORF1a-b. These mutations likely arose during bacterial culture 
following transformation of the ligated unit into bacteria, illustrating the instability of unit 1 (and 
particularly fragment 1B) in bacterial culture. It was decided to proceed with this imperfect unit due 
to time limitations for the project. 
The clone of unit 2 submitted for sequencing (Cl8) was found to have a 410 bp deletion within the 
fragment 2A region. Five clones of unit 2 were therefore digested with appropriate restriction 
enzymes to assess whether the deletion was present (Figure 3.9). Two clones with the correct 
restriction digestion pattern (Cl4 and Cl7) were identified. Cl7 was found to be perfect on sequencing 
so was taken forward. 
Figure 3.9. Analysis of unit 2 by agarose gel electrophoresis. Following identification of a 410 bp deletion in unit 2 clone 8 (Cl8) on 
sequencing, five clones of unit 2 were digested with appropriate restriction enzymes to assess whether the 410 bp deletion was present. 
The digestion products (D) were run alongside an aliquot of undigested plasmid (U) on a 0.7% agarose gel at 100 V for 40 minutes. The 




3.2.4.1 Obtaining a sequence-perfect unit 4 
The clone of unit 4 submitted for sequencing (Cl6) was found on sequencing to have a single 
nucleotide deletion in the region of complementarity between fragments 4B and 4C, which would 
shift the reading frame and render the unit unusable. Three more clones were sequenced over the 
region of the deletion, but all were found to have the same deletion. The NEBuilder HiFi DNA 
assembly ligation reaction was repeated for unit 4 as, being on the border of two fragments, it was 
unclear whether the deletion arose as a result of unit instability in bacterial culture or an issue with 
the assembly reaction. Bacteria were transformed with the new unit 4-containing plasmid, four 
clones were selected and the bacteria were cultured. Only one clone (Cl4N) had the correct 
restriction digestion pattern (Figure 3.10A), so this clone was sequenced over the region of the 
deletion. Unit 4 Cl4N was found to have the same deletion.  
A 773 bp DNA fragment (Appendix A) was designed and synthesised to replace a region of unit 4 
spanning the deletion. Naturally occurring restriction endonuclease sites either side of the deletion 
were identified and the fragment was flanked by these sites, allowing the mutated region to be 
excised and the fragment to be ligated into the unit in its place. The repaired unit was transformed 
into bacteria, eight clones were selected for bacterial culture and the plasmid DNA was extracted. 
On restriction digestion and agarose gel electrophoresis (Figure 3.10B), two clones (Cl6repair and 
Cl7repair) were the correct size. Unit 4 Cl7repair was sequenced but found to contain the same 
deletion, suggesting either that unit 4 is unstable in bacterial culture or the repair had failed. 
An oligonucleotide adaptor (Appendix A) was designed and synthesised to overlap with the 5’ and 3’ 
ends of unit 4 (Figure 5), allowing the unit to be cloned into the low copy number vector pWSK29. 
Following another NEBuilder HiFi DNA assembly reaction to ligate fragments 4A, 4B and 4C into the 
low copy number vector, bacteria were transformed with the resulting plasmid and over 60 clones 
were selected for bacterial culture. None of the clones were of the correct size (Figure 3.10C), 
despite repeating the ligation twice using different insert to vector ratios and culturing the bacteria 
at 28 C. 
Eventually, a sequence-perfect unit 4 was obtained by PCR amplifying the unit from the first 
NEBuilder HiFi DNA assembly ligation reaction (Figure 3.10D) using Twist For and Twist Rev primers 




Figure 3.10. Analysis of unit 4 by agarose gel electrophoresis. All DNA (digestion products for A, B and C, and PCR product for D) was run 
on a 0.7% agarose gel at 100 V for 40 minutes. The DNA bands were visualised under a UV transilluminator. The positions of relevant DNA 
mass markers are shown in bp. 
A: Following detection of a deletion in unit 4 Cl6, the unit 4 ligation reaction was repeated and transformed into bacteria. Four colonies 
(Cl1N-4N) were selected for bacterial culture. Plasmid DNA was extracted and digested with appropriate restriction enzymes to give a 
particular digestion pattern. The digestion products (D) were run alongside an aliquot of undigested plasmid (U). 
B: The repaired unit 4 was transformed into bacteria and eight colonies were selected for bacterial culture. Plasmid DNA was extracted 
and digested with appropriate restriction enzymes to give a particular digestion pattern. The digestion products (D) were run alongside an 
aliquot of undigested plasmid (U). Three of the eight clones (Cl5repair-Cl7repair) are shown here. 
C: Unit 4 was ligated into a low copy number (LCN) vector, the plasmid was transformed into bacteria and over 60 colonies were selected 
for bacterial culture. Plasmid DNA was extracted and digested with appropriate restriction enzymes to give a particular digestion pattern. 
The digestion products (D) were run alongside an aliquot of undigested plasmid (U). Four of the clones (Cl1LCN-Cl4LCN) are shown here. 
D: Unit 4 was PCR amplified from the first ligation reaction using primers that sit within the pTwist vector.  
3.2.5 Amplifying units 
All units had to be amplified to produce sufficient DNA to be ligated into full-length constructs. 
Sequence verified plasmid clones of units 1, 3, 6, 5R and 6R were amplified by large scale bacterial 
culture and plasmid DNA was extracted using a midiprep or maxiprep procedure. This approach was 
attempted for units 5 and 5T2, but it was not possible to obtain enough plasmid DNA for unit 
extraction and ligation, as these units reside in a very low copy number vector. Units 5 and 5T2 were 
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therefore amplified by PCR from sequenced clones, using a proof-reading polymerase and primers 
that are complementary to the pWSK29 vector (Appendix A). 
In an attempt to amplify unit 2 for downstream applications, unit 2 Cl7 plasmid DNA was 
transformed into bacteria then 10 clones were selected for large scale bacterial culture. However, 
none of these 10 clones had the correct restriction digestion pattern, suggesting that unit 2 is 
unstable in large scale bacterial culture. Unit 2 was therefore amplified by PCR from Cl7 using Twist 
For and Twist Rev primers that had been adapted to add flanking sequences on to unit 2 to enable it 
to be cloned into pWSK29 (Appendix A). However, unit 2 was not cloned into pWSK29 during this 
project. 
Unit 4 had to be amplified by PCR since the only correct version of the unit did not reside in a vector. 
This was carried out using Twist For and Twist Rev primers (Appendix A). 
All amplified units were sequenced again and found to be unchanged. See Appendix A for the final 
unit sequences. 
3.2.6 Ligation of units to produce full-length cDNA clones 
As all units were verified to be sequence-perfect (except for unit 1; section 3.2.4) and amplified to a 
sufficient level, the next step was to ligate the units to produce three full-length constructs: T1, T2S 
and replicon. Units were designed to incorporate unique BsmBI (type IIS restriction endonuclease) 
cleavage sites, thereby eventually allowing the units to be assembled seamlessly and directionally 
into a full-length construct (Figure 3.11). Units 2, 3, 4, 5, 5T2 and 5R had BsmBI sites at each end of 
the unit, flanking the genomic sequence, whereas unit 1 had a BsmBI site only at its 3’ end and units 
6 and 6R had BsmBI sites only at their 5’ ends. 
Unit 1 underwent restriction digestion to cut upstream of the unit and linearise the plasmid in which 
it sat. Units 6 and 6R underwent restriction digestion to cut downstream of the units and linearise 
the plasmids in which they sat. The digested plasmids were phosphatase-treated to prevent re-
ligation. All units were then digested with BsmBI to liberate units from their plasmids (or flanking 
sequences in the case of PCR products) and produce uniquely compatible ends between units whilst 
maintaining the viral genome sequence. The digestion products were separated by agarose gel 
electrophoresis (Figure 3.12A) and DNA bands corresponding to the liberated units were excised 
from the gel and extracted (Figure 3.12B). All units were of the correct size (see Table 3.1 for 
expected sizes) and adequate purity.
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Figure 3.11.  Schematic to show the ligation of units into a full-length construct. T1, constructed from units 1-6, is used as an example. ‘A’ illustrates an overview of the process, whereas ‘B’ focuses in more detail 
on the junction between units 1 and 2. 
1: Units are digested with BsmBI: a type IIS restriction enzyme which recognises asymmetric DNA sequences and cleaves outside of its recognition sequence (in blue). The recognition sequence is thereby cleaved 
away from the unit, leaving only coding sequence (in green). 
2: Restriction digestion reveals overhangs between units that are uniquely complementary (represented by yellow, blue, green, orange and black lines), therefore only allow units to assemble directionally and in the 
correct order. 
3: BsmBI-digested units are incubated together in a T4 DNA ligase reaction, where the complementary overhangs anneal and the nicks are sealed. This results in a seamlessly ligated full-length construct.
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Figure 3.12. Analysis by agarose gel electrophoresis of units to be ligated into full-length constructs. All DNA was run on a 0.7% agarose 
gel at 100 V for 40 minutes and DNA bands were imaged under a Dark Reader transilluminator. The positions of relevant DNA mass 
markers are shown in bp. The number above each lane corresponds to the unit number (e.g. 1 is unit 1). 
A: All units were digested with BsmBI to liberate them from their plasmids (or remove flanking sequences in the case of PCR products) and 
reveal uniquely compatible ends. Unit 5R is not shown in this image. Unit 3 appears to have digested partially. 
B: The DNA bands corresponding to units were extracted from the gel, then an aliquot of each digested, extracted unit was run on another 
gel to check for size and purity. 
To produce full-length constructs, the appropriate units were incubated together in a T4 DNA 
ligation reaction. The assembled constructs were analysed by agarose gel electrophoresis, which 
required optimisation due to the large size of the constructs (~29 kb for T1 and T2S and ~26 kb for 
the replicon cDNA). After trialling different conditions, it was found that running a TAE gel in TAE 
buffer at a low voltage (10-15 V) for 24 hours resulted in adequate resolution of large DNA bands. 
Under these conditions, agarose gel electrophoresis revealed a DNA band of the correct size for each 
construct in addition to many non-specific bands (Figure 3.13). In order to optimise the ligation 
reaction, different ligation temperatures and DNA amounts were trialled for the replicon construct, 
but there was no appreciable difference between conditions (Figure 3.14). 
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Figure 3.13. Analysis of the products of full-length construct ligation. Full-length constructs were ligated together from their constituent 
units in a T4 DNA ligation reaction. Ten percent of the ligation reaction was run on a 0.4% agarose gel at 15 V for 24 hours and imaged 
under a UV transilluminator to check for the presence of full-length product. Bands of approximately the correct size for full-length 
product (~29 kb for T1 and T2S, blue arrow; ~26 kb for replicon, white arrow) were present for all constructs, as well as many non-specific 
bands. The positions of relevant DNA mass markers are shown in bp. Rep: replicon. 
Figure 3.14. Comparison of different ligation conditions for replicon ligation. The replicon construct was ligated together from its 
constituent units in T4 DNA ligation reactions with different total DNA amounts (A) and ligation temperatures (B). Ten percent of the 
ligation reaction was run on a 0.4% agarose gel at 15 V for 24 hours and imaged under a UV transilluminator to compare the efficiency of 
the reaction between conditions. The band assumed to represent full-length replicon is indicated with a white arrow. The positions of 




In order to verify that the full-length constructs had been correctly assembled, a set of PCR primers 
was designed to produce seven overlapping amplicons from each assembled full-length construct, 
spanning the construct and ranging from 1.9 to 6.4 kbp in size (Figure 3.15 and Table 3.2). Amplicons 
of the correct size were achieved for all constructs except the replicon, from which ‘amplicon 6’ 
failed to be amplified. Additional primers were therefore designed to divide replicon amplicon 6 into 
two parts (6.1 and 6.2), which yielded amplicons of the correct size (Figure 3.16). 
Figure 3.15. Schematic to show the amplicons obtained by PCR from the three full-length constructs. Constructs (T1, T2S and replicon 
(Rep)) are shown in pale blue, made up from their constituent units. The set of amplicons produced from each construct is shown beneath 
it in dark blue. The positions and sizes of the amplicons are approximately correct relative to the constructs. Amp: amplicon. 
 
Table 3.2. The expected size of the PCR amplicons amplified from the three full-length constructs. Replicon amplicon 6 was divided into 




Figure 3.16. Analysis of the PCR amplicons obtained from each full-length construct by agarose gel electrophoresis. A set of PCR primers 
was designed to produce seven overlapping amplicons spanning each assembled full-length construct. Amplicons were run on a 0.7% 
agarose gel at 100 V for 40 minutes and imaged under a UV transilluminator. The number of the amplicon (Amp) and name of the 
construct from which it is derived is displayed above each lane. Replicon amplicon 6 was divided into two parts (6.1 and 6.2). The positions 
of relevant DNA mass markers are shown in bp. Rep: replicon. 
3.2.7 Transcribing full-length constructs 
The full-length constructs ligation reactions were purified by phenol chloroform extraction and 
ethanol precipitation and used as templates for in vitro transcription. An FCoV N gene DNA template 
was also created by PCR amplifying a ~1.2 kb region encompassing the N gene from unit 6, using 
primers that added a T7 promoter to the 5’ end of the gene and a poly-A tail to the 3’ end (Appendix 
A). 
The first construct to be in vitro transcribed was replicon, which was transcribed alongside N gene 
and a positive control template included with the kit (pTRI-Xef). Analysis of the transcripts by 
spectrophotometer and agarose gel electrophoresis showed that no replicon RNA had been made, 
despite a reasonable yield of N gene RNA (~1,300 ng) and an excellent yield of positive control RNA 
(~30,000 ng) (Figure 3.17A). Although the same mass of replicon and N gene templates had been 
used in the reaction, the replicon template contained many DNA bands in addition to the full-length 
product so on a molar basis less full-length template would have been available for transcription. 
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The in vitro transcription reaction was therefore repeated using a higher concentration of replicon 
DNA template. Replicon RNA was transcribed this time (~800 ng) and a band was detected by 
agarose gel electrophoresis (Figure 3.17B). If the replicon RNA was ~30,000 nt as expected, the band 
should have migrated between the 10,000 and 20,000 bp DNA markers, but it was much larger than 
this. Since the agarose gel was not run under denaturing conditions, this could have been the result 
of secondary structure in the RNA. Replicon RNA was therefore examined by denaturing agarose gel 
electrophoresis (Figure 3.18), which showed a band of over 20,000 nt. It was, however, impossible to 
accurately size the full-length RNA as there is no RNA mass marker available that is large enough. 
Figure 3.17. Analysis of replicon RNA by agarose gel electrophoresis. RNA, obtained by in vitro transcription of replicon (Rep), N gene (N) 
or positive control (Pos.) template DNA, was run on a 1% agarose gel at 100 V for 35 minutes. The RNA was denatured prior to loading but 
the gel was not run under denaturing conditions. Image ‘A’ shows RNA obtained from the first in vitro transcription reaction and image ‘B’ 
shows RNA obtained from the second. Note that a DNA (not RNA) ladder was used for sizing RNA, so RNA is approximately double the size 
that it appears to be. The positions of relevant DNA mass markers are shown in bp. 
Figure 3.18. Analysis of replicon RNA by denaturing agarose gel electrophoresis. RNA, obtained by in vitro transcription of replicon (Rep) 
or N gene (N) template DNA, was run on a 1% agarose gel at 100 V for 35 minutes under denaturing conditions. The positions of relevant 
RNA mass markers are shown in nt. 
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RNA was transcribed from the T1 and T2S DNA templates under the same conditions used for the 
replicon template and the yields were ~700 ng and ~200 ng RNA respectively. Although RNA was 
being produced for the full-length constructs, each transcription reaction consumed a lot of DNA 
template and resulted in a yield that was lower than ideal for downstream applications. In an 
attempt to improve the efficiency of the reaction, in vitro transcription was carried out for four 
hours instead of two. However, this resulted in an even lower RNA yield. A strategy was therefore 
devised to increase the amount and purity of DNA template available for transcription, which 
involved designing primers complementary to the 5’ and 3’ ends of each construct (Appendix A), 
then using long-range PCR to amplify the full-length constructs from their ligation reactions. This 
yielded amplicons that appeared to be the right size by agarose gel electrophoresis for T1 and T2S 
(Figure 3.19), but no specific amplicon could be obtained for the replicon. 
Figure 3.19. Analysis of long-range PCR amplicons by agarose gel electrophoresis. Primers were designed to amplify each full-length 
construct from its respective ligation reaction using long-range PCR. Amplicons were run on a 0.4% agarose gel at 15 V for 24 hours and 
imaged under a UV transilluminator. The name of the construct from which the amplicon is derived is displayed above each lane. The 
positions of relevant DNA mass markers are shown in bp. 
A: Long-range PCR was carried out to amplify replicon (Rep) and T2S in duplicate. 
B: Long-range PCR was carried out to amplify T1 (T1 PCR), and this was run alongside T1 full-length construct DNA (i.e. not PCR-amplified) 
for comparison. 
T1 and T2S long-range PCR products were used as templates for transcription and resulted in an 
approximately 40-fold increase in RNA yield, but when analysed by denaturing agarose gel 
electrophoresis the RNA transcribed from the PCR-amplified templates was smaller than that 
transcribed directly from the ligated template (Figure 3.20). Although an RNA marker large enough 
to verify the size of the full-length RNA was not available, it was assumed that RNA made from PCR-
amplified template DNA was truncated. This was confirmed when RT-PCR failed to amplify the 3’ end 
of the RNA (data not shown). Transcription from this point was only carried out using template that 
had not been PCR-amplified, leading to a lower yield of RNA but a presumably full-length product. 
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Figure 3.20. Analysis of full-length construct RNA by denaturing agarose gel electrophoresis. RNA, obtained by in vitro transcription of 
full-length construct template DNA, full-length construct template DNA amplified by long-range PCR or N gene template DNA, was run on 
a 1% agarose gel at 100 V for 40 minutes under denaturing conditions. The name of the construct is displayed above each lane. The 
positions of relevant RNA mass markers are shown in nt. Rep: replicon, T1 PCR: T1 transcribed from PCR-amplified template, T2S PCR: T2S 
transcribed from PCR-amplified template, N: N gene.  
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3.2.8 Transfecting cells with full-length construct RNA 
With each construct transcribed, work began to transfect the RNA into mammalian cells and 
produce infectious virus or replicon. In all cases, cells were co-transfected with full-length construct 
and N gene RNA, because inclusion of N gene transcripts has been shown to promote the infectivity 
of coronavirus infectious clones assembled by in vitro ligation (Yount et al., 2000). 
3.2.8.1 Transfecting cells with T2S RNA 
T2S RNA was transfected into BHK cells under three conditions: T2S RNA only, T2S+N gene RNA at a 
ratio of 1:1, and N gene RNA only. BHK cells were chosen because they lack an IFN response (Otsuki 
et al., 1979) so may be less resistant to foreign RNA. However, BHK is a hamster cell line that does 
not express feline APN, so even if infectious T2S virions were produced, the infection would be 
abortive in BHK cell culture. The culture supernatant from cells transfected with T2S+N gene was 
therefore passaged on to CrFK cells (known to express feline APN) for two passages. The BHK cells 
that were originally transfected showed no cytopathic effect. On examination by 
immunofluorescence assay using an anti-coronavirus antibody (FIPV3-70) raised against CCoV but 
known to have reactivity with FCoV N protein (Poncelet et al., 2008), no transfected BHK cells were 
stained by the antibody (Figure 3.21), suggesting that coronavirus antigen was not present. A 
positive control for the assay was not available, so it could not be ruled out that infectious T2S had 
been produced but was not being detected. However, FIPV3-70 should have been capable of 
recognising N protein had it been translated from the N gene RNA. To further explore whether the 
transfection was successful, RNA was extracted from an aliquot of cell culture supernatant taken at 
each passage. The RNA was reverse transcribed and a PCR was carried out on the resulting cDNA 
using primers (Appendix A) to generate a 2.2 kb amplicon from the FCoV ORF1a-b gene. The PCR 
products were analysed by agarose gel electrophoresis, but no DNA band was seen for any passage 
(Figure 3.21). These results suggest that T2S RNA did not yield infectious virus. 
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Figure 3.21. Schematic to illustrate the T2S transfection strategy, plus the results of the transfection. BHK cells were transfected with T2S, N gene (N), T2S and N gene (T2S+N) or no (Neg.) RNA (Passage 0). The 
supernatant of the cells transfected with T2S+N gene RNA was passaged on to CrFK cells (Passage 1). The supernatant of the Passage 1 CrFK cells was passaged on to more CrFK cells (Passage 2). The cells that were 
originally transfected underwent an immunofluorescence assay (IFA), in which they were fixed with permeabilisation and incubated with an anti-coronavirus antibody FIPV3-70, followed by a DyLight 488-conjugated 
secondary antibody (green). Nuclei were stained with DAPI (blue). Cells were then viewed using a widefield fluorescence microscope with a 40x oil immersion objective. An aliquot of cell culture supernatant was 
taken at each passage (P0-2) and the RNA was extracted. An RT-PCR was carried out on the RNA, in duplicate, using primers that would yield a 2.2 kb amplicon if FCoV was present. A positive control for the PCR was 
not included. PCR products were run on a 0.7% agarose gel at 100 V for 40 minutes and imaged under a UV transilluminator. 
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3.2.8.2 Transfecting cells with replicon RNA 
In an attempt to establish a replicon cell line, cells were transfected with replicon RNA under three 
conditions: replicon+N gene RNA at a ratio of 4:1, replicon+N gene RNA at a ratio of 1:1, and N gene 
RNA only. The transfection was first carried out using CrFK cells, since they are known to support 
growth of Type 2 FCoV (Van Hamme et al., 2007) so should allow replication of the viral genome. 
Following transfection, puromycin was applied at a concentration of 5 µg/ml to select for cells 
carrying the replicon (which encodes puromycin resistance). This puromycin concentration was 
selected based on a survey of the literature and an experiment demonstrating that this was the 
lowest concentration of puromycin that killed 100% of untransfected CrFK cells (data not shown). No 
cells survived following puromycin selection and no expression of GFP (also encoded by the replicon) 
was observed in dying cells. This result suggests that the replicon RNA had not undergone replication 
to produce sgRNA, or if produced the sgRNA was not translated to detectable levels. 
The transfection was repeated twice using BHK cells. Following the first transfection of BHK cells, 3 
µg/ml puromycin was applied to select for cells carrying the replicon. This puromycin concentration 
was selected based on the protocols previously used in the laboratory. Since no cells survived 
following puromycin selection, a second transfection was carried out and 1.5 µg/ml puromycin was 
used for selection. This was to avoid the possibility that the replicon was being expressed, but the 
puromycin concentration was too high for the puromycin resistance protein to overcome it. Again, 
no cells survived following puromycin selection and no expression of GFP was observed in dying 
cells, suggesting that the replicon RNA either had not undergone replication to produce sgRNA or 




3.2.9 Next generation sequencing 
Since transfection with the full-length constructs failed to produce infectious virus or replicon-
expressing cells, next generation sequencing was used to verify the sequence of the RNA transcripts. 
Full-length in vitro RNA transcripts were reverse transcribed and PCR amplicons were generated 
from the resulting cDNA using the PCR primers described in section 3.2.6 (Figure 3.22). Amplicons of 
the correct size were achieved for all constructs.  
Figure 3.22. Analysis of the RT-PCR amplicons obtained from each full-length construct RNA by agarose gel electrophoresis. A set of PCR 
primers was designed to produce seven or eight overlapping amplicons spanning each full-length in vitro RNA transcript, following a 
reverse transcription step. Amplicons were run on a 0.7% agarose gel at 100 V for 40 minutes and imaged under a UV transilluminator. The 
number of the amplicon (Amp) is displayed above each lane. Replicon (Rep) amplicon 6 was divided into two parts (6.1 and 6.2). The 
positions of relevant DNA mass markers are shown in bp. 
cDNA amplicon pools were created for each construct and these were submitted to the Genomics 
Facility, University of Bristol, for library preparation and next generation sequencing (Figure 3.23). 
The sequencing results showed that there was full coverage of each construct with a minimum 
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depth of 2,625 reads at each base, though there were spikes in read depth corresponding to PCR 
primer annealing sites. The consensus genome of the replicon construct was correct, but the T1 and 
T2S constructs contained three and two areas respectively of sequence that deviated from expected. 
Moving from 5 to 3, the first area of sequence deviation, common to both T1 and T2S, consisted of 
one base and lay within amplicon 1, derived from unit 1. The second area, also common to both T1 
and T2S, consisted of six bases and lay within amplicon 3, derived from unit 2. The third area, only 
present in T1, consisted of six bases and lay within amplicon 6, derived from unit 5. None of the 
areas overlapped with PCR primer annealing sites or unit boundaries. In each of these areas there 
was heterogeneity in the sequence, with a significant proportion (in most cases the majority) of 
reads representing the correct sequence and the remainder representing the incorrect sequence. It 
is unclear what these areas of heterogeneity represent, but the results suggest that the constructs 
were generally ligated and transcribed correctly to produce RNA faithful to the expected sequence. 
It is therefore likely that the attempts to produce infectious virus or replicon-expressing cells 
following transfection of the RNA into cells failed due to a different reason. 
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Figure 3.23. Next generation sequencing results of the three full-length constructs. Full-length RNA transcripts of T1, T2S and replicon 
(Rep) were reverse transcribed and PCR amplified to produce a set of cDNA amplicons ranging from 1.5 to 6.5 kb. The set of amplicons 
representing each construct was pooled in an equimolar fashion and submitted for library preparation and next generation sequencing. 
The reads were aligned against the expected sequence of each construct. Read depth is shown as a grey trace. Where there is significant 
deviation from the expected sequence, that base position is shown in colour instead of grey. A closer view of these areas reveals the 
proportion of reads at the position representing the deviated sequence, with the colour corresponding to the base (red: T, blue: C, green: 




This chapter describes the steps taken towards establishing a Type 1 FCoV reverse genetic system. 
Such a system would allow mutations to be strategically introduced into the viral genome, enabling 
investigation of the consequences of given mutations on virus phenotype. It would also serve as a 
powerful platform for vaccine development and antiviral drug screening. 
An in vitro ligation approach was taken to produce the full-length infectious cDNA clones in this 
project. This method was adopted because it was potentially fast and simple compared to the 
alternatives of the use of vaccinia virus or BAC vectors. Additionally, this method has been used 
successfully to recover a number of other recombinant coronaviruses (Almazan et al., 2014). The 
main obstacle to the production of the full-length constructs built was the instability of certain 
regions of the genome when undergoing amplification in bacteria, leading to deletions, mutations 
and rearrangements. This was particularly the case with units 1, 2 and 4, which all correspond to 
regions within the FCoV ORF1a-b gene. This region has previously been reported to contain 
sequences that are unstable in bacterial culture (Scobey et al., 2013, Yount et al., 2000), including in 
BAC vectors (Thiel et al., 2001). Considering that methods that use vaccinia virus as a vector also 
require some degree of in vitro amplification of genome fragments (Almazan et al., 2014), it is likely 
that this problem would have arisen regardless of the method used to produce the full-length 
infectious cDNA clones.   
To overcome the problem of instability, two strategies were utilised: cloning into a low copy number 
vector and PCR amplification. The only units that were successfully cloned into low copy number 
vectors were units 5 and 5T2, and this was out of necessity because the original strategy of cloning 
all fragments into the fragment ‘A’ plasmid was not possible. A low copy number vector, pWSK29, 
was chosen because it was assumed – given that their ‘A’ fragments could not be amplified 
successfully in bacteria – that units 5 and 5T2 might contain sequences toxic to bacteria. This vector 
in particular was chosen because it has been used to overcome instability issues when assembling 
full-length infectious cDNA clones of SARS-CoV (van den Worm et al., 2012). Primers were designed 
to add flanking sequences on to units 2 and 4, but these units were never cloned into the low copy 
number vector and instead were amplified by PCR before being ligated into the full-length 
constructs. Given more time, it would be beneficial to clone these units into the low copy number 
vector so they are available as stable plasmids that can be amplified in bacterial culture. 
The approach taken in this project was to clone fragments and then units into plasmids and amplify 
them in bacterial culture, only using PCR amplification as a last resort. This is because PCR results in 
DNA polymerase-induced errors in the amplified DNA sequence. However, the error rate is 
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extremely low with proofreading polymerases (Cha and Thilly, 1993). Given the problems 
experienced over the course of this project with amplifying DNA in bacterial culture, using PCR to 
amplify from the beginning would have made the process of assembling full-length infectious clones 
easier. As the project progressed, PCR was increasingly used successfully to amplify fragments (1B) 
and units (2 and 4) that were unstable in bacterial culture. In future, PCR should be considered as a 
strategy for amplifying unstable fragments and units from the beginning. 
Eventually all units taken forward to be ligated into full-length constructs were sequence-perfect 
except for unit 1, where three mutations were introduced when the ligated unit was grown in 
bacterial culture. The mutations were T1796C (T>C at unit 1 position 1796), T2225C (T>C at unit 1 
position 2225) and A2487G (A>G at unit 1 position 2487). The first two mutations are synonymous 
so would not be expected to influence the structure or function of the final infectious clone into 
which the unit would be incorporated, but the latter mutation results in an amino acid substitution 
of valine for isoleucine within the ORF1a gene. Both are aliphatic amino acids with no charge, but 
valine is larger and more hydrophobic than isoleucine.  In order to assess the conservation of 
isoleucine at the position of the substitution, the 70 most similar sequences to FCoV 80F, comprising 
strains of FCoV and CCoV, and two TGEV strains were analysed. All 71 sequences were found to have 
an isoleucine at the position of the substitution, suggesting that this amino acid is highly conserved 
and therefore may be critical for coronavirus replication. However, the position of the substitution 
suggests that, once ORF1a is translated and cleaved, it would sit within nsp2, which is thought to 
interfere with host defences rather than support viral replication directly (Neuman et al., 2014). It is 
unknown whether this amino acid substitution will impact the infectious clones, but, given more 
time, it would be preferable to repair the mutation. A possible strategy for doing this would be to 
PCR amplify the unit from the NEBuilder HiFi DNA assembly ligation reaction, as was done 
successfully for unit 4. This should result in a sequence-perfect unit 1, as the bacterial culture step 
that presumably introduced the mutations would be avoided. 
The full-length constructs were designed to encompass flanking sequences that would allow them to 
be ligated into a vaccinia virus vector. Given that one of the limitations experienced in the project 
was generating enough full-length construct DNA template to get a good yield of RNA, transferring 
the constructs into vaccinia virus seems like an obvious next step to overcome this challenge. Within 
this project, attempts were made to optimise the full-length construct ligation step by changing the 
DNA concentration and temperature of ligation reactions, neither of which made an appreciable 
difference; as well as a strong band corresponding to full-length DNA template seen on agarose gel 
electrophoresis of the ligation reactions, many non-specific bands were present. These bands likely 
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represented units that had joined together incorrectly, though this should not have been able to 
happen since the BsmBI sites between the units were unique.  
Long range PCR was briefly tested as a way of amplifying the full-length DNA template and thereby 
increasing RNA yield. At first this appeared to work extremely well for the T1 and T2S constructs, 
with a 40-fold increase in RNA yield when transcribing PCR-amplified template compared with non-
amplified. However, it soon emerged that the RNA transcribed from PCR-amplified template was 
truncated at the 3 end. The truncation was discovered when PCR failed to produce an amplicon 
from the 3 end of PCR-amplified T2S and T1. Unfortunately, this only occurred after an attempt was 
made to transfect cells with T2S RNA made from PCR-amplified template. It is therefore not 
surprising that the transfection failed to yield infectious virus. In future work this experiment should 
be repeated using T2S RNA transcribed from a non-amplified template, ideally including a positive 
control. In this experiment, transfection success was measured in two ways: an immunofluorescence 
assay examining the transfected cells for coronavirus antigen, and RT-PCR examining the cell culture 
supernatant at each passage for FCoV RNA. A positive control for both assays could be RNA of a 
different coronavirus infectious clone that is known to yield infectious virus in BHK cells. A positive 
control for the PCR element of the RT-PCR could be any of the full-length DNA templates produced 
in this project. 
Attempts were also made to transfect cells with replicon RNA. Despite the RNA being transcribed 
from non-amplified template, the experiment failed in two different cell types (CrFK and BHK). CrFK 
cells were used first because they are feline cells known to support propagation of Type 2 FCoV (Van 
Hamme et al., 2007), but no cells expressed GFP or survived following puromycin selection. It was 
decided to use BHK cells instead, because they lack an interferon response (Otsuki et al., 1979) and 
therefore may be more permissive to the replicon. The transfection was repeated twice using BHK 
cells, the second time using a very low puromycin concentration to ensure that cells expressing the 
replicon were not being killed. However, no cells expressed GFP or survived following puromycin 
selection on both occasions. As a positive control for transfection was not included, it is unknown 
whether the experiments failed at the transfection stage or later. In the future a positive control 
mRNA (e.g. encoding a reporter gene) could be included in the transfection protocol. Almazan et al. 
(2004) demonstrated that the same replicon construct can be cytopathic to some cell types and non-
cytopathic to others. It is possible that the replicon was being expressed but was cytopathic in the 
cell lines used, although, if this was the case, GFP expression should have been observed in cells 
before they died. 
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Cells were co-transfected with full-length construct and N gene RNA because inclusion of N gene 
transcripts has been shown to improve recovery rates and replication efficiency of infectious clones 
(Beall et al., 2016, Yount et al., 2000). The anti-coronavirus antibody (FIPV3-70) used in this project is 
known to specifically recognise the FCoV N protein (Poncelet et al., 2008). If the N gene transcripts 
had been translated, the cells transfected with N gene (with or without T2S) should have been 
positive with this antibody in an immunofluorescence assay. However, this was not the case. The N 
gene is a simple construct that was available in this project at a high purity and concentration, so its 
expression in transfected cells should have been straightforward. The failure to detect N protein in 
an immunofluorescence assay may therefore indicate an issue with the transfection procedure, 
although this cannot be confirmed since a positive control for the assay was not included. 
In this project a chemical method of transfection which had previously been used successfully for 
other coronavirus RNA transcripts was used. If further investigations suggested that the experiment 
was failing at the transfection stage, it would be worthwhile to attempt electroporation of in vitro 
RNA templates into cells instead. Electroporation is known generally to be more efficient than 
chemical methods for the introduction of genetic material into cells (Sharifi Tabar et al., 2015), and 
electroporation has been used successfully for transfection of coronavirus full-length constructs into 
cells by other groups (Beall et al., 2016, Ehmann et al., 2018). 
Given that neither infectious virus nor replicon-expressing cells were produced in the transfection 
experiments, it was decided to sequence cDNA fragments derived from the full-length in vitro RNA 
transcripts to check whether the constructs had been ligated and transcribed properly. A next-
generation sequencing approach was taken because this was how Type 1 FCoV 80F was sequenced 
when it was first isolated from a clinical sample (Lewis et al., 2015), therefore it is an established 
method and primer sequences were available for generating the amplicons. Many of the original 
primer sequences were used in this project, though some were changed to enable the same set of 
primers to produce amplicons from all three constructs. The primers annealing to the 5’ and 3’ 
extremes of the constructs were also redesigned to incorporate the entire sequence. Following 
reverse transcription, a full set of cDNA amplicons of the correct size was obtained for all constructs 
with minimal optimisation, suggesting that they had been ligated and transcribed properly. The 
amplicons were pooled for each construct and submitted for next-generation sequencing, which 
found that the constructs were generally as expected, corroborating that they had been ligated and 
transcribed correctly.  
It is unclear what caused the areas of sequence heterogeneity observed in the T1 and T2S 
constructs, but, considering how many steps there were between ligating the sequenced units (i.e. 
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the last point where the sequence was verified) and next-generation sequencing, it is perhaps not 
surprising that errors were introduced. Due to the nature of the errors, it seems most likely that RNA 
secondary structure was interfering with the ability of the polymerase (either RNA polymerase in the 
transcription step or DNA polymerase in the reverse transcription step) to incorporate bases 
correctly. However, it is impossible to pinpoint at exactly which step the errors arose, therefore it is 
unknown whether some copies of the full-length construct RNA genuinely contained incorrect 
sequence or whether this was an artefact of the RT-PCR, library preparation or next-generation 
sequencing steps. 
Nanopore sequencing was considered as an alternative to next-generation sequencing, since it is 
available and widely used in our laboratory. The advantages of nanopore sequencing are that direct 
RNA sequencing is possible and there is the capability of producing full-length reads. These features 
would avoid the need for reverse transcription of RNA, PCR of cDNA and fragmentation of 
amplicons, saving time and effort as well as circumventing steps that may have introduced errors. 
Additionally, this method can detect diverse and novel sgRNAs and methylation sites (Viehweger et 
al., 2019). However, the main drawback of nanopore sequencing is a high base call error rate, which 
can be overcome when next-generation sequencing data are also available (Laver et al., 2015). It 
could therefore be useful to carry out nanopore sequencing on the full-length construct RNA to 
verify the results of next-generation sequencing. Looking to the future, nanopore sequencing could 
also prove a useful tool to characterise FCoV transcripts produced in infected cells.  
At the start of this project, the only published Type 1 FCoV reverse genetic system was based on the 
FCoV strain ‘Black’, which is laboratory-adapted and cannot be said to represent field strains of Type 
1 FCoV (Pedersen, 2009). The need for a reverse genetic system based on a field strain of Type 1 
FCoV was obvious, hence the decision to base our reverse genetic system on Type 1 FCoV 80F: a 
strain found in the faeces of a naturally-infected, healthy cat (Lewis et al., 2015). Ehmann et al. 
(2018) since developed the first full-length infectious clone based on a field strain of Type 1 FCoV 
(recFECV). The group cloned a cDNA copy of the virus, originally isolated from the faeces of a healthy 
FCoV-infected cat, into a vaccinia virus vector. Like the T2S construct produced in this project, they 
also produced a chimeric construct with a Type 1 FCoV field strain backbone but a Type 2 FCoV ‘79-
1146’ S gene. Since recombinant FCoV carrying the ‘79-1146’ S gene is known to infect FCWF cells 
(Tekes et al., 2012, Thiel et al., 2014), the chimeric construct was used in in vitro assays as a proxy 
for recFECV. The group found that infectious recFECV virions could be recovered from cell culture 
supernatant and, although these particles were not infectious in vitro, they caused productive 
infections in cats that closely mirrored what was seen with the parental virus. Though very similar, it 
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is still worthwhile to persevere with the reverse genetic system developed in this project because it 
offers two novel points: 
1. FCoV mutates readily, so two strains with the same pathotype (i.e. FECV) can be genetically 
distinct, particularly when isolated from different geographical regions and at different time 
points (the Type 1 FCoV 80F used in this project was isolated in the UK in 2011 (Lewis et al., 
2015), whereas the strain used by Ehmann et al. (2018) was isolated in Germany in 2012). 
The production of infectious clones based on a variety of Type 1 FCoV field strains will lead 
to a fuller understanding of the virus. 
2. This project aims to establish the first FCoV replicon. 
A major limitation with the study by Ehmann et al. (2018), and something that has long impeded 
FCoV research, is absence of a cell line in which Type 1 FCoV can be propagated. Due to this, the 
authors had no choice but to employ in vivo propagation by using recFECV to directly infect live cats, 
when an in vitro characterisation stage may have been informative. It was hoped that, by identifying 
a Type 1 FCoV CER and producing a cell line capable of propagating Type 1 FCoV (see Chapter 4), this 
project would not only establish a Type 1 FCoV reverse genetic system but also a way of rescuing 
recombinant viruses in vitro. Part of the reason for developing T2S and replicon constructs in this 
project is that they would be usable even before a cell line supporting Type 1 FCoV propagation is 
developed. As well as helping to assess the success of the reverse genetic system, T2S would be 
useful for exploring the role of the S protein and investigating mutations in parts of the genome 
outside of the S gene. Similarly, the replicon would be a useful tool for investigating the replicative 
machinery of the virus and the effect of viral replication on the transcriptome and proteome of the 
cell, and would provide a fast, high-throughput way of screening anti-viral compounds. 
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4 Identifying a CER for Type 1 FCoV 
4.1 Introduction 
This chapter will describe the validation, optimisation and application of a method of identifying a 
Type 1 FCoV CER. 
There are two FCoV serotypes: Type 1 and Type 2. Though Type 1 FCoV is responsible for most 
natural infections, Type 2 is the predominant serotype used for in vitro work. This is because there 
are many cultured cell lines available in which Type 2 FCoV can be propagated, whereas there are no 
known available cell lines in which Type 1 FCoV can be grown in vitro. On identification of a CER for 
Type 1 FCoV, the receptor could be stably expressed in a cell line, potentially rendering the cells 
permissive to infection. Such a tool would allow strains of FCoV representative of natural infections 
to be propagated in vitro, thus leading to a better understanding of the biology of the virus. A cell 
line which could be used to propagate Type 1 FCoV would also be a crucial component of a reverse 
genetic system, as it would allow rescue of recombinant viruses. A Type 1 FCoV reverse genetic 
system would enable the effects of viral mutations on phenotypic characteristics including tropism 
and virulence to be ascertained, and eventually serve as a platform for vaccine development and 
drug discovery. 
The method used for identifying a Type 1 FCoV receptor in this project will be referred to herein as 
the ‘bait protein’ method. Raj et al. (2013) first used the bait protein method to identify a CER for 
the emerging MERS-CoV. The method involves expression of a chimeric protein comprising the S1 
domain of the viral S protein and the Fc region of human IgG (i.e. the bait protein) and incubating 
the bait protein with cells susceptible to infection. The bait protein can be purified using its IgG Fc 
portion, and the cell surface protein to which the S1 portion binds can then be identified using mass 
spectrometry. Previously in the laboratory, bait proteins bearing the S1 domains of Type 1 (Type 1 
bait protein) and Type 2 (Type 2 bait protein) FCoVs were produced and preliminary experiments 
done to optimise the expression and purification of the bait proteins for use in receptor 
identification experiments (Quirke, 2016). The S1 domain of the Type 1 bait protein is based on the 
FCoV strain 80F, which was isolated from the faeces of a naturally infected cat without FIP (Lewis et 
al., 2015). The S1 domain of Type 2 bait protein is based on FCoV 79-1146, a highly virulent 
laboratory-adapted strain (Pedersen, 2009). In this project, the Type 2 bait protein will be used with 




In the case of Raj et al. (2013), an approximately 110 kDa protein was precipitated from MERS-CoV 
susceptible Huh7 (human liver) and Vero (African green monkey kidney) cells by a bait protein 
bearing the S1 of MERS-CoV. This protein was visualised as a band on a gel, then the band was 
excised and identified as DPP4 by mass spectrometry analysis. In contrast, this project will use mass 
spectrometry and proteomic analysis to identify and quantify the proteins that are precipitated by 
the bait proteins. Tandem Mass Tag (TMT) labels – stable isotope labels that are covalently linked to 
peptides derived from bait protein immunoprecipitates and recognised by the mass spectrometer 
(Bantscheff et al., 2007) – will be utilised to enable the quantification of differences between 
proteins precipitated with the bait proteins and a negative control.  
In order to use the bait protein method to identify a Type 1 FCoV CER, a cell type bearing a Type 1 
FCoV CER must be used for the proteomic screen. In the natural course of infection, FCoV spreads 
from the intestinal epithelium to monocytes and is conveyed systemically via a monocyte-associated 
viraemia (Kipar et al., 1999a, Gunn-Moore et al., 1998, Meli et al., 2004, Desmarets et al., 2016). 
Work by Van Hamme et al. (2007) demonstrated efficient binding and internalisation of a laboratory-
adapted Type 1 FCoV strain by ex vivo feline monocytes, and a preliminary study suggested that viral 
pseudotypes expressing a Type 1 FCoV field strain S protein were able to infect ex vivo feline 
monocytes (Dye, 2006). These results indicate that feline monocytes are permissive to Type 1 FCoV 
entry and therefore likely carry a CER that the virus can utilise. 
Intestinal epithelial cells, and particularly the mature cells situated on the villous tips, have been 
shown to contain FCoV antigen in cats naturally infected with the virus (Kipar et al., 1998b), 
demonstrating that they are permissive to viral entry. This was confirmed when a feline intestinal 
epithelial cell line was developed and successfully infected with a field strain of Type 1 FCoV, albeit 
with low efficiency (Desmarets et al., 2016). Unfortunately, this cell line is not available for this 
project, despite attempts to obtain it for research purposes. 
Intestinal organoids are 3D cultures, derived from clusters of Lgr5+ stem cells (also known as ‘crypts’) 
situated between intestinal villi, that self-organise into ‘mini guts’ containing all the cells present in 
the normal intestinal epithelium. Not only do these organoid cultures better recapitulate the 
organisation, functionality and heterogeneity of the intestine than cell lines, they also benefit from 
being self-propagating without the need for transformation (Ramani et al., 2018). Intestinal 
organoids were first developed by Sato et al. (2009), who found that Lgr5+ stem cells isolated from 
murine small intestine spontaneously developed into crypt-villus units. Intestinal organoids have 
since been established from a range of species including cats (Powell and Behnke, 2017), and have 
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been used to further our understanding of intestinal epithelial biology, as the basis of disease 
models and even to regenerate the intestinal epithelium (Date and Sato, 2015).  
Just as researchers have struggled to propagate field strains of Type 1 FCoV in vitro, this was also the 
case for human noroviruses (HuNoVs); intestinal pathogens which for over 40 years could be not 
grown in cell culture until Ettayebi et al. (2016) demonstrated that human intestinal organoids 
support HuNoV replication. Similarly, human rotaviruses, which generally replicate poorly in 
transformed cell lines, grew successfully in human intestinal organoids and even induced 
physiological changes typical of rotavirus diarrhoea (Saxena et al., 2016).  Since Type 1 FCoV is also 
an intestinal pathogen, it is feasible that these breakthroughs could be repeated with feline 
intestinal organoids and Type 1 FCoV. If feline intestinal organoids could support in vitro propagation 
of field strains of Type 1 FCoV, this would circumvent the need to create a susceptible cell line.  
4.1.1 Aims 
The aims of this part of the project were to: 
• Validate and optimise the bait protein method by using it to ‘identify’ the Type 2 FCoV CER, 
using cells known to express this receptor 
• Identify a cell type bearing a Type 1 FCoV CER 






4.2.1 Production and analysis of bait proteins 
Plasmids encoding Type 1 (pT1) and Type 2 (pT2) FCoV bait proteins, produced previously by Quirke 
(2016), were transformed into bacteria and amplified in bacterial culture. Plasmid DNA was 
extracted using a midiprep procedure and analysed by restriction digestion (Figure 4.1). Agarose gel 
electrophoresis showed that the plasmids were of the expected size; pT1 and pT2 both showed 
bands of approximately 5,000 bp and 3,000 bp when digested, which corresponds with the expected 
sizes of the pCAGGS vector and inserts respectively. The plasmid DNA was purified and concentrated 
using ethanol precipitation, ready for transfection into mammalian cells for bait protein production. 
Figure 4.1. Analysis of bait protein-encoding plasmids by agarose gel electrophoresis.  Plasmids encoding Type 1 (pT1) and Type 2 (pT2) 
FCoV bait proteins were amplified in bacterial culture, then the plasmid DNA was extracted and digested with appropriate restriction 
enzymes to liberate the inserts from their plasmids. The digestion products (D) were run alongside an aliquot of undigested plasmid (U) on 
a 1% agarose gel at 100 V for 40 minutes. The DNA bands were visualised under a UV transilluminator. The positions of relevant DNA mass 
markers are shown in bp. 
HEK293T cells were transfected with pT1 and pT2, as well as pmaxGFP as a positive control and the 
empty parental pCAGGS vector as a negative control (obtained from Quirke (2016)). Using the 
transfection protocol developed by Quirke (2016), a transfection efficiency of approximately 50% 
(measured by the proportion of transfected cells expressing GFP) was observed. An experiment was 
set up to optimise the transfection procedure, whereby two variables – the source of HEK293T cells 
and age of Lipofectamine transfection reagent – were evaluated. The former variable was chosen 
because HEK293T cells (‘HEK293T new’) that had been clonally selected for optimal transfection 
efficiency in lentivirus packaging experiments were available in the laboratory, whereas the 
provenance of the cells used in the first transfection experiment in this project (‘HEK293T old’) was 
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unknown. The latter variable was chosen because the performance of Lipofectamine is only 
guaranteed for six months following purchase (Thermo-Fisher, 2015), and the batch used for the 
original transfection experiments (‘Lipofectamine old’) was over a year old. The new batch 
(‘Lipofectamine new’) was less than six months old. The two different cell lines were transfected 
with pmaxGFP, each using ‘Lipofectamine old’ and ‘Lipofectamine new’ and viewed using light and 
fluorescence microscopy (Figure 4.2). Transfection efficiency was similar (between 73% and 78%) 
under all conditions, except when ‘Lipofectamine old’ and ‘HEK293T old’ were used together and 
efficiency dropped to 52%. The efficiency of transfection was significantly associated with both 
HEK293T type and Lipofectamine age (p<0.001). 
Figure 4.2. Examination of transfected cells to determine the impact on transfection efficiency of two variables. HEK293T cells, 
transfected with pmaxGFP, were viewed using light (left) and fluorescence (right) microscopy at 100x magnification, and the percentage of 
cells expressing GFP (green) was counted manually. The experiment was carried out in duplicate but only one set of results is shown.  
A+B: ‘HEK293T old’, ‘Lipofectamine new’;  
C+D: ‘HEK293T old’, ‘Lipofectamine old’;  
E+F: ‘HEK293T new’, ‘Lipofectamine new’; 
G+H: ‘HEK293T new’, ‘Lipofectamine old’. 
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Following transfection with pT1, pT2 and empty pCAGGS using the optimised conditions, transfected 
cells were cultured for 72 hours (identified as the optimal culture length by Quirke (2016)) and the 
cell culture supernatants were harvested. Some of the culture supernatant containing each bait 
protein was purified by affinity chromatography. The raw and purified supernatants were examined 
by SDS-PAGE and Coomassie Brilliant Blue staining or western blot (Figure 4.3), which showed that 
bait proteins of the correct sizes (140 kDa for Type 1 and 150 kDa for Type 2) were produced and 
secreted into the culture supernatant, and were still present in the purified eluate.  
Figure 4.3. Demonstration of the presence of bait protein in transfected cell culture supernatant. Proteins in equal volumes of raw cell 
culture supernatant, produced from approximately equal numbers of cells transfected with pT1 (T1), pT2 (T2) or empty pCAGGS vector (-), 
were denatured and run on a 4-12% SDS-PAGE Bis-Tris mini gel. Proteins in the gel were transferred onto a membrane and this was 
probed with anti-human IgG Fc antibody. The membrane was then incubated with a horseradish peroxidase-labelled secondary antibody, 
prior to application of a chemiluminescent substrate and exposure to x-ray film. Bait proteins produced in two separate transfections 
(Transfection 1 and Transfection 2) are shown. The positions of relevant molecular mass markers are shown in kDa.  
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4.2.2 Validation of the bait protein method 
In order to validate and optimise the bait protein method as a way of identifying a Type 1 FCoV CER, 
the method was first used to ‘identify’ the Type 2 FCoV CER on CrFK cells, which are known to carry 
the Type 2 FCoV CER, fAPN. 
An immunofluorescence assay was carried out to screen CrFK cells with the bait proteins (Figure 
4.4). This was done to check whether Type 2 bait protein was capable of recognising fAPN on the 
surface of CrFK cells, and to compare the performance of neat and purified and concentrated Type 2 
bait protein. Where the bait protein was used as neat culture supernatant, it was diluted 1 in 2 in 
blocking buffer before use in the assay. Although this dilution was simply chosen as a starting point, 
the assays worked well, so no further optimisation of the bait protein dilution was carried out. By 
visualising different dilutions of neat and purified bait protein alongside each other with SDS-PAGE 
and Coomassie Blue staining (data not shown), neat bait protein at a dilution of 1 in 2 was calculated 
to be equivalent to purified bait protein at a dilution of 1 in 14.   
Figure 4.4. Examination of CrFK cells by immunofluorescence assay for bait protein recognition. CrFK cells were grown on glass coverslips 
then fixed without permeabilisation. The cells were incubated with neat Type 1 (1 in 2; B), neat Type 2 (1 in 2; C), purified Type 2 (1 in 14; 
D) or no (A) bait protein, followed by a DyLight 488-conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Cells 
were then viewed using a confocal laser scanning microscope with a 40x oil immersion objective. 
The immunofluorescence assay demonstrated staining with the Type 2 but not Type 1 bait protein, 
indicating a specific interaction between the Type 2 bait protein and CrFK cells. This staining 
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occurred with both neat and purified Type 2 bait protein, with little visible difference between the 
two. From this point of the project onwards, only neat bait protein was used. 
The specific interaction between CrFK cells and Type 2 bait protein was confirmed using flow 
cytometry (Figure 4.5), which demonstrated a clear divide between cells incubated with Type 2 and 
no bait protein. 
Figure 4.5. Examination of CrFK cells by flow cytometry for bait protein recognition. A CrFK cell suspension was made using ACCUTASE™ 
cell detachment solution. Cells were incubated with Type 2 or no bait protein, followed by a CF 633-conjugated secondary antibody. Cells 
were analysed on an LSR II flow cytometer, using a 633 nm laser for excitation and a 660/20 band pass filter for detection. The plot 
displays intensity of light emitted from CrFK cells incubated with Type 2 (blue dots) and no (red dots) bait protein and is gated to include 
only live, single cells. FSC-A: forward scatter (a measure of cell size). 
The next step was to determine by immunoprecipitation, mass spectrometry and proteomics what 
the Type 2 bait protein recognised on CrFK cells. Following the protocol that Raj et al. (2013) used to 
identify the CER for MERS-CoV, lysates were prepared from CrFK cells using a detergent (n-Dodecyl 
ß-D-maltopyranoside; DDM) designed to isolate cell surface proteins. The lysates were incubated 
with the Type 1 and 2 bait proteins, plus, as a negative control, culture supernatant not containing 
bait protein. This in turn was incubated with Protein A resin, which binds the IgG Fc portion of the 
bait proteins, coprecipitating anything which the bait proteins have bound. A proportion of the 
proteins eluted from the Protein A resin were analysed by SDS-PAGE and Coomassie Blue staining 
(Figure 4.6), which showed bands for the Type 1 and 2 bait proteins but no other visible difference 
between the three conditions. A 109 kDa band representing fAPN was not detectable in the Type 2 
bait protein immunoprecipitate, but this may have simply meant that the amount of fAPN was below 
the level of detection for Coomassie blue staining. Very strong bands were present at approximately 
160 kDa under all three conditions, suggesting a strong, non-specific interaction between Protein A 
and a component of the eluates. Using the same protocol this protein band was also recognised by 
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Quirke (2016), who analysed the protein by mass spectrometry and identified it as feline myosin-9. A 
step to pre-clear myosin-9 from the CrFK cell lysate and culture supernatants was considered, but 
Quirke (2016) found this to have little impact on the amount of myosin-9 in the final eluates. This 
step was therefore omitted. 
Figure 4.6. Analysis of the proteins present at different stages of an immunoprecipitation experiment with CrFK cells and the bait 
proteins. CrFK cells were lysed and membrane proteins solubilised using a detergent designed specifically to isolate cell surface proteins 
(Lysate). The lysate was incubated with an equal volume of Type 1 (T1), Type 2 (T2) or no (-) bait protein, and these in turn were incubated 
with Protein A resin, which binds the IgG part of the bait proteins. Lysate, proteins that did not bind to Protein A resin (flow through; FT) 
and proteins that bound to and were eluted from Protein A resin (eluate) were denatured and run on a 4-12% SDS-PAGE Bis-Tris mini gel, 
followed by Coomassie Brilliant Blue staining. The positions of relevant molecular mass markers are shown in kDa. 
Despite the issue with myosin-9, it was decided to continue with the procedure because this project 
used quantitative mass spectrometry, so any protein enriched under all conditions could be 
excluded from the analysis. Immunoprecipitated proteins were digested in solution, and the 
resulting peptides TMT-labelled and identified through mass spectrometry. Only 18 feline proteins, 
none of which were fAPN, were identified, despite the detection of more than 18 proteins by SDS-
PAGE and Coomassie Blue staining.  
The experiment was repeated as described above and similarly resulted in an extremely limited 
protein list. At this point it was unknown whether the problem lay with the immunoprecipitation 
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protocol, peptide preparation (i.e. in-solution digestion or TMT-labelling) or the feline protein 
database. To troubleshoot, a CrFK whole cell lysate was analysed by mass spectrometry, without 
TMT-labelling. Additionally, in-gel (as opposed to in-solution) digestion was carried out to remove 
any residual DDM from the samples; since it is not a commonly used detergent in 
immunoprecipitation experiments, DDM may have been causing an issue. Over 2,000 feline proteins 
were identified (Appendix D), indicating that the problem was with immunoprecipitation or peptide 
preparation as opposed to the feline database. Next, this in-gel digestion and non-TMT approach 
was carried out on proteins immunoprecipitated from a CrFK cell lysate by the bait proteins. Over 
1,000 proteins were identified (Appendix D), indicating that immunoprecipitation was not the issue 
and rather the problem lay with peptide preparation. Though not quantitative, this experiment 
identified fAPN as one of the 20 most abundant proteins, compared to the negative control in which 
fAPN was not identified at all. 
Finally, proteins obtained through immunoprecipitation by the bait proteins underwent in-gel 
digestion and TMT-labelling. Over 700 proteins were identified through mass spectrometry 
(Appendix D), and fAPN was identified as the second hit for the immunoprecipitation with the Type 2 
bait protein. In contrast, the top five proteins for the immunoprecipitation with the Type 1 bait 
protein did not include fAPN, and instead comprised proteins that are not known to localise at the 
cell surface or function as receptors (Tables 4.1 and 4.2). The top hit for the immunoprecipitation 
with the Type 2 bait protein, putative small glutamine-rich tetratricopeptide repeat-containing 
protein alpha (SGTA), was the fourth most enriched by Type 1 bait protein, suggesting a common 
interaction with both serotypes. 
Having optimised the immunoprecipitation, mass spectrometry and proteomics procedure and 
‘identified’ fAPN on CrFK cells using the Type 2 bait protein, the procedure was now ready to be 




Table 4.1. The top five proteins immunoprecipitated from CrFK cells by the Type 1 bait protein. Proteins were identified following in-gel 
digestion, TMT-labelling and mass spectrometry of the immunoprecipitates, then sorted based on the log2 fold change in their abundance 
compared with the control immunoprecipitation. 
 
Table 4.2. The top five proteins immunoprecipitated from CrFK cells by the Type 2 bait protein. Proteins were identified following in-gel 
digestion, TMT-labelling and mass spectrometry of the immunoprecipitates, then sorted based on the log2 fold change in their abundance 





4.2.3 Screening cell lines for a Type 1 FCoV CER 
On validating and optimising the bait protein method, work began to identify a cell type expressing a 
Type 1 FCoV CER. Two cell lines that had not been previously tested for their permissibility to Type 1 
FCoV infection, DH82 (a canine macrophage-like line) and FE-A (a feline embryonic line), were 
analysed. Though a canine cell line, DH82 was chosen because FCoV has a tropism for macrophages 
and, owing to the evolutionary relatedness of cats and dogs and the origin of Type 2 FCoV, 
interspecific circulation of FCoV in dogs is plausible (Le Poder, 2011). As DH82 is a macrophage-like 
cell line and macrophages are known to express Fc receptors, human IgG Fc was used to control for 
Fc receptor binding. To determine a concentration of human IgG Fc equivalent to the bait proteins in 
culture supernatant, three dilutions of IgG Fc were analysed alongside the bait proteins by SDS-PAGE 
and western blotting (Figure 4.7). Bands of the expected size were detected for human IgG Fc (32 
kDa), Type 1 bait protein (140 kDa) and Type 2 bait protein (150 kDa). It is unknown what the 
additional non-specific bands represented. Neat bait protein was estimated to contain the same 
amount of protein as IgG Fc diluted 1:500, which was equivalent to 4.6 µg/ml. 
Figure 4.7. Analysis by western blot of the concentration of protein in human IgG Fc compared with culture supernatant containing the 
Type 1 and 2 bait proteins. Human IgG Fc at various dilutions, neat Type 1 bait protein-containing culture supernatant (T1), neat Type 2 
bait protein-containing culture supernatant (T2) or neat culture supernatant containing no bait protein (-) was denatured and loaded onto 
a 4-12% SDS-PAGE Bis-Tris mini gel. Proteins in the gel were transferred onto a membrane and this was probed with anti-human IgG Fc 
antibody. The membrane was then incubated with a horseradish peroxidase-labelled secondary antibody, prior to application of a 
chemiluminescent substrate and exposure to x-ray film. The positions of relevant molecular mass markers are shown in kDa. 
104 
 
On determining the correct dilution of IgG Fc to use, an immunofluorescence experiment was 
carried out using the bait proteins and IgG Fc as a negative control with DH82 and FE-A cells (Figure 
4.8). The results demonstrated specific staining of DH82 cells with the Type 2 but not the Type 1 bait 
protein, and no staining of FE-A cells with either bait protein. This suggested that something on the 
surface of DH82 cells was recognised by the Type 2 bait protein, but that neither DH82 nor FE-A cells 
carry a Type 1 FCoV CER. 
Figure 4.8. Examination of DH82 and FE-A cells by immunofluorescence assay for bait protein recognition. Cells were grown on glass 
coverslips then fixed without permeabilisation. The cells were incubated with either the Type 1 bait protein, Type 2 bait protein or human 
IgG Fc – negative control, followed by a DyLight 488-conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Cells 
were then viewed using a confocal laser scanning microscope with a 40x oil immersion objective. These results are typical of two 
replicates. 
A: DH82, IgG Fc – negative control; B: DH82, Type 1 bait protein; C: DH82, Type 2 bait protein; 




4.2.4 Screening feline PBMC for a Type 1 FCoV CER 
Feline PBMC were chosen next to be screened for a Type 1 FCoV CER because the virus infects 
monocytes – a component of PBMC – in the natural course of a Type 1 infection (Kipar and Meli, 
2014). The PBMC were prepared from individual whole blood samples in EDTA using a density 
gradient medium method. All but one of the blood samples were obtained from the collection 
established for the ELISpot analysis (see Chapter 5), where a free FCoV antibody titre test was 
offered in exchange for a feline blood sample. Samples from 16 cats were not used for ELISpot 
analysis due to insufficient time, so the PBMC were frozen down and used in this part of the project 
instead. These 16 cats were all from the UK and comprised four Ragdolls, four Maine Coons, four 
British Shorthair, one Sphinx, one Exotic Shorthair, one Burmese and one Persian. Their ages ranged 
from five months to nine years, with over half of cats three years or less. Cats of all sexes were 
represented, with over half unneutered. The remaining blood sample was obtained post mortem 
from an adult, female neutered Domestic Shorthair cat, who was euthanased for reasons unrelated 
to this study. 
PBMC from 10 cats were screened with the Type 1 and 2 bait proteins using an immunofluorescence 
assay, with human IgG Fc used again as a control for Fc receptor binding (a typical example is shown 
in Figure 4.9).  
Figure 4.9. Examination of feline PBMC by immunofluorescence assay for bait protein recognition. PBMC were applied to glass coverslips 
by cytocentrifugation, then fixed without permeabilisation. The cells were incubated with the the Type 1 bait protein, Type 2 bait protein 
or a human IgG Fc – negative control. The cells were then incubated with a DyLight 488-conjugated secondary antibody (green). Nuclei 
were stained with DAPI (blue). Cells were then viewed using a confocal laser scanning microscope with a 40x oil immersion objective. 
These results are typical of five replicates. Close up views of an area of each image, indicated by the grey box, are displayed beneath their 
corresponding images. 
A: IgG Fc – negative control; B: Type 1 bait protein; C: Type 2 bait protein. 
106 
 
The assay showed staining with the Type 1 and 2 bait proteins, but the pattern was irregular and the 
intensity variable. There was also some staining with the IgG Fc fragment, indicating that the bait 
protein interaction with PBMC did not represent specific recognition of a CER. Flow cytometry was 
carried out on PBMC from two cats to see if a specific interaction between a population of the cells 
and the Type 1 bait protein could be identified using a different method, but on both occasions no 
difference was observed between feline PBMC incubated with the negative control (IgG Fc) and Type 
1 bait protein (Figure 4.10). 
Figure 4.10. Examination of feline PBMC by flow cytometry for bait protein recognition. A suspension of ≥200,000 live PBMC was 
incubated with 100 µl neat Type 1 bait protein or human IgG Fc – negative control, followed by a CF 633-conjugated secondary antibody. 
Cells were analysed on an LSR II flow cytometer, using a 633 nm laser for excitation and a 660/20 band pass filter for detection. The plot 
displays intensity of light emitted from cells incubated with the Type 1 (blue dots) and no (red dots) bait protein and is gated to include 
only live, single cells. FSC-A: forward scatter (a measure of cell size). These results are typical of two replicates. 
Other studies demonstrating monocyte entry and infection with FCoV did so after the cells adhered 
to a tissue culture surface and underwent a period of differentiation (Van Hamme et al., 2007, 
Dewerchin et al., 2005), so this approach was taken next. Monocytes from the remaining five PBMC 
samples were allowed to adhere to glass coverslips for 24 hours prior to washing away unadhered 
cells, which is recognised as an effective way of obtaining a cell population mostly consisting of 
monocytes (Dewerchin et al., 2005). The monocytes were cultured for a further 4 days or until they 
began to take on a macrophage-like appearance: becoming larger, in some cases becoming 
elongated and often developing processes (data not shown). The resulting monocyte-derived cells 
were screened with the Type 1 and 2 bait proteins, and human IgG Fc as a negative control, in an 




Figure 4.11. Examination of feline monocyte-derived cells by immunofluorescence assay for bait protein recognition. Monocytes were 
selected from PBMC by adherence to glass coverslips following culture for 24 hours. These monocytes were cultured for a further four 
days, then fixed without permeabilisation. The cells were incubated with the Type 1 bait protein, Type 2 bait protein or human IgG Fc – 
negative control, followed by a DyLight 488-conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Cells were then 
viewed using a confocal laser scanning microscope with a 40x oil immersion objective. These results are typical of five replicates. Close up 
views of an area of each image, indicated by the grey box, are displayed beneath their corresponding images. 
A: IgG Fc – negative control; B: Type 1 bait protein; C: Type 2 bait protein. 
The results appear to demonstrate cell surface staining of a proportion of monocyte-derived cells 
with both the Type 2 and Type 1 bait proteins, but this was difficult to differentiate from the green 
fluorescence detected in the negative control condition and was not reliably repeatable.  
At this point no more PBMC were available for this study, and it was decided not to collect more 
because the flow cytometry experiments showed no specific staining of the PBMC with Type 1 bait 






4.2.5 Establishing feline intestinal organoid cultures 
As the experiments investigating the presence of the Type I FCoV CER on PBMC were inconclusive, it 
was decided to focus next on feline intestinal epithelial cells. This cell type was chosen since it is a 
natural target for infection with Type 1 FCoV (Kipar and Meli, 2014). Initial attempts to isolate feline 
intestinal epithelial cells were made following a slightly modified protocol of Desmarets et al. (2013), 
where intestinal tissue was washed thoroughly of mucus and debris then enzymes were used to 
dissociate the epithelium from underlying structures. The epithelium was mechanically removed, 
digested further with enzymes to produce a cell suspension and pelleted. This procedure yielded a 
loose and mucinous cell pellet which, on cytological analysis, was found to contain low cell numbers, 
mostly poor cell preservation and moderate to high amounts of mucus and microbes (data not 
shown). The procedure was repeated, this time using a cell strainer to remove any undigested pieces 
of tissue and mucus from the cell suspension. The resulting suspension was seeded into a cell culture 
flask, but no cells were recovered. This was carried out once more with the same result. Due to the 
difficulties experienced with this method and the relative advantages of organoids compared to 
immortalised cell lines (described in section 4.1), the focus of the investigation changed to the 
establishment of feline intestinal organoid cultures. 
Initially murine intestinal organoids, obtained as in vitro cultures from Dr R. Jenkinson, University of 
Bristol, were used to practice organoid subculture technique (Figure 4.12). L-WRN conditioned 
medium, made in-house following the protocol of Miyoshi and Stappenbeck (2013), was also tested 
at this point with a view to using it for feline intestinal organoid cultivation as reported by Powell 
and Behnke (2017). The murine organoids were grown in two media in parallel: conditioned medium 
and the commercially available IntestiCult organoid growth medium mouse (IC mouse). Initially, the 
organoids in IC mouse grew much more robustly than those in conditioned medium, forming large, 
budding structures within a few days of passage (Figure 4.13). The organoids in conditioned medium 
remained small and did not bud. However, after two passages the growth of organoids in both 
media was comparable, suggesting that the organoids had adapted to the conditioned medium. 
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Figure 4.12. Schematic to show the process for subculturing organoid cultures. Each step shows a side view of one well of a cell culture 
plate, except for step 4 which shows a side view of a conical centrifuge tube. 
1: Organoids, suspended in Matrigel matrix and submerged in medium, are ready to be subcultured. 
2: The Matrigel matrix is dissociated by placing the plate on ice or mechanically disrupting the matrix by pipetting. 
3: Once the Matrigel matrix has turned to liquid, the organoids can be fragmented by enzymatic digestion and/or mechanical disruption by 
pipetting. 
4: The organoid fragments are collected into a centrifuge tube and pelleted by centrifugation. 
5: The organoid fragments are resuspended in Matrigel matrix and an aliquot is seeded into a new well. 
6: The organoid fragments, suspended in Matrigel matrix and submerged in medium, reform into spheroids and grow larger. 
Figure 4.13. Examination of a large, budding murine intestinal organoid. This organoid was cultured in Matrigel matrix, submerged in IC 
mouse, for around 5 days following passage, then imaged under a light microscope at 200x magnification. 
Having had some practice handling the murine intestinal organoids and ascertained that the 
conditioned medium was fit for purpose, the next step was to establish feline intestinal organoid 
cultures. Feline organoids were first obtained from Dr M. Behnke, Louisiana State University, as 
frozen cultures (Table 4.3). The first feline organoids that were thawed and cultured were from Cat 
11, Passage 10 (C11P10), and these were grown in conditioned medium containing nicotinamide, Y-
27632 and SB-43154 (as instructed by Dr M. Behnke). The published report describing feline 
organoid culture states that cat organoids cease to expand at around passage 10 and undergo 
growth arrest at passage 13 to 18 (Powell and Behnke, 2017), but in personal correspondence Dr M. 
Behnke explained that this problem has since been overcome by adding a high concentration of 
nicotinamide to the conditioned medium. This high concentration of nicotinamide was used for 
feline intestinal organoid culture throughout this project. 
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Table 4.3. Summary of the feline organoids available as frozen cultures from Dr M. Behnke. Ten frozen vials were received in total, 
containing organoids from three cats at different passage numbers. 
Though lots of cellular material was present when C11P10 was plated, only a single organoid 
survived, and this died after the first passage. 
The next organoids that were thawed and cultured were from Cat 19, Passage 16 (C19P16), and 
these were grown in conditioned medium, IC mouse and IntestiCult organoid growth medium 
human (IC Human). Those in conditioned medium were initially viable but never expanded and died 
after the first passage. Those in IC mouse and IC human survived and grew very well, with those in IC 
human becoming particularly large and cystic after the second passage. However, following the third 
passage the organoids in both IC mouse and IC human remained very small and died after around 7 
days. 
Organoids from Cat 14, Passage 7 (C14P7) were thawed and cultured, and these were initially split 
into conditioned medium and IC human. In parallel, murine organoids were thawed and cultured in 
conditioned medium to re-test its ability to support organoid growth. The murine organoids grew 
very robustly in conditioned medium, showing again that the medium could support organoid 
growth. This time the feline organoids grew better in conditioned medium than in IC human, with 
more viable organoids reaching larger sizes. Following the first passage, all the feline organoids were 
grown in conditioned medium. C14P7 survived for seven passages, with growth slowly declining 
from around the third passage. The organoids that grew were large and cystic with no budding, as is 
typical for feline intestinal organoids (Powell and Behnke, 2017).  
Though C14P7 survived for longer than any of the previous attempts, they still ceased to expand far 
sooner than reported by Powell and Behnke (2017). To eliminate the possibility that the reagents 
could be causing a problem, Dr M. Behnke kindly donated aliquots of all the reagents used for 
organoid culture in his laboratory. Organoids from Cat 14 Passage 4 were split into two, with half 
cultured using in-house reagents and the other half cultured using reagents from Dr M. Behnke. In 
both cases, growth was similarly sluggish and only a few passages were achieved before the cultures 
began to die off. 
Considering the problems experienced recovering frozen organoid cultures and propagating them 
beyond a few passages, work began to isolate crypts from feline intestinal tissue and cultivate 
organoids from them. Intestinal tissue was obtained from three adult Domestic Shorthair cats who 
111 
 
were euthanased at a local animal shelter for reasons unrelated to this project. None of the cats 
were known to have intestinal disease, and their FCoV status was undefined. The tissue was 
collected no longer than 30 minutes after death and processed within an hour following the protocol 
of Powell and Behnke (2017), which involved cleaning, mincing and enzymatically digesting the 
tissue, then straining and centrifuging the resulting cell suspension to enrich for crypts. The 
remainder of the protocol is illustrated in Figure 4.12, steps 5 and 6. Organoids were grown in 
conditioned medium supplemented with nicotinamide, Y-27632 and SB-43154. Figure 4.14 depicts 
the cultivation of feline intestinal organoids from crypts. 
Organoids from all three cats grew readily from the isolated crypts. Vigorous cultures were 
established by day 7 in all cases, organoids were passaged every 3-7 days and 7-9 passages were 
achieved before organoids began growth arrest. Most organoids displayed a cystic phenotype, but in 
some cases there was a mixed phenotype within the same culture of cystic and budding (Figure 
4.15). Cells with a mesenchymal morphology were observed to co-culture with the organoids 




Figure 4.14. The cultivation of feline intestinal organoids from intestinal crypts. Organoids, derived in-house from feline intestinal tissue, 
were cultured in Matrigel matrix, submerged in conditioned medium, and imaged under a light microscope at 100x magnification at 
various time points, as indicated. Organoids were passaged every 3-7 days. 
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 Figure 4.15. Examination of a typical cystic (A) and budding (B) feline intestinal organoid. Organoids, derived in-house from feline 
intestinal tissue, were cultured in Matrigel matrix, submerged in conditioned medium, for around 5 days following passage, then imaged 
under a light microscope at 400x magnification. 
Figure 4.16. Examination of a mixed culture containing feline intestinal organoids and spindle cells. Organoids, derived in-house from 
feline intestinal tissue, were cultured in Matrigel matrix, submerged in conditioned medium, for around 5 days following passage 4, then 
imaged under a light microscope at 100x magnification. Many mesenchymal cells are present in this image, but a typical example of a 




4.2.6 Screening feline intestinal organoids for a Type 1 FCoV CER 
Though feline intestinal organoid cultures could not be propagated beyond nine passages, it was 
decided to go ahead and screen them for a Type 1 FCoV CER, rather than spend more time 
optimising their cultivation. Initially, the organoids were screened for bait protein recognition in an 
immunofluorescence assay that involved fixing and staining the organoids in situ, embedded in 
Matrigel matrix. The results of this assay were extremely difficult to interpret with lots of non-
specific staining (Figure 4.17). Considering that the CER, if present, was likely to be expressed on the 
apical (lumen-facing) surface of the organoid cells, methods allowing the bait protein to access this 
surface were pursued hereafter.  
Figure 4.17. Examination of feline intestinal organoids by immunofluorescence assay by bait protein recognition. Feline intestinal 
organoids were cultured in chamber slides, fixed in situ and incubated with IgG Fc – negative control (A) or the Type 1 bait protein (B). The 
organoids were then incubated with a CF 633-conjugated secondary antibody (red). Nuclei were stained with DAPI (blue). Cells were then 
viewed using a widefield fluorescence and phase contrast microscope with a 40x oil immersion objective. 
A method was trialled whereby the organoids were broken up mechanically by pipetting them and 
passing them through a needle before they were applied to glass slides by cytocentrifugation. Two 
variations of this method were tested: where the broken-up organoids were incubated with bait 
protein before being fixed (‘incubate first’ protocol), and where they were incubated with bait 
protein after (‘fix first’ protocol; Figure 4.18). Cell surface staining with the Type 2 bait protein was 
observed in a small population of cells under both protocols, though staining was brighter when cells 
were fixed first. Bright, stippled cytoplasmic staining with the Type 1 bait protein was observed in a 
small population of cells only when they were incubated with bait protein before being fixed, 
therefore organoids from different cats and passage numbers were screened using the ‘incubate 





Figure 4.18. Comparing two protocols for examination of single cells from feline intestinal organoids by immunofluorescence assay for 
bait protein recognition. Feline intestinal organoids were mechanically dissociated. For conditions A-C, the cells were applied to glass 
slides by cytocentrifugation, fixed without permeabilisation then incubated with IgG Fc – negative control (A), Type 1 bait protein (B) or 
Type 2 bait protein (C; ‘fix first’ protocol). For conditions D-F, the cells were incubated with IgG Fc – negative control (D), Type 1 bait 
protein (E) or Type 2 bait protein (F) then applied to glass slides by cytocentrifugation and fixed without permeabilisation (‘incubate first’ 
protocol). In all conditions the cells were then incubated with a DyLight 488-conjugated secondary antibody (green). Nuclei were stained 
with DAPI (blue). Cells were then viewed using a confocal laser scanning microscope with a 40x oil immersion objective.  
Figure 4.19. Examination of single cells from feline intestinal organoids by immunofluorescence assay for bait protein recognition. 
Feline intestinal organoids were mechanically dissociated. The cells were incubated with IgG Fc – negative control (A), Type 1 bait protein 
(B) or Type 2 bait protein (C+D) then applied to glass slides by cytocentrifugation and fixed. The cells were then incubated with a DyLight 
488-conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Cells were then viewed using a confocal laser scanning 
microscope with a 40x oil immersion objective. These results are typical of 12 replicates. 
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Across organoids from different cats and passage numbers, the following staining pattern was 
consistently observed: a very small population of cells showed bright, stippled cytoplasmic staining 
with the Type 1 (B) and 2 (D) bait proteins, and a distinct small population of cells showed fainter 
surface staining with the Type 2 bait protein only (C). Cells staining with the T1 bait protein appeared 
to have a rounded morphology with little cytoplasm, but since a cell surface marker was not used it 
could not be ruled out that the staining was just perinuclear and the cell was larger than it appeared 
to be. To address this question, an image of a positive cell was taken under a light microscope to get 
a better idea of its morphology (Figure 4.20). This confirmed that the staining was cytoplasmic and 
the cell has very little cytoplasm, rather than the staining just being perinuclear. 
Figure 4.20. Image of a single feline intestinal organoid cell that is positive for staining with the Type 1 bait protein, taken to assess the 
morphology of the cell. Feline intestinal organoids were mechanically dissociated. The cells were incubated with the Type 1 bait protein 
then applied to glass slides by cytocentrifugation and fixed. The cells were then incubated with a DyLight 488-conjugated secondary 
antibody (green). Nuclei were stained with DAPI (blue). Cells were then viewed using a widefield fluorescence and phase contrast 
microscope with a 40x oil immersion objective. 
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4.2.7 Proteomic analysis of the proteins precipitated from organoids by bait proteins 
If the Type 1 bait protein was recognising a CER on feline intestinal organoid cells, the staining would 
be expected to be cell surface rather than cytoplasmic. However, the organoid cells had been 
processed in such a way that could affect their morphology, and it is possible that a Type 1 FCoV CER 
is only expressed at the cell surface transiently. Since there seemed to be a consistent interaction 
between the Type 1 bait protein and a component of the organoid cells, identification of that 
component was attempted using immunoprecipitation followed by mass spectrometry analysis (as 
optimised in section 4.2.2).  
Lysates were prepared from feline intestinal organoids from different cats and at different passage 
numbers, and these lysates were incubated with the Type 1 and 2 bait proteins, and, as a negative 
control, human IgG Fc. The bait proteins and IgG Fc in turn were then captured with Protein A resin. 
Proteins eluted from the resin were then separated by SDS-PAGE prior to in-gel digestion, TMT-
labelling, mass spectrometry and proteomic analysis. Across seven replicates of this experiment 
comprising different cat and passage numbers, the mean number of proteins identified was 118 
(±15.1; Appendix D). Eight proteins were significantly enriched (i.e. paired sample t-test p value 
<0.05) across all replicates with the Type 1 bait protein (Table 4.4), whereas only four were 




Table 4.4. The proteins significantly enriched by the Type 1 bait protein from feline intestinal organoids across all replicates. A 
consensus is shown from seven replicates. Proteins were identified following in-gel digestion, TMT-labelling and mass spectrometry 
analysis of the immunoprecipitates, then sorted based on the log2 fold change in their abundance compared with the negative control 
immunoprecipitation. Only proteins that were significantly elevated across all replicates (p≤0.05) are shown. 
 
Table 4.5. The proteins significantly enriched by the Type 2 bait protein from feline intestinal organoids across all replicates. A 
consensus is shown from seven biological replicates. Proteins were identified following in-gel digestion, TMT-labelling and mass 
spectrometry analysis of the immunoprecipitates, then sorted based on the log2 fold change in their abundance compared with the 




4.2.8 Validation of HSPA1A as a CER for Type 1 FCoV 
Of the proteins enriched by the Type 1 bait protein from feline intestinal organoids, the strongest 
interactor was putative serine/threonine-protein kinase Nek3 (Nek3). However, putative heat shock 
70 kDa protein 1a (HSPA1A) was pursued as a potential Type 1 FCoV CER because it appeared to be 
the most biologically relevant, having been identified as a putative CER or attachment factor for 
other viruses (Reyes-Del Valle et al., 2005, Zhu et al., 2012, Das et al., 2009, Pujhari et al., 2019, 
Khachatoorian et al., 2018) and part of the receptor complex for the Gammacoronavirus IBV (Zhang 
et al., 2017). In contrast, Nek3 has not been identified as a CER and is not known to be present on 
the plasma membrane. Putative heat shock cognate 71 kDa protein, also known as Hsc70, was the 
fifth most enriched protein from feline intestinal organoids. Hsc70 is considered to be the 
constitutively expressed form of HSPA1A and has been identified as a receptor for rotavirus (Perez-
Vargas et al., 2006). 
A small proportion of each immunoprecipitate was not submitted for mass spectrometry and 
proteomic analysis, but instead was analysed by SDS-PAGE and western blot for the presence of 
HSPA1A. However, a band of the correct size was not found and the results were inconclusive (data 
not shown). Since there is not an anti-HSPA1A antibody validated for use in cats, it was assumed that 
the antibody used in the western blot may not have either recognised the protein of interest or 
allowed sufficient sensitivity of detection by western blot analysis. 
Next, CrFK cells were heat shocked to induce expression of HSPA1A (Bilog et al., 2019). An 
immunofluorescence experiment was carried out on the heat shocked cells to determine whether 
they would show surface staining with the Type 1 bait protein compared to non-heat shocked cells 
(Figure 4.21). Neither heat shocked nor non-heat shocked cells were stained by the Type 1 bait 
protein, suggesting that heat shock did not induce expression of a protein that could be detected by 
the Type 1 bait protein. Again, since an antibody known to be capable of recognising feline HSPA1A 
is not available, it is unknown whether the heat shocked cells failed to express HSPA1A or if HSPA1A 
was expressed but not recognised by the Type 1 bait protein. 
To explore the interaction between the Type 1 bait protein and HSPA1A, a different approach was 
taken, whereby recombinant HSPA1A was expressed in CrFK cells. A plasmid containing the feline 
HSPA1A coding sequence was synthesised and the coding sequence was then subcloned into 
mammalian expression vector pcDV4 to create a plasmid termed pHSPA1A. To circumvent the 
problem of not having an anti-HSPA1A antibody validated for use in cats, sequence encoding a FLAG 
(polypeptide) tag was fused to the 3´ HSPA1A sequence, allowing the recombinant protein to be 
detected using a commercially available anti-FLAG antibody. See Appendix A for the sequence of 
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pHSPA1A. In order to determine the optimal transfection conditions, CrFK cells were transfected 
with pHSPA1A using a range of Lipofectamine concentrations, fixing the cells at two different time 
points and carrying out an immunofluorescence assay with and without permeabilisation (Figure 
4.22). The strongest expression of HSPA1A appeared to be in cells that were transfected with a high 
Lipofectamine concentration, fixed at 24 hours and permeabilised. Although the expression of a 
Type 1 FCoV CER would be expected to be cell surface, expression of recombinant HSPA1A in 
transfected cells was mostly cytoplasmic so permeabilisation to allow the bait protein to reach 




Figure 4.21. Examination of heat shocked CrFK cells by immunofluorescence assay for bait protein recognition. The CrFK cells were 
grown on glass coverslips and either cultured under normal conditions (A, C, E, F) or heat shocked at 42C for two hours then recovered at 
37C for 16 hours (B, D, G). Cells were fixed without permeabilisation then incubated with IgG Fc – negative control (A, B), Type 1 bait 
protein (C, D), Type 2 bait protein (E) or an anti-HSPA1A antibody (F, G). This was followed by a DyLight 488-conjugated secondary 
antibody (green) and nuclei were stained with DAPI (blue). Cells were then viewed using a confocal laser scanning microscope with a 40x 




Figure 4.22. Examination of pHSPA1A-transfected CrFK cells by immunofluorescence assay for HSPA1A-FLAG recognition. The CrFK cells 
were grown on glass coverslips, transfected with pHSPA1A using a low (A-B, F-G) and high (C-E, H-J) concentration of Lipofectamine, then 
fixed at 24 hours (A, C, E, F, H, J) or 48 hours (B, D, G, I) with (F-J) and without (A-E) permeabilisation. The cells were incubated with an 
anti-FLAG antibody (A-D, F-I) or blocking buffer only as a negative control (E, J), followed by a DyLight 488-conjugated secondary antibody 
(green). Nuclei were stained with DAPI (blue). Cells were then viewed using a widefield fluorescence microscope with a 40x oil immersion 
objective.  
A: Low lipofectamine concentration, fixed at 24 hours, not permeabilised, anti-FLAG antibody; 
B: Low lipofectamine concentration, fixed at 48 hours, not permeabilised, anti-FLAG antibody; 
C: High lipofectamine concentration, fixed at 24 hours, not permeabilised, anti-FLAG antibody; 
D: High lipofectamine concentration, fixed at 48 hours, not permeabilised, anti-FLAG antibody; 
E: High lipofectamine concentration, fixed at 24 hours, not permeabilised, negative control; 
F: Low lipofectamine concentration, fixed at 24 hours, permeabilised, anti-FLAG antibody; 
G: Low lipofectamine concentration, fixed at 48 hours, permeabilised, anti-FLAG antibody; 
H: High lipofectamine concentration, fixed at 24 hours, permeabilised, anti-FLAG antibody; 
I: High lipofectamine concentration, fixed at 48 hours, permeabilised, anti-FLAG antibody; 




On establishing the optimal conditions for CrFK transfection with pHSPA1A, an immunofluorescence 
assay was carried out using these conditions to determine whether the Type 1 bait protein 
recognised HSPA1A expressed in CrFK cells (Figure 4.23). The assay demonstrated no interaction 
between pHSPA1A-transfected cells and Type 1 bait protein.  
Figure 4.23. Examination of pHSPA1A-transfected CrFK cells by immunofluorescence assay for Type 1 bait protein recognition. The CrFK 
cells were grown on glass coverslips, transfected with pHSPA1A then fixed at 24 hours with permeabilisation. The cells were incubated 
with IgG Fc – negative control (A), an anti-FLAG antibody (B) or Type 1 bait protein (C), followed by a DyLight 488-conjugated anti-Fc 
secondary antibody (green) and a CF 633-conjugated anti-FLAG secondary antibody (red). Nuclei were stained with DAPI (blue). Cells were 
then viewed using a widefield fluorescence microscope with a 40x oil immersion objective. 
Finally, an immunoprecipitation assay was carried out whereby pHSPA1A-transfected CrFK cells were 
lysed and incubated with the Type 1 and 2 bait proteins, and, as a negative control, human IgG Fc. 
These proteins in turn were incubated with Protein A resin, and the proteins eluted from the resin 
were analysed by SDS-PAGE and western blot (Figure 4.24). This demonstrated a protein of around 
70 kDa (identified by the FLAG tag) present only in the transfected cells, which was assumed to be 
HSPA1A. This protein was extremely abundant in the transfected cell lysate, and less abundant but 
still present in all transfected cell immunoprecipitates. When normalised by the intensity of the bait 
protein (or human IgG Fc for negative control) band in that lane, the quantified intensity of the 
HSPA1A band was 0.56 with Type 1 bait protein, 0.26 with Type 2 bait protein and 0.16 with negative 
control. This demonstrates a 3.5-fold enrichment of HSPA1A with the Type 1 bait protein compared 




Figure 4.24. Analysis by western blot of the proteins immunoprecipitated from pHSPA1A-transfected cells by the bait proteins. Lysates 
of pHSPA1A-transfected and untransfected CrFK cells were divided into three and incubated with Type 1 bait protein (T1), Type 2 bait 
protein (T2) or IgG Fc – negative control (IgG). These in turn were incubated with Protein A resin, which binds the IgG part of the bait 
proteins or IgG Fc. Proteins at different stages of the procedure were denatured and run on a 4-12% SDS-PAGE Bis-Tris mini gel. Proteins 
on the gel were transferred on to a membrane, which was probed with anti-human IgG Fc antibody (upper and lower sections of the 
membrane) or anti-FLAG antibody (middle section of the membrane). The membrane was then incubated with a horseradish peroxidase-
labelled secondary antibody, prior to application of a chemiluminescent substrate and exposure to x-ray film. The positions of relevant 





This chapter describes an investigation aiming to identify a Type 1 FCoV CER. Knowledge of the 
receptor utilised by Type 1 FCoV would constitute a step towards in vitro propagation of strains of 
FCoV representative of natural infections. The production of a cell-based system to grow such strains 
in vitro would facilitate our understanding of the virus, as well as enabling rescue of recombinant 
viruses as part of a reverse genetic system. 
The ‘bait protein’ method – developed by Raj et al. (2013) to identify a MERS-CoV receptor – was 
utilised in the quest to identify a Type 1 FCoV CER. Raj et al. (2013) incubated MERS-CoV bait protein 
with lysates of Vero and Huh7 cells, which are both susceptible to infection with the virus. This 
approach was not possible in this project, because there are no cell lines available to us that are 
susceptible to infection with Type 1 FCoV. However, there are many available cell lines (including 
CrFK) that carry fAPN and are susceptible to infection with Type 2 FCoV. Both Type 1 and Type 2 bait 
proteins were therefore produced in this project, and the method was validated and optimised using 
the Type 2 bait protein with CrFK cells. The ‘identification’ of fAPN in this project was encouraging, 
as it demonstrated that the Type 2 bait protein was produced in a conformationally faithful, active 
form and suggested that the Type 1 bait protein might also be capable of recognising its receptor. An 
assumption made in this project is that a CER for Type 1 FCoV would be a protein as opposed to a 
carbohydrate. The known CERs for all Alphacoronaviruses and most coronaviruses in general are 
proteins (Jaimes and Whittaker, 2018), but carbohydrates have been reported as receptors for some 
Beta- and Gammacoronaviruses (Li, 2015). However, current evidence suggests that in some cases 
these molecules serve as attachment factors rather than CERs (Szczepanski et al., 2019), allowing the 
virus to attach to the host cell but not mediating cell entry. If Type 1 FCoV used a carbohydrate as its 
CER this molecule may not be recognised by our approach, but on the balance of evidence this 
situation seems very unlikely. 
The next step towards identifying a Type 1 FCoV CER was to find a cell type expressing the receptor. 
Cell lines that have been identified as resistant to infection with Type 1 FCoV include FCWF, feline 
kidney Colorado University, HEK293T and swine testicular cells (Dye et al., 2007), so these were not 
screened. Two cell lines that had not been previously investigated – DH82 and FE-A – were, 
however, screened, which identified specific staining of DH82 cells with the Type 2 but not Type 1 
bait protein. As cell lines carrying the Type 2 FCoV receptor are already available, the interaction 
between DH82 cells and Type 2 bait protein was not pursued. Developed originally to isolate and 
propagate feline leukaemia virus (Jarrett et al., 1973), FE-A cells are feline whole embryo cells. They 
are currently used by some laboratories to culture Type 2 FCoV, for the purpose of measuring FCoV 
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antibody serum titre by immunofluorescent antibody test (Addie et al., 2015). In this study, two 
separate experiments demonstrated no staining of FE-A cells with either Type 1 or Type 2 bait 
protein. These two ideas are at odds, because in order to be permissive to Type 2 FCoV, this cell type 
must carry a receptor recognised by the Type 2 FCoV spike protein. It is unknown why FE-A cells 
were not recognised by Type 2 bait protein, but some possible explanations could include FE-A cells 
only expressing APN under certain conditions, FE-A cells expressing APN below the limit of detection 
for the assay or cells other than FE-A being mistakenly used in the assay. 
Monocytes were examined next as a cell type potentially expressing a Type 1 FCoV CER. As well as 
being infected by the virus in the natural course of infection (Kipar and Meli, 2014), feline monocytes 
are permissive to Type 1 FCoV in vitro (Van Hamme et al., 2007), albeit to a strain – ‘Black’ – that is 
so adapted to cell culture it can no longer be said to represent Type 1 FCoVs found in the field 
(Pedersen, 2009). Additionally, preliminary work by Dye (2006) suggested that viral pseudotypes 
expressing a Type 1 FCoV field strain S protein were able to infect ex vivo feline monocytes. After 
encountering issues with non-specific staining when using feline PBMC, live monocytes were 
selected by adherence to a culture surface and allowed to mature. As well as selecting for 
monocytes, this approach excluded the dead cells and debris that may have been causing false 
positive results with PBMC. A preliminary immunofluorescence experiment suggested that both the 
Type 1 and 2 bait proteins may be specifically binding to the surface of a small population of these 
monocyte-derived cells, but this was not consistently repeatable across experiments and was at 
times difficult to differentiate from the negative control. It would have been interesting to pursue 
this further, but the PBMC ran out and the results were not promising enough to warrant collecting 
more. 
Feline intestinal epithelial cells were explored next, as it is known that FCoV enters these cells during 
the natural course of infection (Kipar et al., 1998b). The S1 portion of the Type 1 bait protein was 
based on FCoV strain 80F, which was isolated from the faeces of a healthy, FCoV-infected cat (Lewis 
et al., 2015). Though Type 1 FCoV is known to infect monocytes, using intestinal epithelial cells may 
be more relevant because a virus isolated from the faeces would be expected to have a very strong 
tropism for the intestinal epithelium. Desmarets et al. (2013) had success in isolating feline intestinal 
epithelial cells, culturing them and infecting them with Type 1 FCoV. Unfortunately, the intestinal 
epithelial cell line developed by this group was not available for this investigation. Their method of 
isolating and culturing intestinal epithelial cells was attempted but proved unsuccessful due to poor 
cell viability and mucus contamination, and it has since been learnt that the group were unable to 
repeat their original result (Professor H. Nauwynck, personal communication, 27 January 2017). So 
far there has been no report in the literature of the use of this cell line to identify a Type 1 FCoV CER. 
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Feline intestinal organoids – three-dimensional cell cultures containing a stem cell population that 
differentiates into all the cells of the intestinal epithelium – were chosen as a ‘source’ of feline 
intestinal epithelial cells. On contacting Dr M. Behnke, who recently published a report detailing the 
acquisition and propagation of feline intestinal organoids (Powell and Behnke, 2017), his group was 
extremely cooperative and willing to share feline intestinal organoid cultures. The published report 
describes difficulties in growing feline intestinal organoids beyond around 10 passages, but in 
personal correspondence Dr M. Behnke explained that this problem has since been overcome by 
adding a high concentration of nicotinamide to the conditioned medium. Nicotinamide is a precursor 
to nicotinamide adenine dinucleotide (NAD): a molecule that inhibits a class of protein deacetylases 
known as sirtuins, that are involved in transcriptional regulation, metabolism, apoptosis, 
differentiation and ageing (Denu, 2005). Treatment with nicotinamide was shown to reverse key 
signs of senescence in murine intestinal organoids (Uchida et al., 2019) and improve the efficiency 
and longevity of human intestinal organoids (Sato et al., 2011). Despite following the 
recommendation to add a high concentration of nicotinamide to the medium, the recovered feline 
organoid cultures in this project failed to grow robustly beyond nine passages. 
At this point it was unclear where the problem lay: with one or more of the reagents used, with 
organoid handling technique or with the viability of the organoid cultures. When using reagents 
donated by Dr M. Behnke failed to make a difference, the first problem was ruled out. It seemed 
unlikely that the problem lay with technique, since no issues arose when cultivating murine 
intestinal organoids. It therefore seemed most probable that the viability of the organoid cultures 
was compromised, perhaps because of temperature or pressure fluctuations encountered during 
shipping. Organoid cultures established in-house performed better, growing robustly for 7 to 9 
passages before ceasing to expand. Similarly to Powell and Behnke (2017), a mesenchymal-like cell 
type was observed to co-culture with the organoids until around passage 7. These cells are likely 
subepithelial myofibroblasts, which have been reported to support the growth, differentiation and 
expansion of human intestinal organoids (Lahar et al., 2011). It is possible that the mesenchymal-like 
cells were supporting organoid growth either structurally or through secretion of signalling 
molecules. In contrast to mouse and human systems, feline intestinal organoid cultures are not well 
characterised and their growth requirements are not completely understood, so there is not a wide 
evidence base to draw from when establishing the correct conditions for growth.  
Although it was difficult to propagate the organoids beyond several passages, there was enough 
opportunity while the organoids were growing robustly to screen them for a Type 1 FCoV CER and 
make lysates for immunoprecipitation experiments. However, if the organoids are to be used to 
propagate Type 1 FCoV in the future, further optimisation would be advantageous to identify 
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conditions for continuous growth. This could involve establishing a co-culture system with the 
mesenchymal-like cells, perhaps by immortalising them or renewing them every few passages. The 
organoids cultured in this project are technically enteroids because they are derived from intestinal 
stem cells and contain only an epithelial cell layer (though they are referred to in this project as 
organoids as this term is more commonly used and understood). In contrast, authentic organoids are 
derived from pluripotent stem cells and contain a mesenchymal as well as an epithelial cell layer 
(Ramani et al., 2018). An alternative to immortalising the mesenchymal-like cells could be to develop 
authentic feline intestinal organoids, containing a mesenchymal layer, from feline pluripotent stem 
cells. 
Though 3D cultures are excellent in recapitulating the organs from which the organoids are derived, 
the main drawback is that access to the apical (lumen-facing) surface of the cells is restricted. This is 
a particular problem for infection of the organoids; since intestinal pathogens access the epithelial 
cells via the intestinal lumen, their receptors would be expected to be expressed on the apical 
surface of the cell. This problem has been overcome through microinjection, where the pathogen is 
injected directly into the lumen of the organoid (Bartfeld and Clevers, 2015). The 3D nature of 
organoid cultures also poses a problem when attempting to access the apical surface of the cells for 
staining with antibodies or bait proteins. A method whereby the organoids were fixed and stained in 
situ was trialled, but, despite following the protocol used successfully by Mahe et al. (2013), this 
resulted in non-specific staining and uninterpretable results. Monolayers, organoid cultures grown in 
2D rather than 3D, present a solution, because they provide access to the apical surface of the cell 
while still recapitulating the intestinal environment (van der Hee et al., 2018), and indeed they have 
been used to successfully propagate intestinal viruses (Ettayebi et al., 2016, Saxena et al., 2016). In 
the future, developing feline intestinal organoid monolayer cultures would be a priority objective for 
furthering this project. 
In the absence of monolayers, a method was developed in-house to allow access to the apical 
surface of the epithelial cells. In this method, organoids were liberated from the Matrigel matrix and 
mechanically dissociated before incubation with bait protein, application to glass slides and fixation 
(‘incubate first’ protocol). Across different cats and passage numbers, a consistently repeatable 
result was observed: a small population of cells showed bright, stippled cytoplasmic staining with 
the Type 1 and 2 bait proteins, and a distinct small population of cells showed fainter surface 
staining with the Type 2 bait protein only. The surface staining observed with Type 2 bait protein is 
the staining pattern that was expected, but the cytoplasmic staining observed with both bait 
proteins is a conundrum for two reasons: the morphology of this cell type is unexpected for an 
129 
 
epithelial cell, and the presence of staining in the cytoplasm as opposed to on the cell surface is 
unexpected. 
The cells with cytoplasmic staining were always small, round cells with very large, fluffy nuclei and 
very little cytoplasm. This appearance is not typical for an epithelial cell, but perhaps more 
suggestive of a lymphocyte (Murphy et al., 2012). Although it is feasible that lymphocytes could be 
carried over from blood or Peyer’s patches during the crypt isolation process, this has not been 
reported and was not observed in our cultures. Alternatively, the cells may have been epithelial but 
with disturbed morphology due to being liberated from a multicellular structure or some other 
aspect of the immunofluorescence protocol, or they may have represented a less typical component 
of intestinal organoids (e.g. Paneth cells). Regardless of the cell type, cytoplasmic staining should not 
be present because at no point were the cells permeabilised. It is conceivable that the bait protein 
was taken up by live cells during incubation, but this is unlikely because the incubation step was 
performed at 4 °C. Besides, this still would not explain the cytoplasmic staining, because the 
secondary antibody was applied to fixed, non-permeabilised cells so should have not been able to 
get past the cell’s plasma membrane. Perhaps it is more likely that the plasma membrane was 
compromised during the process of mechanical dissociation, allowing the bait protein to bind to an 
internal protein and the secondary antibody to subsequently enter the cell. To further investigate 
both problems, an antibody could be included in the immunofluorescence protocol to detect a cell 
surface epithelial antigen. If positive, this would suggest both presence of a plasma membrane and 
epithelial origin of the cells. Alternatively, a live/dead stain could be used to determine whether the 
cells have an intact plasma membrane.  
A variant of the organoid immunofluorescence method was trialled, whereby the organoid cells 
were fixed prior to incubation with bait protein (‘fix first’ protocol). Interestingly, this yielded only 
Type 2 bait protein surface staining and not the cytoplasmic staining seen with both bait proteins. 
This could be because the cell’s plasma membrane is not damaged by this method, the bait protein 
is being taken up by some other mechanism (e.g. phagocytosis) or the protein of interest is not 
recognisable by Type 1 bait protein when it is fixed. If it is assumed that the bait protein is 
recognising an intracellular target that has become accessible due to plasma membrane damage 
with the ‘incubate first’ protocol, it is conceivable that the ‘fix first’ protocol avoided this damage 
and therefore left the target inaccessible. However, this seems unlikely for two reasons. If any part 
of the method is going to damage the plasma membrane, it would be the shear forces generated by 
passing the cells through a needle, and this step is common to both protocols. Additionally, organoid 
cells undergoing the ‘fix first’ protocol that were permeabilised following fixation (data not shown) 
were still negative for staining with Type 1 bait protein. This result raises the question of whether 
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the staining with both bait proteins in the ‘incubate first’ method represents another mechanism 
such as phagocytosis rather than genuine receptor binding. An alternative mechanism of bait protein 
internalisation, though possible, seems unlikely, since it would require a cell type capable of 
phagocytosis in the organoid cultures and would not explain how secondary antibody is able to enter 
cells. Additionally, if phagocytosis was occurring, cells should also be positive with the IgG Fc 
negative control condition. The most likely option is that fixation renders the protein of interest 
unrecognisable to the bait protein, although this suggests that it would be worthwhile to screen 
DH82 cells, FE-A cells and PBMC/monocytes in an immunofluorescence experiment where they are 
incubated with the bait proteins prior to fixation. 
Regardless of the questions raised by the nature of the staining, the Type 1 bait protein appeared to 
be consistently recognising a component of the organoid cells. The next step was therefore to carry 
out immunoprecipitation, mass spectrometry and proteomics experiments with the bait proteins 
and lysates prepared from feline intestinal organoids. Despite consistent surface staining of a 
population of cells across the immunofluorescence experiments, only four proteins were 
significantly enriched with the Type 2 bait protein across all seven replicates, and none of these are 
known virus receptors. Moreover, fAPN was not identified in any of the experiments. This may 
suggest that fAPN is not used as a CER by Type 2 FCoV in natural infections of intestinal epithelial 
cells, although this is contradicted by the fact that fAPN was found in a feline intestinal brush border 
preparation (Hohdatsu et al., 1998). Alternatively, it may suggest a problem with the 
immunoprecipitation experiments. If this is the case, it seems most likely that the problem was lack 
of starting material. This would also explain why fewer proteins were identified proteomically with 
the organoids (on average 118 in each experiment) compared to CrFK cells (over 700). Due to the 
nature of the organoids, it was challenging to start with as many cells as would be possible when 
working with cell lines. This could potentially be overcome by growing the organoids on a larger 
scale, or pooling organoids from different cats and passage numbers. 
The protocol that was optimised for CrFK cells and the Type 2 bait protein was followed when 
working with organoids, which involved using a detergent designed to specifically isolate cell surface 
proteins. In retrospect this was not the best detergent to use, as the immunofluorescence staining 
with the Type 1 bait protein was not on the cell surface. Despite this, eight proteins were 
significantly enriched using the Type 1 bait protein across all seven replicates. It was decided to 
focus on the 641 aa uncharacterised product of feline gene LOC105260573 (Uniprot accession 
number A0A337RXE8), which was inferred by homology to be feline heat shock 70 kDa protein 1a, 
also known as HSPA1A and Hsp70. HSPA1A is part of the HSP70 family: a group of ATP-dependent 
chaperones that participate in the cellular protein surveillance network and are involved in protein 
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folding (Mayer, 2013). HSPA1A is known to localise at the plasma membrane when cells are 
subjected to stress through association with the lipid phosphatidylserine (Bilog et al., 2019), and its 
expression has been observed in a number of cell lines including Neuro-2a (mouse neuroblastoma) 
(Das et al., 2009), chicken embryo kidney (Zhang et al., 2017), U397 (human monocyte), human 
neuroblastoma (Reyes-Del Valle et al., 2005), Huh7 and Vero cells (Zhu et al., 2012). Since HSPA1A is 
not well characterised in cats, it is unknown whether this protein is expressed in any feline cell lines. 
Along with its constitutive form Hsc70, which was also enriched from feline intestinal organoids by 
Type 1 bait protein, HSPA1A has been identified as a putative CER or attachment factor for a range 
of viruses including IBV (Zhang et al., 2017), rotavirus (Perez-Vargas et al., 2006), Dengue virus 
(Reyes-Del Valle et al., 2005), Japanese encephalitis virus (Zhu et al., 2012, Das et al., 2009) and Zika 
virus (Pujhari et al., 2019, Khachatoorian et al., 2018). This suggests that HSPA1A is a feasible 
candidate receptor for Type 1 FCoV.  
An alternative explanation of the interaction between Type 1 bait protein and HSPA1A is that the 
latter is an attachment factor, rather than a CER, for Type 1 FCoV. Attachment factors are receptors 
that a virus can bind to in order to get a foothold at the host cell membrane, but, unlike CERs, they 
do not mediate viral entry into the cell (Jolly and Sattentau, 2013). Examples of attachment factors 
for coronaviruses include sialic acid for MERS-CoV (Widagdo et al., 2019), BCoV and TGEV 
(Schwegmann-Wessels and Herrler, 2006), heparan sulfate for PEDV (Huan et al., 2015) and DC-SIGN 
for Type 2 FCoV (Regan and Whittaker, 2008) and Type 1 FCoV strain Black (Van Hamme et al., 2011, 
Regan et al., 2010). It is perhaps more likely that HSPA1A is an attachment factor for Type 1 FCoV 
rather than a CER, because, although not in the top five proteins, HSPA1A was enriched from CrFK 
cells by Type 1 bait protein. This is inconsistent with HSPA1A being a CER for Type 1 FCoV because 
CrFK cells are not permissive to infection with this virus, although HSPA1A is known to only localise 
to the plasma membrane under certain conditions (Bilog et al., 2019). Though identification in this 
project of an attachment factor rather than a CER for Type 1 FCoV would not be so much of a 
breakthrough, it would still be an important finding that could give insight into the tropism, 
pathogenesis and in vitro culture requirements of the virus. Interestingly, the only protein in the top 
five interactors with both Type 1 and 2 bait proteins in the immunoprecipitation with CrFK cells, 
putative SGTA (Uniprot accession number M3WN94), is a co-chaperone known to interact with 
HSPA1A and Hsc70. Interactions between SGTA and a range of viral proteins have also been 
reported, though not coronavirus S protein (Roberts et al., 2015).  
Despite being more enriched from feline intestinal organoids by Type 1 bait protein than HSPA1A, 
the 478 aa uncharacterised product of feline gene NEK3 (Uniprot accession number M3W0U2), 
inferred by homology to be Nek3, was not investigated further. This is because Nek3 has not been 
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identified as a CER, is not known to be present on the plasma membrane and was the second 
strongest interactor in the immunoprecipitation with CrFK cells and Type 1 bait protein. The latter 
point is inconsistent with Nek3 being a CER for Type 1 FCoV, since CrFK cells are resistant to this 
serotype. However, the interaction between Type 1 bait protein and Nek3 appears to be very strong 
and consistent, so in the future it would be interesting to investigate whether this protein plays a 
role as an attachment factor, or in the FCoV replication cycle post-internalisation. This could also be 
the case for the three proteins that were found to be enriched from feline organoid lysates by both 
Type 1 and Type 2 bait proteins: elongation factor 1-alpha, putative actin (cytoplasmic 2) and 
putative alpha-enolase. It is in fact more likely that the bright staining seen on immunofluorescence 
represents an interaction with one of these proteins, since this staining pattern was seen equally 
with both Type 1 and Type 2 bait proteins. Immunoprecipitation, mass spectrometry and proteomics 
is a much more sensitive way of identifying an interaction between two proteins than 
immunofluorescence, so it is possible that the interaction between Type 1 bait protein and HSPA1A 
in organoid cells was not detectable by immunofluorescence. 
Since proteins of the HSP70 family are inducible by stress and HSPA1A is known to localise to the 
plasma membrane under stressful conditions (Bilog et al., 2019), an attempt was made to heat shock 
CrFK cells to induce expression of HSPA1A. The heat shock treatment did not render the cells 
recognisable to Type 1 bait protein, but as an antibody known to be capable of recognising feline 
HSPA1A was not available it is unclear whether this represented no expression of HSPA1A or no 
interaction between HSPA1A and the bait protein. The results of a western blot carried out to 
confirm the enrichment of HSPA1A by Type 1 bait protein seen proteomically were similarly 
inconclusive. Only one anti-HSPA1A antibody was tested in this project: a recombinant antibody 
raised against human HSPA1A aa 50-300. Due to the homology of the human and feline HSPA1A 
sequences this antibody would be expected to recognise feline HSPA1A, but this does not consider 
post-translational modifications or possible splice variants that could obscure or remove this 
epitope. Given more time it would be useful to test other anti-HSPA1A antibodies. 
That HSPA1A is induced and recruited to the plasma membrane under stressful conditions is 
interesting because, should HSPA1A be confirmed as a CER for Type 1 FCoV, this could go some way 
to explaining the different infection patterns seen in different cats. It is plausible that, for example, 
increased expression of HSPA1A on the surface of monocytes due to locally stressful conditions such 
as inflammation or co-infection could lead to increased infection of this cell type and therefore 
susceptibility to the development of FIP from FCoV infection. Conversely, the small proportion of 
cats who appear to be completely resistant to infection with FCoV (Addie and Jarrett, 2001) could 
have no expression of HSPA1A on their intestinal epithelial cells. 
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To further explore the interaction between HSPA1A and Type 1 FCoV, a FLAG-tagged feline HSPA1A 
expression plasmid was created and the recombinant protein expressed in CrFK cells. No interaction 
was found between Type 1 bait protein and the cells expressing HSPA1A on an immunofluorescence 
assay, but, using an immunoprecipitation assay, HSPA1A was found to be 3.5 times more abundant 
with the Type 1 bait protein than negative control. This demonstrates a specific interaction between 
the Type 1 bait protein and HSPA1A, confirming that HSPA1A is a CER or attachment factor for Type 
1 FCoV. This result also supports the theory that the fixation method used for the 
immunofluorescence analysis rendered the protein of interest unrecognisable to the Type 1 bait 
protein, as there is no fixation step in the immunoprecipitation assay. Given more time, it would be 
informative to screen pHSPA1A-transfected CrFK cells in an immunofluorescence assay where the 
bait proteins are incubated with the cells prior to fixation. It is also possible that the FLAG tag could 
have interfered with the interaction between HSPA1A and Type 1 bait protein in the 
immunofluorescence assay. If a reliable anti-feline HSPA1A antibody was obtained, this possible 
complication could be circumvented by expressing the protein without a FLAG tag. 
To take this work further, the obvious next step would be to express recombinant HSPA1A in CrFK 
cells and see whether this renders them infectable by field strains of Type 1 FCoV. Should this prove 
to be the case, HSPA1A could confidently be identified as a CER for Type 1 FCoV and work could 
begin to stably express this protein in CrFK cells. The resulting cell line would support the 




5 Measuring the immunogenicity of FCoV-derived peptides using ELISpot 
5.1 Introduction 
This chapter will describe the optimisation and use of a feline IFN- ELISpot assay to measure the 
immunogenicity of different FCoV-derived peptides. 
The ELISpot assay enables a wide range of antigens, including whole organisms, proteins and 
peptides, to be tested for their ability to elicit a T cell response, by the detection of cytokine 
secretion (Abbott et al., 2012). The cells that go into the ELISpot assay are PBMC, which consist of T 
cells, B cells, natural killer cells and monocytes. Antigen-presenting cells in this mix (i.e. B cells, 
monocytes and monocyte-derived cells) display the antigen of interest to the T cells. Peptides are 
the simplest kind of antigen to use in ELISpot assays because they bind directly to empty major 
histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells, whereas 
whole organisms and proteins must be internalised and processed before their antigens can be 
presented (Schmittel et al., 2001). 
On recognition of an antigen presented by an antigen-presenting cell, T cells become activated and 
release effector cytokines. One such effector cytokine is IFN-; IFN- is mainly secreted by CD4+ T 
helper 1 (Th1) and CD8+ T cells, which play a major role in the cellular immune response (Murphy et 
al., 2012). Production of IFN- is therefore a marker for cellular immunity. The cytokine is captured 
by specific antibodies (e.g. anti-IFN-) that coat the ELISpot plate, and, following application of an 
enzyme-linked secondary antibody and a chromogen, the presence of cytokine is visualised by the 
appearance of a ‘spot’. In an ELISpot assay, one activated T cell results in one spot, allowing 
activated T cells to be enumerated. Though an advantage of ELISpot is that it can detect a low 
frequency of antigen-specific T cells (Slota et al., 2011), immunological priming to the antigen(s) 
used in the assay is necessary to boost the number of T cells able to recognise the antigen and 
increase the chance of a response. This is achieved by exposing the animal to the antigen through 
infection or vaccination before PBMC are taken for use in the assay. 
An understanding of which parts of the FCoV proteome are most immunogenic, and the type of 
immune response they stimulate, will provide insight into the effect of mutations that overlap with 
these areas and potentially guide vaccine design. Since a robust cellular immune response appears 
to be important in overcoming FCoV infection (de Groot-Mijnes et al., 2005, Pedersen et al., 2015), 
work has begun to map the FCoV proteome for T cell epitopes: specific regions of antigens 
recognised by T cells. By engineering almost the entire genome of FCoV into recombinant vaccinia 
viruses and observing the ability of these recombinant viruses to stimulate T cells, de Groot-Mijnes 
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et al. (2005) found that the S protein of a virulent Type 2 FCoV was the main source of T cell epitopes 
in this virus strain. 
Following a study demonstrating the ability of peptides derived from laboratory-adapted Type 1 
FCoV strain ‘KU-2’ S2 protein to induce a Th1-type immune response in a mouse model (Satoh et al., 
2010), Satoh et al. (2011a) screened the N and S2 proteins of KU-2 and Type 2 FCoV strain ‘79-1146’ 
more closely for T cell epitopes. The study exposed PBMC from cats experimentally infected with 
either strain to a series of overlapping peptides representing these areas, and measured IFN-γ 
production as an indicator of a cellular immune response. Cats were exposed to S2 peptides 
representing the serotype with which they had been infected. Most T cell epitopes for the Type 1 
FCoV were found within the HR1 region of S2, and most T cell epitopes for the Type 2 FCoV were 
within the HR1 region of S2 and the IH region. Interestingly, these sites did not contain any antibody-
binding epitopes, therefore would be expected to stimulate a selectively cellular immune response. 
Takano et al. (2014) screened the S1 and M proteins of the KU-2 and 79-1146 FCoV strains in the 
same way as Satoh et al. (2011a), but found only T cell epitopes that overlapped with antibody-
binding epitopes. These findings suggest that the HR1 region of S2 from both Type 1 and Type 2 
FCoV is a promising source of peptides for stimulating a strong, selective cellular immune response. 
Though ADE of disease is not thought to be an issue in cats naturally infected with FCoV (Addie et al., 
1995), choosing T cell epitopes that do not overlap with antibody-binding epitopes could be 
advantageous when designing a peptide-based vaccine against FCoV because ADE has been 
demonstrated in vaccinated, experimentally-infected cats (Balint et al., 2014, Takano et al., 2019b). 
The immune response of an individual is determined by many factors. One explanation for why a 
strong cellular response to FCoV would be mounted in some cats and not others is that some 
variants of the virus contain epitopes that are better at stimulating T cells. Lewis et al. (2015) 
sequenced the genomes of six FCoVs: three from the faeces of healthy cats and three from the 
tissue lesions of cats with FIP. A consistent substitution of isoleucine with threonine at amino acid 
1108 (I1108T), located in the HR1 region of S2, was found in all samples from FIP cats and none from 
healthy cats. This amino acid sits within a major T cell epitope for Type 1 FCoV (I-S2-6; KU-2 amino 
acid position 1089-1108) (Satoh et al., 2011a). By testing peptides representing epitopes with and 
without this substitution for their ability to stimulate a cellular immune response, one could 
ascertain whether the substitution could have an influence on the immune response of the infected 
cat and therefore its clinical course and outcome.  
The overall aim of this project is to develop a reverse genetic system for Type 1 FCoV, and one of the 
uses of a reverse genetic platform is the rational development of vaccines through targeted 
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introduction of mutations into the viral genome. Knowledge of the FCoV T cell epitopes and their 
variants that are best suited to stimulating a selectively cellular immune response in the host would 
guide rational vaccine design, thus allowing the platform to be used to its full advantage. 
5.1.1 Aims 
The aims of this part of the project were: 
• To optimise a feline IFN-γ ELISpot assay that will screen overlapping peptides, representing 
the HR1 region of a field strain Type 1 FCoV S2 protein, for their ability to stimulate T cells.  
• To ascertain whether the I1108T substitution alters the T cell response to the surrounding 




5.2.1 Peptides synthesised 
Twenty-eight overlapping 15-mer peptides (‘HR1 peptides’) were synthesised to span the HR1 region 
of the Type 1 FCoV strain ‘80F’ S2 protein (Appendix C). This strain was identified in the faeces of a 
healthy, FCoV-infected cat (Lewis et al., 2015). Peptides of 15 amino acids were chosen because they 
should be able to bind to both MHC-I and MHC-II, stimulating CD8+ and CD4+ T cells respectively. 
Overlapping peptides ensured that no epitopes were missed (Abbott et al., 2012). 
Peptides 28-33 covered the I1108T substitution that sits within this region, with peptides 28, 30 and 
33 representing the isoleucine variant (‘isoleucine peptides’) and peptides 29, 31 and 32 
representing the threonine variant (‘threonine peptides’; Table 5.1). 
Table 5.1. Sequences of the six overlapping peptides spanning the site of the isoleucine to threonine mutation. Peptides 28, 30, 33 




5.2.2 Obtaining PBMC 
Surplus blood was available from cats who had blood samples submitted for FCoV antibody titre 
testing free of charge. The free testing was initially run through a local veterinary practice and the 
Langford Vets Small Animal Referral Hospital, University of Bristol, where the veterinarian caring for 
the cat gained consent from the cat’s guardian, took approximately 1 ml of blood from the cat into 
an EDTA tube and submitted the sample to us. When the samples were received, they were 
processed within two days into PBMC and plasma.  
The entire yield of viable PBMC from each sample was used fresh in the ELISpot assay; freezing was 
trialled but was found to severely impact the recovery of viable cells. The plasma from each sample 
was sent to Veterinary Diagnostic Services, University of Glasgow, and underwent an indirect 
immunofluorescent antibody test to measure FCoV antibody titre, using Type 2 FCoV grown in FE-A 
cells as the antigen. This test is reported to have 100% sensitivity and specificity (Addie et al., 2015) 
but does not distinguish between Type 1 and 2 FCoV. The FCoV antibody titre obtained for each cat 
was relayed to the veterinarian who originally submitted the sample. By offering FCoV serology, cats 
who had been immunologically primed to FCoV (i.e. were seropositive) could be identified and taken 
forward into the ELISpot assay. 
Though this system of sample recruitment worked well, recruitment of cats was extremely slow. A 
new strategy was devised whereby cat breeders were offered the FCoV antibody titre test for any of 
their cats free of charge. Since FCoV is often present, and can be an issue, in multi-cat environments 
such as breeding households (Drechsler et al., 2011), we correctly predicted that breeders would be 
very interested in taking up the testing. Information about the project and the laboratory’s contact 
details were disseminated via a newsletter to cat breeders, which resulted in a very large number of 
responses. Interested breeders were advised to make an appointment with their veterinarian, and 
blood sampling, submission and communication of results were coordinated through the 
veterinarian. Most cats recruited in this way were from the UK to enable samples to be processed as 
quickly as possible, but one breeder resided in Norway and another in Italy. 
5.2.2.1 Population description 
In total 110 blood samples were received from 110 cats before recruitment was terminated due to 
time limitations. Twenty-seven cats (25%) were from non-breeding households (‘non-breeder’) and 
83 (75%) were from breeding households (‘breeder’). A plasma antibody titre was obtained for all 
110 cats to determine their exposure to FCoV. Thirty-two (29%) had a titre of 0 (i.e. they were 
seronegative), three (3%) had a titre of 80, seven (6%) had a titre of 160, four (4%) had a titre of 320, 
eight (7%) had a titre of 640, 31 (28%) had a titre of 1280 and 25 (23%) had a titre of >1280 (Figure 
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5.1). Just two (7%) non-breeder cats were seropositive, compared to 76 (92%) breeder cats 
(p<0.001). 
Figure 5.1. The FCoV antibody titres and source of the individual cats whose blood samples were collected for this study. Whole blood 
from 110 cats was collected into EDTA, and the plasma was removed after allowing the blood cells to settle by gravity. The plasma was 
submitted to an external laboratory for immunofluorescent antibody testing. The number of cats with each plasma FCoV antibody titre is 
shown as a histogram plot. The numbers of cats from ‘Breeder’ or ‘Non-Breeder’ households are indicated by the shading. 
The PBMC of 82 cats were used in the ELISpot assay, with 26 (both FCoV seronegative and 
seropositive) of these used for optimisation purposes and the remaining 56 (FCoV seropositive only) 
used for experimental purposes. Samples from FCoV seronegative cats were not used for 
experimental purposes because they may have been naïve to FCoV and so sufficient T cells to 
respond to FCoV antigens would not be expected to be present. Otherwise, the 56 cats were not 
selected for any particular reason; samples were simply processed and used in the order that they 
arrived. Of the 56 cats, five could not be included in the analysis due to a failure of the positive 
control (section 5.2.3). Of the remaining 51 cats, six were 0-6 months, 26 were 7 months-2 years, 17 
were 3-6 years, one was 9 years and one was 13 years of age. Eighty-eight percent were unneutered, 
likely reflecting the source of the cats as all but one were used as breeding cats (Figure 5.2). Twenty-
one cats were British Shorthair, 10 were Ragdoll, five were Maine Coon, three were Birman, three 
were Persian and nine were ‘other’ pedigrees (British Longhair, Domestic Longhair, Burmese, 




Figure 5.2. The age groups and sexes of the 51 cats whose PBMC were used in the ELISpot study. The number of cats within each age 
group is shown as a histogram plot. The number of cats of each sex are indicated by the shading. MN: male neutered, ME: male entire, FN: 
female neutered, FE: female entire. Ages are categorised as per the International Cat Care ‘Life Stages’ guidelines (ICC, 2015); Kitten: 0-6 
months, Junior: 7 months-2 years, Prime: 3-6 years, Mature: 7-10 years, Senior: 11-14 years. 
Figure 5.3. The breeds of the 51 cats whose PBMC were used in the ELISpot study. Breeds for which there were less than three cats are 





5.2.3 Optimisation of ELISpot assay 
The feline IFN- ELISpot assay (Figure 5.4) was carried out following the protocol provided by the kit 
manufacturer. 
Figure 5.4. Schematic to illustrate a feline IFN- ELISpot assay. Each step depicts one well of a 96 well plate. 
1: Wells of a plate are coated in anti-IFN- antibody (capture antibody; orange). Feline PBMC (blue) are added to the well, along with the 
peptide(s) of interest. Antigen-presenting cells present the peptide(s) to T cells, but this aspect of the assay is not represented here. 
2: If T cells recognise the peptide(s), they become activated (shown as enlarged and green) and secrete IFN- (green rhombi). The IFN- 
binds to the anti-IFN- antibody in the vicinity of the activated cell. 
3: The well is washed to remove the cells and any unbound IFN-. An enzyme-linked secondary anti-IFN- antibody (detection antibody; 
orange) is applied, and this binds to any IFN- that was captured by the capture antibody. A substrate is applied that reacts with the 
detection antibody, resulting in a purple spot. One spot is formed per activated T cell.  
To optimise the assay before using it for experimental purposes, serial dilutions of feline PBMC, all 
stimulated with the mitogen phytohaemagglutinin (PHA) at 10 µg/ml, were used. This dose of PHA is 
expected to stimulate T cells to produce IFN- in the absence of antigen (Passlack et al., 2017). It was 
found that spots were visible with 10,000 cells per well and above, but that it was difficult to 
distinguish spots from background colouration. To reduce the level of background colouration, an 
ethanol pre-wetting step was trialled based on the plate manufacturer’s advice, but pre-wetted 
wells did not show any spot formation. Various other steps were therefore taken to reduce 
background colouration and/or increase the intensity of the spots, as follows: 
• Incubation lengths of PBMC with PHA from 18 to 48 hours were tested, based on a range 
recommended by Nordone et al. (2005). 
• The PBMC were rested for 24 hours prior to use in the assay, based on advice from Nordone 
et al. (2005). 
• The underdrain was removed and both sides of the plate rinsed under tap water after the 
final incubation period with the chromogen, based on advice from Nordone et al. (2005). 
• Colour development reagents were brought to room temperature before use, based on the 
manufacturer’s recommendation (R&D, 2016). 
• The plate was dried for at least 24 hours at 2-8 °C, based on advice from Abcam (2016). 
Upon the testing of these conditions, incubating PBMC for 24 hours and not resting them prior to 
use in the assay were found to result in the most intense spots (Figure 5.5). Rinsing the plate, 
bringing the colour development reagents to room temperature and drying the plate were found to 
reduce background colouration, so were incorporated into the protocol. 
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Figure 5.5. Comparison of the feline IFN- ELISpot assay before and after optimisation. The PBMC in well A were incubated in the assay 
for 18 hours and were rested prior to use in the assay, whereas the PBMC in well B were incubated in the assay for 24 hours and were not 
rested prior to use in the assay. The PBMC in both wells were stimulated with 10 µg/ml PHA and were plated at the same density, but they 
were taken from different cats. 
With these steps in place, experiments began to test the ability of the peptide pools to stimulate 
PBMC, using cells stimulated with PHA as a positive control and unstimulated cells as a negative 
control. However, it was found that around 50% of the feline PBMC populations did not respond 
adequately to PHA (i.e. there were too few spots to distinguish the positive control from 
background; Figure 5.6). An experiment was therefore carried out to compare PHA (10 µg/ml) 
(Passlack et al., 2017), concanavalin A (5 µg/ml) (Abbott et al., 2012) and phorbol 12-myristate 13-
acetate (PMA)/ionomycin (100/600 ng/ml) (Nordone et al., 2005) as positive control mitogens 
(Figure 5.7). Concanavalin A was chosen as the best mitogen because PBMC responded to it more 
strongly than PHA, but not so strongly that spots became confluent, as was the case with 
PMA/ionomycin. 
Figure 5.6. Example of a PBMC population that failed to respond to PHA in a feline IFN- ELISpot assay. Well A is the positive control (i.e. 
PBMC were treated with 10 µg/ml PHA) and well B is the negative control. The PBMC in both wells were from the same cat and were 




Figure 5.7. Results of a feline IFN- ELISpot assay carried out to determine the optimal positive control mitogen. Well A is the negative 
control, well B has been treated for 24 hours with PHA (10 µg/ml), well B for 24 hours with concanavalin A (5 µg/ml) and well C for 24 
hours with PMA/ionomycin (100/600 ng/ml). The PBMC in all wells were from the same cat and were plated at the same density. 
Another issue encountered was the high incidence of artefactual spots found under all conditions, 
including the negative control, that likely represented cell debris or reagent aggregation (Nordone et 
al., 2005). The following steps were therefore taken to overcome this problem: 
• Diluted reagents were passed through at 0.2 µm syringe filter before being used in the assay 
to remove any aggregates that may have been causing artefactual spots. 
• A washing step using deionised H2O was incorporated after cell incubation in order to lyse 
the cells and remove them from the plate, overcoming the problem of cell debris. 
The incidence of artefactual spots was reduced to an acceptable level, but it was decided that spots 
would be counted by eye due to difficulty finding an ELISpot reader setting that reliably 




5.2.4 Response of PBMC to peptide pools on ELISpot assay 
Having optimised the feline IFN- ELISpot assay, PBMC from 51 seropositive cats were analysed for 
spot forming cells (SFC) per 106 cells in response to each peptide pool (peptides 28, 30 and 33: 
isoleucine peptides, peptides 29, 31 and 32: threonine peptides, peptides 19-46: HR1 peptides; 
section 5.2.1). The PBMC from each cat were counted and divided evenly into ten, to be incubated, 
in duplicate, with concanavalin A (positive control), culture medium only (negative control), 
isoleucine peptides, threonine peptides or HR1 peptides. Samples from many cats were run through 
the assay simultaneously. Figure 5.8 shows the typical setup of an ELISpot assay in this project. 
Figure 5.8. A typical 96 well plate plan for the ELISpot assay. Concanavalin A (positive control), culture medium (negative control) or a 
peptide pool was added to PBMC at the concentrations specified before incubation for 24 hours. 
Being a larger peptide pool, HR1 peptides were included to see whether a greater response was 
elicited when more potential T cell epitopes were included. The data points of SFC per 106 cells were 
not normally distributed. The median value of SFC per 106 cells using the peptide pools for 
stimulation was 0 (range: 0 to 43) for the isoleucine peptides, 0 (range: 0 to 29) for the threonine 
peptides and 0 (range: 0 to 36) for the HR1 peptides (Figure 5.9). 
This result showed that there was no median response to any peptide pool above background, likely 
because any response seen using the PBMC from an individual cat was obscured by the large 
number of PBMC populations that failed to respond to any peptide pool. The SFC per 106 cells for 
the 31 cats that responded above background to at least one peptide pool were therefore analysed 
separately (Figure 5.10). These data were not normally distributed. A statistically significant 
difference was identified between the median PBMC response to the three peptide pools (p=0.025), 
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with the response to the HR1 peptides being significantly higher than to both the isoleucine 
(p=0.001) and threonine (p<0.001) peptides.  
In order to explore any difference between the responses to the isoleucine and threonine peptides, 
a third analysis was carried out only on the 17 cats that showed a response above background to 
either of these peptide pools (Figure 5.11). The data were not normally distributed. The median 
value of SFC per 106 cells using the isoleucine peptides was 3 (range: 0 to 43) and using the 
threonine peptides was 2 (range: 0 to 29), but this difference was not statistically significant 
(p=0.461). Of these 17 cats, nine (53%) showed a greater response to the isoleucine peptides, six 
(35%) showed a greater response to the threonine peptides and two (12%) showed an equal 
response to both. The 17 cats represented here had an extremely similar distribution of breeds, sex 
and age groups to the 51 cats originally analysed, therefore no unique factors were identified that 
could be associated with their response to isoleucine or threonine peptides. 
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Figure 5.9. The response of feline PBMC to each peptide pool. The PBMC from 51 cats were incubated with isoleucine, threonine or HR1 
peptide pools in a feline IFN- ELISpot assay and the number of SFC per 106 cells using each peptide pool were counted. The data are 
represented as a box plot, with the box representing the interquartile range, the thick black line representing the median, the whisker 
representing the maximum value excluding outliers and the circles representing outliers. 
Figure 5.10. The response of feline PBMC to each peptide pool, of the cats that showed a response above background to at least one 
peptide pool. PBMC from 31 cats were incubated with isoleucine, threonine or HR1 peptide pools in a feline IFN- ELISpot assay and the 
number of SFC per 106 cells using each peptide pool were counted. The data are represented as a box plot, with the box representing the 
interquartile range, the thick black line representing the median, the whiskers representing the minimum and maximum values excluding 




Figure 5.11. The response of feline PBMC to isoleucine or threonine peptides, of the cats that showed a response above background to 
either peptide pool. PBMC from 17 cats were incubated with isoleucine or threonine peptides in a feline IFN- ELISpot assay and the 
number of SFC per 106 cells using each peptide pool were counted; 
A: The data are represented as a box plot, with the box representing the interquartile range, the thick black line representing the median, 
the whisker representing the minimum and maximum values excluding outliers and the circles representing outliers; 





This chapter describes the optimisation and use of a feline IFN-γ ELISpot assay to assess the 
immunogenicity of Type 1 FCoV-derived peptides. Knowledge of the viral epitopes and variants 
thereof that are best suited to stimulating a selectively cellular immune response in the host would 
form a strong basis for rational vaccine design. 
The first aim of this project was to optimise a feline IFN-γ ELISpot assay in order to test FCoV 
peptides for their ability to stimulate T cells. Though the use of a feline IFN-γ ELISpot has been 
reported (Satoh et al., 2011a, Nordone et al., 2005, Abbott et al., 2012, Gutierrez, 2008), it is a 
relatively novel technique and the published literature is often in disagreement regarding the 
optimal methods to use. This project used a commercially available feline IFN-γ ELISpot kit 
containing capture and detection antibodies that are known to function together in this kind of assay 
at defined concentrations, but other aspects of the assay, including the length of time for which cells 
should be incubated, had to be optimised. Other conditions were also tested to increase spot 
intensity and/or reduce background colouration based on published literature and the plate 
manufacturer’s advice.  
An optimised protocol was finally deduced that produced consistent and reliable results using 
control mitogens for PBMC stimulation. However, one aspect of the assay that was not optimised in 
this project was the dose of peptide. A final concentration of 10 µM (approximately 15 µg/ml) of 
each peptide was chosen based on previous studies performed in the laboratory, though 
concentrations from 10 µg/ml (Abbott et al., 2012) to 30 µg/ml (Satoh et al., 2011a) have been 
described in the literature. As a dose of 10 µM seemed to produce adequate results (i.e. the dose 
produced SFC in some PBMC populations but not so many SFC as to render counting difficult), 
different concentrations were not trialled in this project. However, it is possible that 10 µM is not 
the optimal concentration, and that the frequency of SFC could be higher with a different 
concentration. Future work exploring varied doses of peptide would be useful. 
The second aim of this project was to ascertain whether the isoleucine to threonine substitution at 
amino acid position 1108, located in the HR1 region of the FCoV S2 protein, alters the T cell response 
to this epitope, by testing variant peptides with PBMC in a feline IFN-γ ELISpot assay. Using the 
optimised protocol, PBMC from 51 cats were successfully tested with the isoleucine and threonine 
peptides, as well as a larger peptide pool covering the entire HR1 region (HR1 peptides). The 
response to the HR1 peptides was found to be significantly higher than the response to the 
isoleucine (p=0.001) and threonine (p<0.001) peptides when PBMC from the 31 cats who responded 
above background to any of the peptide conditions were analysed separately. By excluding non-
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responders from the analysis in this way, the problem of a large number of zero data lowering the 
median could be overcome.  
A greater response to HR1 than isoleucine or threonine peptides was expected as the larger HR1 
pool contained more potential T cell epitopes, which increased the likelihood of a T cell response. 
Since each peptide was used at 10 µM and there were many more peptides in the HR1 than other 
pools, the overall concentration of peptide in the HR1-treated wells would have been higher. This 
should not affect the result since T cells should only become activated if they recognise specific 
epitopes, but it is possible that peptides in general provided a non-specific stimulatory effect on T 
cells, and so a higher concentration of peptides led to more non-specific stimulation. Inclusion of a 
peptide control to which cats are known to not respond, at the same concentration as the HR1 
peptides, would rule out this effect. 
Though a good indicator that at least some of the peptides were immunogenic, this analysis gave no 
insight into whether the I1108T mutation affects the T cell response to this particular epitope. 
Further analysis was therefore carried out only on the 17 cats who responded above background to 
either the threonine or isoleucine peptides; this showed a higher median response to the isoleucine 
compared to the threonine peptides, but this was not statistically significant. To overcome the 
possible issue of opposite trends in individual responses to isoleucine or threonine peptides 
offsetting each other, the response of each individual cat to the two peptide pools was compared. It 
was found that 53% of cats showed a greater response to the isoleucine than threonine peptides 
(compared to 35% for the reverse). Taken together, these results suggest that the threonine epitope 
variant may be less effective at stimulating T cells, which would support the hypothesis that FCoV 
with the I1108T substitution is less able to elicit an adequate cellular immune response in the cat. A 
larger sample size is required to further investigate this hypothesis and trend. 
A feature of the ELISpot assays run in this project was that the frequency of SFC was generally very 
low. Actual counts ranged from zero to ten, though by calculating the number of SFC per 106 cells 
these counts could be amplified and compared side by side despite differing numbers of cells in the 
assay. A simple explanation as to why spot frequency was so low is that the number of cells used 
was low. Nordone et al. (2005) recommend 500,000 cells per well for an optimal immune response 
when performing feline cytokine ELISpot assays, but this was rarely achieved because too few PBMC 
(typically ~3,000,000) were extracted from the small surplus blood volumes available. This is a 
problem intrinsic to using clinical samples from cats; it is near impossible to have residual samples of 
1.5 ml or more of blood in a clinical setting. Another way to improve PBMC yield from the small 
amount of blood available could be to trial different anticoagulants with the blood samples; EDTA 
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was used in this project because it is commonly used in veterinary practice therefore widely 
available, but Nordone et al. (2005) suggest that EDTA could impair cytokine induction, and instead 
suggest using acid citrate dextrose or sodium citrate. 
Another explanation for the low frequency of spots is that some of the peptides were not 
immunogenic. Though the isoleucine and threonine peptides covered the amino acid sequence of 
the major T cell epitope described by Satoh et al. (2011a), this project used 15-mer peptides 
compared to the 20-mers used in Satoh’s experiments. The reason for using 15-mers in the current 
project is that they should be capable of recognition by both CD4+ and CD8+ T cells, whereas 20-mers 
would likely only be recognised by CD4+ T cells (Abbott et al., 2012). Thus it was hoped that the 15-
mers would have a better chance of eliciting a T cell response. However, it cannot be assumed that 
the effect found by Satoh et al. (2011a) would also be observed with 15-mer peptides. In future 
investigations, the peptides could also be designed as 20-mers to allow comparison studies. 
Peptide pools, potentially containing many T cell epitopes, are commonly used in ELISpot assays as a 
screening tool to broadly identify regions of a protein that stimulate a T cell response. If a response 
is identified to a peptide pool, individual peptides can then be used in the assay to further localise 
the epitope(s). When a single peptide is identified as containing a T cell epitope, the specific amino 
acid sequence functioning as an epitope can be identified by dividing that peptide into smaller 
pieces or using different sequence overlaps of the peptide (Abbott et al., 2012). This project, though 
concerned with a specific T cell epitope, used overlapping peptide pools because it is unknown 
exactly what sequence the epitope spans and how it is best presented to T cells. The HR1 peptide 
pool was used, in effect, as a positive control in this project; being a larger peptide pool and thus 
potentially containing more T cell epitopes, HR1 should have a higher likelihood of eliciting a T cell 
response. Additionally, Satoh et al. (2011a) identified HR1 as a major source of T cell epitopes, with 
four of 14 peptides covering the region stimulating a significant IFN- response in the study. 
However, HR1 peptides still only cover a small region of an FCoV protein, and a lack of response to 
them does not mean that the cat would be unable to mount a T cell response against another part of 
the virus. A stimulus such as whole inactivated virus (Satoh et al., 2011a) may have been a better 
control for the individual’s T cell response to FCoV than the HR1 peptides used in the current 
project. 
The number of SFC per 106 cells was calculated from the raw counts in order to compare results 
between different cats, but this is potentially problematic. Since far fewer than 106 cells were 
seeded per well, a difference of one spot between wells was amplified to look like a very large 
difference, which may have led to placing more significance on a result than was warranted. This is a 
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particular hazard when spots are counted by eye, as, despite extensive efforts in the current project 
by the operator, such counts are always somewhat subjective. This problem could be overcome by 
only using samples containing PBMC above a threshold number in order to prevent over-
amplification of results, and by using the ELISpot reader to count spots automatically. Another 
solution could be to calculate the number of SFC per a lower number of cells. This would prevent 
over-amplification but could lead to a situation where many of the resulting data are very low and 
difficult to distinguish from each other. 
The PBMC from some cats were not used in the ELISpot assay, largely because of issues around the 
coordination of clinical sample submission. It was decided to recruit samples by advertising to 
breeders due to the low number of samples that were obtained through the original recruitment 
strategy. However, involvement of the breeders greatly increased the number of samples submitted, 
introducing difficulties in coordinating sample arrival in the laboratory and ensuring that they could 
all be used in the ELISpot assay. Freezing of extracted PBMC was initially trialled but it was found 
that this markedly decreased the viable cell count. It was also specified to breeders and 
veterinarians that submitted blood samples must be at least 1 ml in volume and delivered within 
two days of collection from the cat. However, some samples did not meet these requirements and it 
was therefore difficult or impossible to extract enough viable PBMC. In total, 12 samples were 
unsuitable for use in the assay; three were too small a volume, one arrived after the project had 
finished and eight were unsuitable for reasons unrelated to volume or time (four were haemolysed 
and four were clotted). Twenty samples had a smaller volume than was specified but sufficient 
PBMC could be extracted to permit their use in the assay. 
Seroprevalence amongst the ‘breeder’ cohort of cats was 92%, compared to just 7% for the ‘non-
breeder’ cohort. By recruiting samples from breeders, not only were almost all PBMC used in the 
ELISpot assay from young, unneutered pedigrees, but the breeders who took part were also not 
likely to be randomly selected in terms of FCoV infection status. Those who chose to participate in 
the study by obtaining free of charge FCoV serology testing for their cats were likely to have an 
interest in FCoV, possibly because of problems with FIP or previous positive results on FCoV 
serology. Though the population in this project was not representative of the wider cat population, 
recruiting in this way meant that most cats were FCoV seropositive so their PBMC could be used to 
measure T cell responses to FCoV peptides. The original recruitment strategy may have led to a more 
representative population but would have also meant that most samples could not have likely been 
used in the ELISpot assay if more had been derived from seronegative cats. 
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An assumption made in this project is that seropositive cats had been exposed to Type 1 FCoV. This 
is a reasonable assumption since the vast majority of FCoV field strains in the UK are Type 1 (Addie 
et al., 2003) but there is a chance that some of the cats could have been infected with Type 2 FCoV. 
The indirect immunofluorescent antibody test used in this project to measure FCoV antibody titre 
recognises antibodies to both Type 1 and Type 2 FCoV so does not distinguish between the 
serotypes. This is an important factor, since this project looked at T cell epitopes situated in the FCoV 
S2 protein; a region that would vary considerably between Type 1 and Type 2 FCoV. However, 
methods to distinguish the two serotypes (e.g. RT-PCR and sequencing) rely on direct detection of 
virus, and seropositivity does not always equate to active virus shedding (Addie and Jarrett, 2001), 
so it may have been problematic to identify any infecting FCoV serotype in the cats. Although such a 
step could be introduced in the future, it is worth remembering that Type 2 FCoV is rare in the UK 
(Addie et al., 2003). 
In order to learn more about the impact of the FCoV I1108T substitution on the T cell response, it 
would be useful to run more PBMC samples from a wider range of cat breeds, age groups and sexes 
through the optimised IFN- ELISpot assay, increasing sample size and therefore the power to detect 
a significant difference in the response to the isoleucine and threonine peptides, if one exists. It 
would also be useful to gather more information about the cats such as existing morbidities that 
could affect T cell function, for example feline immunodeficiency virus.  
Though no significant difference was found in the ability of the isoleucine and threonine peptide 
variants to stimulate T cells, an optimised ELISpot assay has been developed in this study that could 
be used in the future to measure the immunogenicity of T cell epitopes and their variants, and 
therefore guide rational vaccine design. Thinking into the future, a feline IFN- ELISpot assay could 
be a useful tool for assessing cellular immunity to FCoV post-vaccination (Abbott et al., 2012, Slota et 
al., 2011). Knowing the importance of the cellular immune response in overcoming FIP challenge, 
there is also the potential to use an IFN-γ ELISpot as a prognostic indicator in cats with FIP or, given 
the recent breakthroughs in FIP treatment with GC376 (Pedersen et al., 2017) and GS-441524 




6 Final perspectives and future work 
The overall aim of this project was to establish a reverse genetic system for Type 1 FCoV. Such a 
system constitutes a powerful tool for better understanding the molecular pathogenesis of FCoV and 
the development of FIP, as it allows targeted mutations to be introduced into the FCoV genome and 
the effects of these mutations on the virus phenotype to be studied. Reverse genetic systems have 
also been used to generate vaccine candidates, as the platform lends itself to attenuating viruses in 
a rational and strategic way (Stobart and Moore, 2014). 
At the beginning of this project, the only Type 1 FCoV reverse genetic system was based on the 
‘Black’ virus strain (Tekes et al., 2008). ‘Black’ is technically a Type 1 FCoV but is so adapted to cell 
culture it can no longer be said to represent field strains of the virus (Pedersen, 2009). This project 
therefore endeavored to achieve something novel by building a reverse genetic system based on a 
clinically relevant field strain of Type 1 FCoV. Three years into the project, Ehmann et al. (2018) 
achieved this aim and published the first report of a Type 1 FCoV reverse genetic system based on a 
field strain of the virus. This groundbreaking study demonstrated that cells transfected with full-
length RNA encoding this recombinant Type 1 FCoV produced viral particles that, while not 
infectious in vitro, resulted in productive infection when given to cats. 
During this project, full-length constructs representing a field strain of Type 1 FCoV, chimeric Type 1 
FCoV with a Type 2 FCoV S gene and an FCoV replicon were designed and built through in vitro 
ligation. These constructs were transcribed and the latter two were transfected into cells, but no 
detectable virus or replicon-expressing cells were made. Infectious virus was likely not recovered 
from cells transfected with the chimeric construct because the construct was truncated, though 
unfortunately this was not discovered until after the experiment was carried out. The likely reasons 
that replicon-expressing cells could not be established are discussed in depth in chapter 3.3, but 
briefly include a non-synonymous mutation that was unavoidably introduced into the ORF1a gene 
during amplification in bacterial culture, and issues with the transfection method; specifically, using 
chemical transfection rather than electroporation.  
It would be worthwhile to persevere with the constructs developed in this project, because they are 
based on a different strain of FCoV from that used by Ehmann et al. (2018) so would contribute to a 
fuller understanding of the virus. Additionally, an FCoV replicon has not been reported before in the 
literature so, if established, would be a completely novel tool for exploring the impact of virus 
replication on cells and rapidly screening antivirals targeting the non-structural parts of the virus. To 
move forward with this part of the project, the full-length constructs could be cloned into vaccinia 
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virus vectors. This would overcome the problem experienced in this project of having a limited 
amount of RNA to work with, and the mutation in the ORF1a gene could be repaired. 
Unlike Type 2 FCoV, a CER for Type 1 FCoV has not been identified and there are no available cell 
lines in which field strains of the virus can be propagated. This is a major hurdle in FCoV research, 
because Type 1 FCoV is by far the most abundant serotype in nature (Benetka et al., 2004, Addie et 
al., 2003, Li et al., 2018) and therefore the most biologically relevant. Ehmann et al. (2018) 
circumvented this problem by inoculating cats with their recombinant Type 1 FCoV, but the 
development of a system to recover recombinant virus (as well as field strains of Type 1 FCoV) in 
vitro would represent a huge leap forward in FCoV research. Not only is it more ethical and 
straightforward to characterise recombinant mutant viruses in cells rather than in cats, a cell-based 
virus replication system would facilitate the dissection of the steps that potentially lead to FIP 
without the complicating factors of host and environment.  
That is why an important second aim of this project was to identify a CER for Type 1 FCoV. With 
knowledge of a receptor that this serotype uses to gain entry to its target cells, it would be possible 
to engineer that receptor into a cell line, rendering it permissive to infection with Type 1 FCoV and 
therefore overcoming an obstacle that has impeded FCoV research for many years. Prior to the start 
of this project, Desmarets et al. (2013) developed an immortalised feline intestinal epithelial cell line 
that was able to support the propagation of field strains of Type 1 FCoV. However, the group were 
unwilling to share this cell line with the scientific community, and it was not possible to replicate 
their results in this study despite a number of attempts.  
As well as a useful tool in itself to support virus replication, the intestinal epithelial cell line 
previously reported by Desmarets et al. (2013) would have been invaluable to this project for the 
identification of a Type 1 FCoV CER. The approach taken in this project to identify the CER involved 
incubating a chimeric ‘bait protein’, comprising the FCoV S1 (receptor binding) domain and human 
IgG Fc, with a lysate of a cell type permissive to infection with the virus (and therefore bearing a CER 
for the virus). The bait protein was then purified via its IgG Fc portion, and the protein to which it 
had bound characterised using mass spectrometry and proteomics. This method was first used to 
identify a CER for MERS-CoV (Raj et al., 2013), and was used in this project to ‘identify’ APN as a CER 
for Type 2 FCoV. The latter identification was straightforward and achieved with minimal 
optimisation, suggesting that the methodology was sound and a Type 1 FCoV CER could have been 
easily identified given a suitable cell line to work with. 
In the absence of the use of the aforementioned intestinal cell line, two alternative cell lines, feline 
PBMC and feline monocyte-derived cells, were screened for expression of a Type 1 FCoV CER with no 
155 
 
success. A breakthrough came when lysates of feline intestinal organoids, 3D cultures derived from 
stem cells that self-organise into ‘mini guts’, were incubated with the bait proteins, and HSPA1A was 
found to be significantly enriched with Type 1 bait protein. This interaction was confirmed when the 
Type 1 bait protein was found to precipitate HSPA1A from pHSPA1A-transfected cells. Interestingly, 
HSPA1A is a plausible CER for Type 1 FCoV because it has been found located at the plasma 
membrane in a human cell line (Bilog et al., 2019) and is a putative CER for a range of other viruses 
including intestinal rotavirus (Perez-Vargas et al., 2006). An urgent next step for validating HSPA1A 
as a CER for Type 1 FCoV would be to test whether resistant cells are rendered infectable by Type 1 
FCoV when they are made to express HSPA1A. If this is the case, HSPA1A could confidently be 
identified as a CER for Type 1 FCoV and work could begin to stably express this protein in, for 
example, CrFK cells, creating a cell line in which field strains of the virus can be propagated. 
In the absence of the definitive identification of a Type 1 FCoV CER, feline intestinal organoids could 
still support in vitro propagation of Type 1 viruses. The utility of intestinal organoids for this purpose 
was demonstrated by Ettayebi et al. (2016), when the group used these cultures to grow HuNoVs in 
vitro for the first time. This was achieved through the development of monolayers: organoid cultures 
grown in 2D rather than 3D, to allow access to the apical (receptor-bearing) surface of the cell (van 
der Hee et al., 2018). Intestinal organoids are more difficult to work with than most immortalised 
cell lines, but they more closely recapitulate the natural site of infection of FCoV so may be more 
biologically relevant. Organoids also carry the genetic signature of the individual from which they 
were derived (Ramani et al., 2018), suggesting that they may offer the potential to explore virus-host 
interactions in vitro. Development of feline intestinal organoid monolayers would be the next step in 
exploring this avenue of research. 
The purpose of this project was to build a tool that would allow researchers to gain a better 
understanding of how FIP develops from FCoV, and rationally design vaccines to prevent this 
disease. To this end, a feline IFN- ELISpot assay was first optimised, then used to measure the 
immunogenicity of peptides representing a region of the FCoV S2 protein with and without an amino 
acid substitution. This substitution, identified by Lewis et al. (2015), was found in all FCoVs from the 
tissues of cats with FIP but no FCoVs from the faeces of healthy cats. Sitting within a major T cell 
epitope for Type 1 FCoV as identified by Satoh et al. (2011a), it was hypothesised that the 
substitution could influence the immune response of the infected cat and therefore its clinical 
course and outcome. This project found that peptides representing the FIP-related FCoV variant 
were slightly less immunogenic, which would support the hypothesis. However, the difference 
between the two variants was not statistically significant. Beyond investigating the question of this 
specific substitution, it was worthwhile to optimise and gain experience of working with the assay. 
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The IFN- ELISpot assay is an established method to assess cellular immunity (Slota et al., 2011, 
Schmittel et al., 2001), which is thought to be an important factor in preventing the development of 
FIP from FCoV (Pedersen, 2014b). Any successful vaccine against FIP will likely have to be capable of 
stimulating a cellular immune response in the cat, and a feline IFN- ELISpot assay provides a 
straightforward and relevant way of testing this capability in the future. 
Although a reverse genetic system for Type 1 FCoV could not be established within the time 
constraints of this project, the methods that have been optimised and the constructs that have been 
built provide a solid foundation for a future project to achieve this aim. Similarly, a cell line in which 
to propagate Type 1 FCoV could not be developed within the time constraints of this project, but the 
promising lead on a candidate receptor is ready to be followed up in a future project. This will 
hopefully result in the definitive identification of a Type 1 FCoV CER and a way of propagating field 





ABBOTT, J. R., PU, R., COLEMAN, J. K. & YAMAMOTO, J. K. 2012. Utilization of feline ELISPOT for 
mapping vaccine epitopes. Methods Mol Biol, 792, 47-63. 
ABCAM. 2016. ELISPOT troubleshooting tips [Online]. Available: 
http://www.abcam.com/index.html?pageconfig=resource&rid=11457 [Accessed 25 
February 2016]. 
ACAR, D. D., OLYSLAEGERS, D. A., DEDEURWAERDER, A., ROUKAERTS, I. D., BAETENS, W., VAN 
BOCKSTAEL, S., DE GRYSE, G. M., DESMARETS, L. M. & NAUWYNCK, H. J. 2016. Upregulation 
of endothelial cell adhesion molecules characterizes veins close to granulomatous infiltrates 
in the renal cortex of cats with feline infectious peritonitis and is indirectly triggered by 
feline infectious peritonitis virus infected monocytes in vitro. J Gen Virol. 
ADDIE, D. 2012. Feline Coronavirus Infections, St. Louis, MO, Elsevier/Saunders. 
ADDIE, D., BELAK, S., BOUCRAUT-BARALON, C., EGBERINK, H., FRYMUS, T., GRUFFYDD-JONES, T., 
HARTMANN, K., HOSIE, M. J., LLORET, A., LUTZ, H., MARSILIO, F., PENNISI, M. G., RADFORD, 
A. D., THIRY, E., TRUYEN, U. & HORZINEK, M. C. 2009. Feline infectious peritonitis. ABCD 
guidelines on prevention and management. J Feline Med Surg, 11, 594-604. 
ADDIE, D., HOUE, L., MAITLAND, K., PASSANTINO, G. & DECARO, N. 2019. Effect of cat litters on 
feline coronavirus infection of cell culture and cats. J Feline Med Surg, 1098612X19848167. 
ADDIE, D. D. & JARRETT, O. 1992. A study of naturally occurring feline coronavirus infections in 
kittens. Vet Rec, 130, 133-7. 
ADDIE, D. D. & JARRETT, O. 2001. Use of a reverse-transcriptase polymerase chain reaction for 
monitoring the shedding of feline coronavirus by healthy cats. Vet Rec, 148, 649-53. 
ADDIE, D. D., LE PODER, S., BURR, P., DECARO, N., GRAHAM, E., HOFMANN-LEHMANN, R., JARRETT, 
O., MCDONALD, M. & MELI, M. L. 2015. Utility of feline coronavirus antibody tests. J Feline 
Med Surg, 17, 152-62. 
ADDIE, D. D., PALTRINIERI, S., PEDERSEN, N. C. & SECONG INTERNATIONAL FELINE 
CORONAVIRUS/FELINE INFECTIOUS PERITONITIS, S. 2004. Recommendations from 
workshops of the second international feline coronavirus/feline infectious peritonitis 
symposium. J Feline Med Surg, 6, 125-30. 
ADDIE, D. D., SCHAAP, I. A., NICOLSON, L. & JARRETT, O. 2003. Persistence and transmission of 
natural type I feline coronavirus infection. J Gen Virol, 84, 2735-44. 
ADDIE, D. D., TOTH, S., MURRAY, G. D. & JARRETT, O. 1995. Risk of feline infectious peritonitis in cats 
naturally infected with feline coronavirus. Am J Vet Res, 56, 429-34. 
ALAGAILI, A. N., BRIESE, T., MISHRA, N., KAPOOR, V., SAMEROFF, S. C., BURBELO, P. D., DE WIT, E., 
MUNSTER, V. J., HENSLEY, L. E., ZALMOUT, I. S., KAPOOR, A., EPSTEIN, J. H., KARESH, W. B., 
DASZAK, P., MOHAMMED, O. B. & LIPKIN, W. I. 2014. Middle East respiratory syndrome 
coronavirus infection in dromedary camels in Saudi Arabia. MBio, 5, e00884-14. 
ALMAZAN, F., GALAN, C. & ENJUANES, L. 2004. The nucleoprotein is required for efficient 
coronavirus genome replication. J Virol, 78, 12683-8. 
ALMAZAN, F., SOLA, I., ZUNIGA, S., MARQUEZ-JURADO, S., MORALES, L., BECARES, M. & ENJUANES, 
L. 2014. Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res, 189, 
262-70. 
ALSAADI, E. A. J. & JONES, I. M. 2019. Membrane binding proteins of coronaviruses. 14, 275-286. 
ANIS, E. A., DHAR, M., LEGENDRE, A. M. & WILKES, R. P. 2016. Transduction of hematopoietic stem 
cells to stimulate RNA interference against feline infectious peritonitis. J Feline Med Surg. 
BALINT, A., FARSANG, A., SZEREDI, L., ZADORI, Z. & BELAK, S. 2014. Recombinant feline 
coronaviruses as vaccine candidates confer protection in SPF but not in conventional cats. 
Vet Microbiol, 169, 154-62. 
158 
 
BALINT, A., FARSANG, A., ZADORI, Z., HORNYAK, A., DENCSO, L., ALMAZAN, F., ENJUANES, L. & 
BELAK, S. 2012. Molecular characterization of feline infectious peritonitis virus strain DF-2 
and studies of the role of ORF3abc in viral cell tropism. J Virol, 86, 6258-67. 
BANK-WOLF, B. R., STALLKAMP, I., WIESE, S., MORITZ, A., TEKES, G. & THIEL, H. J. 2014. Mutations of 
3c and spike protein genes correlate with the occurrence of feline infectious peritonitis. Vet 
Microbiol, 173, 177-88. 
BANTSCHEFF, M., SCHIRLE, M., SWEETMAN, G., RICK, J. & KUSTER, B. 2007. Quantitative mass 
spectrometry in proteomics: a critical review. Anal Bioanal Chem, 389, 1017-31. 
BARIC, R. S., NELSON, G. W., FLEMING, J. O., DEANS, R. J., KECK, J. G., CASTEEL, N. & STOHLMAN, S. 
A. 1988. Interactions between coronavirus nucleocapsid protein and viral RNAs: implications 
for viral transcription. J Virol, 62, 4280-7. 
BARKER, E. N., STRANIERI, A., HELPS, C. R., PORTER, E. L., DAVIDSON, A. D., DAY, M. J., KNOWLES, T., 
KIPAR, A. & TASKER, S. 2017. Limitations of using feline coronavirus spike protein gene 
mutations to diagnose feline infectious peritonitis. Vet Res, 48, 60. 
BARTFELD, S. & CLEVERS, H. 2015. Organoids as Model for Infectious Diseases: Culture of Human and 
Murine Stomach Organoids and Microinjection of Helicobacter Pylori. J Vis Exp. 
BEALL, A., YOUNT, B., LIN, C. M., HOU, Y., WANG, Q., SAIF, L. & BARIC, R. 2016. Characterization of a 
Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea 
Virus Strain PC22A. MBio, 7, e01451-15. 
BELOUZARD, S., MILLET, J. K., LICITRA, B. N. & WHITTAKER, G. R. 2012. Mechanisms of coronavirus 
cell entry mediated by the viral spike protein. Viruses, 4, 1011-33. 
BENBACER, L., KUT, E., BESNARDEAU, L., LAUDE, H. & DELMAS, B. 1997. Interspecies 
aminopeptidase-N chimeras reveal species-specific receptor recognition by canine 
coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus. J Virol, 
71, 734-7. 
BENETKA, V., KUBBER-HEISS, A., KOLODZIEJEK, J., NOWOTNY, N., HOFMANN-PARISOT, M. & MOSTL, 
K. 2004. Prevalence of feline coronavirus types I and II in cats with histopathologically 
verified feline infectious peritonitis. Vet Microbiol, 99, 31-42. 
BILOG, A. D., SMULDERS, L., OLIVERIO, R., LABANIEH, C., ZAPANTA, J., STAHELIN, R. V. & NIKOLAIDIS, 
N. 2019. Membrane Localization of HspA1A, a Stress Inducible 70-kDa Heat-Shock Protein, 
Depends on Its Interaction with Intracellular Phosphatidylserine. Biomolecules, 9. 
BOETTCHER, I. C., STEINBERG, T., MATIASEK, K., GREENE, C. E., HARTMANN, K. & FISCHER, A. 2007. 
Use of anti-coronavirus antibody testing of cerebrospinal fluid for diagnosis of feline 
infectious peritonitis involving the central nervous system in cats. J Am Vet Med Assoc, 230, 
199-205. 
BORSCHENSKY, C. M. & REINACHER, M. 2014. Mutations in the 3c and 7b genes of feline coronavirus 
in spontaneously affected FIP cats. Res Vet Sci, 97, 333-40. 
BOSCH, B. J., VAN DER ZEE, R., DE HAAN, C. A. & ROTTIER, P. J. 2003. The coronavirus spike protein is 
a class I virus fusion protein: structural and functional characterization of the fusion core 
complex. J Virol, 77, 8801-11. 
BROWN, M. A., TROYER, J. L., PECON-SLATTERY, J., ROELKE, M. E. & O'BRIEN, S. J. 2009. Genetics and 
pathogenesis of feline infectious peritonitis virus. Emerg Infect Dis, 15, 1445-52. 
BURKARD, C., VERHEIJE, M. H., WICHT, O., VAN KASTEREN, S. I., VAN KUPPEVELD, F. J., HAAGMANS, 
B. L., PELKMANS, L., ROTTIER, P. J., BOSCH, B. J. & DE HAAN, C. A. 2014. Coronavirus cell 
entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. 
PLoS Pathog, 10, e1004502. 
CAVANAGH, D. P. D. 2008. SARS- and other coronaviruses : laboratory protocols, New York, N.Y., 
Humana Press. 




CHANG, H. W., DE GROOT, R. J., EGBERINK, H. F. & ROTTIER, P. J. 2010. Feline infectious peritonitis: 
insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis 
of the viral 3c gene. J Gen Virol, 91, 415-20. 
CHANG, H. W., EGBERINK, H. F., HALPIN, R., SPIRO, D. J. & ROTTIER, P. J. 2012. Spike protein fusion 
peptide and feline coronavirus virulence. Emerg Infect Dis, 18, 1089-95. 
CHRISTIANSON, K. K., INGERSOLL, J. D., LANDON, R. M., PFEIFFER, N. E. & GERBER, J. D. 1989. 
Characterization of a temperature sensitive feline infectious peritonitis coronavirus. Arch 
Virol, 109, 185-96. 
CORAPI, W. V., OLSEN, C. W. & SCOTT, F. W. 1992. Monoclonal antibody analysis of neutralization 
and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol, 66, 6695-
705. 
CORNELISSEN, E., DEWERCHIN, H. L., VAN HAMME, E. & NAUWYNCK, H. J. 2009. Absence of 
antibody-dependent, complement-mediated lysis of feline infectious peritonitis virus-
infected cells. Virus Res, 144, 285-9. 
DAS, S., LAXMINARAYANA, S. V., CHANDRA, N., RAVI, V. & DESAI, A. 2009. Heat shock protein 70 on 
Neuro2a cells is a putative receptor for Japanese encephalitis virus. Virology, 385, 47-57. 
DATE, S. & SATO, T. 2015. Mini-gut organoids: reconstitution of the stem cell niche. Annu Rev Cell 
Dev Biol, 31, 269-89. 
DE GROOT-MIJNES, J. D., VAN DUN, J. M., VAN DER MOST, R. G. & DE GROOT, R. J. 2005. Natural 
history of a recurrent feline coronavirus infection and the role of cellular immunity in 
survival and disease. J Virol, 79, 1036-44. 
DE GROOT, R. J., BAKER, S. C., BARIC, R. S., BROWN, C. S., DROSTEN, C., ENJUANES, L., FOUCHIER, R. 
A., GALIANO, M., GORBALENYA, A. E., MEMISH, Z. A., PERLMAN, S., POON, L. L., SNIJDER, E. 
J., STEPHENS, G. M., WOO, P. C., ZAKI, A. M., ZAMBON, M. & ZIEBUHR, J. 2013. Middle East 
respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study 
Group. J Virol, 87, 7790-2. 
DE HAAN, C. A., HAIJEMA, B. J., SCHELLEN, P., WICHGERS SCHREUR, P., TE LINTELO, E., VENNEMA, H. 
& ROTTIER, P. J. 2008. Cleavage of group 1 coronavirus spike proteins: how furin cleavage is 
traded off against heparan sulfate binding upon cell culture adaptation. J Virol, 82, 6078-83. 
DECLERCQ, J., DE BOSSCHERE, H., SCHWARZKOPF, I. & DECLERCQ, L. 2008. Papular cutaneous lesions 
in a cat associated with feline infectious peritonitis. Vet Dermatol, 19, 255-8. 
DEDEURWAERDER, A., DESMARETS, L. M., OLYSLAEGERS, D. A., VERMEULEN, B. L., DEWERCHIN, H. L. 
& NAUWYNCK, H. J. 2013. The role of accessory proteins in the replication of feline 
infectious peritonitis virus in peripheral blood monocytes. Vet Microbiol, 162, 447-55. 
DEDEURWAERDER, A., OLYSLAEGERS, D. A., DESMARETS, L. M., ROUKAERTS, I. D., THEUNS, S. & 
NAUWYNCK, H. J. 2014. ORF7-encoded accessory protein 7a of feline infectious peritonitis 
virus as a counteragent against IFN-alpha-induced antiviral response. J Gen Virol, 95, 393-
402. 
DELMAS, B., GELFI, J., L'HARIDON, R., VOGEL, L. K., SJOSTROM, H., NOREN, O. & LAUDE, H. 1992. 
Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature, 
357, 417-20. 
DENISON, M. R., GRAHAM, R. L., DONALDSON, E. F., ECKERLE, L. D. & BARIC, R. S. 2011. 
Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. 
RNA Biol, 8, 270-9. 
DENU, J. M. 2005. Vitamin B3 and sirtuin function. Trends Biochem Sci, 30, 479-83. 
DESMARETS, L. M., THEUNS, S., OLYSLAEGERS, D. A., DEDEURWAERDER, A., VERMEULEN, B. L., 
ROUKAERTS, I. D. & NAUWYNCK, H. J. 2013. Establishment of feline intestinal epithelial cell 
cultures for the propagation and study of feline enteric coronaviruses. Vet Res, 44, 71. 
DESMARETS, L. M., VERMEULEN, B. L., THEUNS, S., CONCEICAO-NETO, N., ZELLER, M., ROUKAERTS, I. 
D., ACAR, D. D., OLYSLAEGERS, D. A., VAN RANST, M., MATTHIJNSSENS, J. & NAUWYNCK, H. 
J. 2016. Experimental feline enteric coronavirus infection reveals an aberrant infection 
160 
 
pattern and shedding of mutants with impaired infectivity in enterocyte cultures. Sci Rep, 6, 
20022. 
DEWERCHIN, H. L., CORNELISSEN, E. & NAUWYNCK, H. J. 2005. Replication of feline coronaviruses in 
peripheral blood monocytes. Arch Virol, 150, 2483-500. 
DOENGES, S. J., WEBER, K., DORSCH, R., FUX, R., FISCHER, A., MATIASEK, L. A., MATIASEK, K. & 
HARTMANN, K. 2016a. Detection of feline coronavirus in cerebrospinal fluid for diagnosis of 
feline infectious peritonitis in cats with and without neurological signs. J Feline Med Surg, 18, 
104-9. 
DOENGES, S. J., WEBER, K., DORSCH, R., FUX, R. & HARTMANN, K. 2016b. Comparison of real-time 
reverse transcriptase polymerase chain reaction of peripheral blood mononuclear cells, 
serum and cell-free body cavity effusion for the diagnosis of feline infectious peritonitis. J 
Feline Med Surg. 
DOKI, T., TAKANO, T., KAWAGOE, K., KITO, A. & HOHDATSU, T. 2016. Therapeutic effect of anti-feline 
TNF-alpha monoclonal antibody for feline infectious peritonitis. Res Vet Sci, 104, 17-23. 
DOKI, T., TAKANO, T., KOYAMA, Y. & HOHDATSU, T. 2015. Identification of the peptide derived from 
S1 domain that inhibits type I and type II feline infectious peritonitis virus infection. Virus 
Res, 204, 13-20. 
DRECHSLER, Y., ALCARAZ, A., BOSSONG, F. J., COLLISSON, E. W. & DINIZ, P. P. 2011. Feline 
coronavirus in multicat environments. Vet Clin North Am Small Anim Pract, 41, 1133-69. 
DUARTE, A., VEIGA, I. & TAVARES, L. 2009. Genetic diversity and phylogenetic analysis of Feline 
Coronavirus sequences from Portugal. Vet Microbiol, 138, 163-8. 
DUFOUR, D., MATEOS-GOMEZ, P. A., ENJUANES, L., GALLEGO, J. & SOLA, I. 2011. Structure and 
functional relevance of a transcription-regulating sequence involved in coronavirus 
discontinuous RNA synthesis. J Virol, 85, 4963-73. 
DUNBAR, D., KWOK, W., GRAHAM, E., ARMITAGE, A., IRVINE, R., JOHNSTON, P., MCDONALD, M., 
MONTGOMERY, D., NICOLSON, L., ROBERTSON, E., WEIR, W. & ADDIE, D. D. 2018. Diagnosis 
of non-effusive feline infectious peritonitis by reverse transcriptase quantitative PCR from 
mesenteric lymph node fine-needle aspirates. J Feline Med Surg, 1098612X18809165. 
DUTHIE, S., ECKERSALL, P. D., ADDIE, D. D., LAWRENCE, C. E. & JARRETT, O. 1997. Value of alpha 1-
acid glycoprotein in the diagnosis of feline infectious peritonitis. Vet Rec, 141, 299-303. 
DVEKSLER, G. S., PENSIERO, M. N., CARDELLICHIO, C. B., WILLIAMS, R. K., JIANG, G. S., HOLMES, K. V. 
& DIEFFENBACH, C. W. 1991. Cloning of the mouse hepatitis virus (MHV) receptor: 
expression in human and hamster cell lines confers susceptibility to MHV. J Virol, 65, 6881-
91. 
DYE, C. 2006. Molecular characterisation of type I and type II feline coronavirus genomes. PhD, 
University of Bristol. 
DYE, C., TEMPERTON, N. & SIDDELL, S. G. 2007. Type I feline coronavirus spike glycoprotein fails to 
recognize aminopeptidase N as a functional receptor on feline cell lines. J Gen Virol, 88, 
1753-60. 
EHMANN, R., KRISTEN-BURMANN, C., BANK-WOLF, B., KONIG, M., HERDEN, C., HAIN, T., THIEL, H. J., 
ZIEBUHR, J. & TEKES, G. 2018. Reverse Genetics for Type I Feline Coronavirus Field Isolate To 
Study the Molecular Pathogenesis of Feline Infectious Peritonitis. MBio, 9. 
ETTAYEBI, K., CRAWFORD, S. E., MURAKAMI, K., BROUGHMAN, J. R., KARANDIKAR, U., TENGE, V. R., 
NEILL, F. H., BLUTT, S. E., ZENG, X. L., QU, L., KOU, B., OPEKUN, A. R., BURRIN, D., GRAHAM, 
D. Y., RAMANI, S., ATMAR, R. L. & ESTES, M. K. 2016. Replication of human noroviruses in 
stem cell-derived human enteroids. Science, 353, 1387-1393. 
FEHR, A. R. & PERLMAN, S. 2015. Coronaviruses: an overview of their replication and pathogenesis. 
Methods Mol Biol, 1282, 1-23. 
FELTEN, S., LEUTENEGGER, C. M., BALZER, H. J., PANTCHEV, N., MATIASEK, K., WESS, G., EGBERINK, 
H. & HARTMANN, K. 2017a. Sensitivity and specificity of a real-time reverse transcriptase 
161 
 
polymerase chain reaction detecting feline coronavirus mutations in effusion and 
serum/plasma of cats to diagnose feline infectious peritonitis. BMC Vet Res, 13, 228. 
FELTEN, S., MATIASEK, K., GRUENDL, S., SANGL, L. & HARTMANN, K. 2017b. Utility of an 
immunocytochemical assay using aqueous humor in the diagnosis of feline infectious 
peritonitis. Vet Ophthalmol. 
FELTEN, S., MATIASEK, K., GRUENDL, S., SANGL, L., WESS, G. & HARTMANN, K. 2016. Investigation 
into the utility of an immunocytochemical assay in body cavity effusions for diagnosis of 
feline infectious peritonitis. J Feline Med Surg. 
FELTEN, S., WEIDER, K., DOENGES, S., GRUENDL, S., MATIASEK, K., HERMANNS, W., MUELLER, E., 
MATIASEK, L., FISCHER, A., WEBER, K., HIRSCHBERGER, J., WESS, G. & HARTMANN, K. 2015. 
Detection of feline coronavirus spike gene mutations as a tool to diagnose feline infectious 
peritonitis. J Feline Med Surg. 
FIELDS, B. N., KNIPE, D. M. & HOWLEY, P. M. 2013. Fields virology, Philadelphia, Pa., Wolters 
Kluwer/Lippincott Williams & Wilkins. 
FISCHER, Y., RITZ, S., WEBER, K., SAUTER-LOUIS, C. & HARTMANN, K. 2011. Randomized, placebo 
controlled study of the effect of propentofylline on survival time and quality of life of cats 
with feline infectious peritonitis. J Vet Intern Med, 25, 1270-6. 
FOLEY, J. E., POLAND, A., CARLSON, J. & PEDERSEN, N. C. 1997. Risk factors for feline infectious 
peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. 
J Am Vet Med Assoc, 210, 1313-8. 
GIORI, L., GIORDANO, A., GIUDICE, C., GRIECO, V. & PALTRINIERI, S. 2011. Performances of different 
diagnostic tests for feline infectious peritonitis in challenging clinical cases. J Small Anim 
Pract, 52, 152-7. 
GLANSBEEK, H. L., HAAGMANS, B. L., TE LINTELO, E. G., EGBERINK, H. F., DUQUESNE, V., AUBERT, A., 
HORZINEK, M. C. & ROTTIER, P. J. 2002. Adverse effects of feline IL-12 during DNA 
vaccination against feline infectious peritonitis virus. J Gen Virol, 83, 1-10. 
GOEBEL, S. J., HSUE, B., DOMBROWSKI, T. F. & MASTERS, P. S. 2004. Characterization of the RNA 
components of a putative molecular switch in the 3' untranslated region of the murine 
coronavirus genome. J Virol, 78, 669-82. 
GOLOVKO, L., LYONS, L. A., LIU, H., SORENSEN, A., WEHNERT, S. & PEDERSEN, N. C. 2013. Genetic 
susceptibility to feline infectious peritonitis in Birman cats. Virus Res, 175, 58-63. 
GONON, V., DUQUESNE, V., KLONJKOWSKI, B., MONTEIL, M., AUBERT, A. & ELOIT, M. 1999. 
Clearance of infection in cats naturally infected with feline coronaviruses is associated with 
an anti-S glycoprotein antibody response. J Gen Virol, 80 ( Pt 9), 2315-7. 
GRIFFITHS, A. J. F. 2000. An introduction to genetic analysis, New York, W.H. Freeman. 
GUNN-MOORE, D. A., GRUFFYDD-JONES, T. J. & HARBOUR, D. A. 1998. Detection of feline 
coronaviruses by culture and reverse transcriptase-polymerase chain reaction of blood 
samples from healthy cats and cats with clinical feline infectious peritonitis. Vet Microbiol, 
62, 193-205. 
GUTIERREZ, A. M. 2008. Priming Immunization with a vif-deleted Feline Immunodeficiency Virus 
Proviral DNA Vaccine Boosted with a Killed Whole Virus Vaccine. Doctor of Philosophy, 
University of California Davis. 
HAIJEMA, B. J., VOLDERS, H. & ROTTIER, P. J. M. 2003. Switching Species Tropism: an Effective Way 
To Manipulate the Feline Coronavirus Genome. Journal of Virology, 77, 4528-4538. 
HAIJEMA, B. J., VOLDERS, H. & ROTTIER, P. J. M. 2004. Live, Attenuated Coronavirus Vaccines 
through the Directed Deletion of Group-Specific Genes Provide Protection against Feline 
Infectious Peritonitis. Journal of Virology, 78, 3863-3871. 
HANNEMANN, H., SUNG, P. Y., CHIU, H. C., YOUSUF, A., BIRD, J., LIM, S. P. & DAVIDSON, A. D. 2013. 
Serotype-specific differences in dengue virus non-structural protein 5 nuclear localization. J 
Biol Chem, 288, 22621-35. 
HARTMANN, K. 2005. Feline infectious peritonitis. Vet Clin North Am Small Anim Pract, 35, 39-79, vi. 
162 
 
HARTMANN, K., BINDER, C., HIRSCHBERGER, J., COLE, D., REINACHER, M., SCHROO, S., FROST, J., 
EGBERINK, H., LUTZ, H. & HERMANNS, W. 2003. Comparison of different tests to diagnose 
feline infectious peritonitis. J Vet Intern Med, 17, 781-90. 
HARUN, M. S., KUAN, C. O., SELVARAJAH, G. T., WEI, T. S., ARSHAD, S. S., HAIR BEJO, M. & OMAR, A. 
R. 2013. Transcriptional profiling of feline infectious peritonitis virus infection in CRFK cells 
and in PBMCs from FIP diagnosed cats. Virol J, 10, 329. 
HARVEY, C. J., LOPEZ, J. W. & HENDRICK, M. J. 1996. An uncommon intestinal manifestation of feline 
infectious peritonitis: 26 cases (1986-1993). J Am Vet Med Assoc, 209, 1117-20. 
HAZUCHOVA, K., HELD, S. & NEIGER, R. 2016. Usefulness of acute phase proteins in differentiating 
between feline infectious peritonitis and other diseases in cats with body cavity effusions. J 
Feline Med Surg. 
HERREWEGH, A. A., VENNEMA, H., HORZINEK, M. C., ROTTIER, P. J. & DE GROOT, R. J. 1995. The 
molecular genetics of feline coronaviruses: comparative sequence analysis of the ORF7a/7b 
transcription unit of different biotypes. Virology, 212, 622-31. 
HOHDATSU, T., IZUMIYA, Y., YOKOYAMA, Y., KIDA, K. & KOYAMA, H. 1998. Differences in virus 
receptor for type I and type II feline infectious peritonitis virus. Arch Virol, 143, 839-50. 
HOHDATSU, T., OKADA, S., ISHIZUKA, Y., YAMADA, H. & KOYAMA, H. 1992. The prevalence of types I 
and II feline coronavirus infections in cats. J Vet Med Sci, 54, 557-62. 
HORA, A. S., TONIETTI, P. O., TANIWAKI, S. A., ASANO, K. M., MAIORKA, P., RICHTZENHAIN, L. J. & 
BRANDAO, P. E. 2016. Feline Coronavirus 3c Protein: A Candidate for a Virulence Marker? 
Biomed Res Int, 2016, 8560691. 
HSIEH, L. E. & CHUEH, L. L. 2014. Identification and genotyping of feline infectious peritonitis-
associated single nucleotide polymorphisms in the feline interferon-gamma gene. Vet Res, 
45, 57. 
HU, C. J., CHANG, W. S., FANG, Z. S., CHEN, Y. T., WANG, W. L., TSAI, H. H., CHUEH, L. L., TAKANO, T., 
HOHDATSU, T. & CHEN, H. W. 2017. Nanoparticulate vacuolar ATPase blocker exhibits 
potent host-targeted antiviral activity against feline coronavirus. Sci Rep, 7, 13043. 
HUAN, C. C., WANG, Y., NI, B., WANG, R., HUANG, L., REN, X. F., TONG, G. Z., DING, C., FAN, H. J. & 
MAO, X. 2015. Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an 
attachment factor. Arch Virol, 160, 1621-8. 
HURST, K. R., YE, R., GOEBEL, S. J., JAYARAMAN, P. & MASTERS, P. S. 2010. An interaction between 
the nucleocapsid protein and a component of the replicase-transcriptase complex is crucial 
for the infectivity of coronavirus genomic RNA. J Virol, 84, 10276-88. 
ICC. 2015. Life Stages [Online]. Available: http://icatcare.org/advice/life-stages [Accessed 23 
February 2016]. 
ISHIDA, T., SHIBANAI, A., TANAKA, S., UCHIDA, K. & MOCHIZUKI, M. 2004. Use of recombinant feline 
interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med 
Surg, 6, 107-9. 
IVES, E. J., VANHAESEBROUCK, A. E. & CIAN, F. 2013. Immunocytochemical demonstration of feline 
infectious peritonitis virus within cerebrospinal fluid macrophages. J Feline Med Surg, 15, 
1149-53. 
JAIMES, J. A. & WHITTAKER, G. R. 2018. Feline coronavirus: Insights into viral pathogenesis based on 
the spike protein structure and function. Virology. 
JARRETT, O., LAIRD, H. M. & HAY, D. 1973. Determinants of the host range of feline leukaemia 
viruses. J Gen Virol, 20, 169-75. 
JOLLY, C. L. & SATTENTAU, Q. J. 2013. Attachment factors. Adv Exp Med Biol, 790, 1-23. 
KASS, P., DENT, T. 1995. The Epidemiology of Feline Infectious Peritonitis in Catteries. Feline Practice, 
23, 27-32. 
KEDWARD-DIXON, H., BARKER, E. N., TASKER, S., KIPAR, A. & HELPS, C. R. 2019. Evaluation of 
polymorphisms in inflammatory mediator and cellular adhesion genes as risk factors for 
feline infectious peritonitis. J Feline Med Surg, 1098612X19865637. 
163 
 
KENNEDY, M., BOEDEKER, N., GIBBS, P. & KANIA, S. 2001. Deletions in the 7a ORF of feline 
coronavirus associated with an epidemic of feline infectious peritonitis. Vet Microbiol, 81, 
227-34. 
KHACHATOORIAN, R., COHN, W., BUZZANCO, A., RIAHI, R., ARUMUGASWAMI, V., DASGUPTA, A., 
WHITELEGGE, J. P. & FRENCH, S. W. 2018. HSP70 Copurifies with Zika Virus Particles. 
Virology, 522, 228-233. 
KIPAR, A., BAPTISTE, K., BARTH, A. & REINACHER, M. 2006. Natural FCoV infection: cats with FIP 
exhibit significantly higher viral loads than healthy infected cats. J Feline Med Surg, 8, 69-72. 
KIPAR, A., BELLMANN, S., GUNN-MOORE, D. A., LEUKERT, W., KOHLER, K., MENGER, S. & REINACHER, 
M. 1999a. Histopathological alterations of lymphatic tissues in cats without feline infectious 
peritonitis after long-term exposure to FIP virus. Vet Microbiol, 69, 131-7. 
KIPAR, A., BELLMANN, S., KREMENDAHL, J., KOHLER, K. & REINACHER, M. 1998a. Cellular 
composition, coronavirus antigen expression and production of specific antibodies in lesions 
in feline infectious peritonitis. Vet Immunol Immunopathol, 65, 243-57. 
KIPAR, A., KOEHLER, K., BELLMANN, S. & REINACHER, M. 1999b. Feline infectious peritonitis 
presenting as a tumour in the abdominal cavity. Vet Rec, 144, 118-22. 
KIPAR, A., KOHLER, K., LEUKERT, W. & REINACHER, M. 2001. A comparison of lymphatic tissues from 
cats with spontaneous feline infectious peritonitis (FIP), cats with FIP virus infection but no 
FIP, and cats with no infection. J Comp Pathol, 125, 182-91. 
KIPAR, A., KREMENDAHL, J., ADDIE, D. D., LEUKERT, W., GRANT, C. K. & REINACHER, M. 1998b. Fatal 
enteritis associated with coronavirus infection in cats. J Comp Pathol, 119, 1-14. 
KIPAR, A., MAY, H., MENGER, S., WEBER, M., LEUKERT, W. & REINACHER, M. 2005. Morphologic 
features and development of granulomatous vasculitis in feline infectious peritonitis. Vet 
Pathol, 42, 321-30. 
KIPAR, A. & MELI, M. L. 2014. Feline infectious peritonitis: still an enigma? Vet Pathol, 51, 505-26. 
KIPAR, A., MELI, M. L., BAPTISTE, K. E., BOWKER, L. J. & LUTZ, H. 2010. Sites of feline coronavirus 
persistence in healthy cats. J Gen Virol, 91, 1698-707. 
KISS, I., POLAND, A. M. & PEDERSEN, N. C. 2004. Disease outcome and cytokine responses in cats 
immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-
exposed with virulent FIPV-UCD8. J Feline Med Surg, 6, 89-97. 
KLEPFER, S., REED, A. P., MARTINEZ, M., BHOGAL, B., JONES, E. & MILLER, T. J. 1995. Cloning and 
expression of FECV spike gene in vaccinia virus. Immunization with FECV S causes early death 
after FIPV challenge. Adv Exp Med Biol, 380, 235-41. 
KUMMROW, M., MELI, M. L., HAESSIG, M., GOENCZI, E., POLAND, A., PEDERSEN, N. C., HOFMANN-
LEHMANN, R. & LUTZ, H. 2005. Feline coronavirus serotypes 1 and 2: seroprevalence and 
association with disease in Switzerland. Clin Diagn Lab Immunol, 12, 1209-15. 
LAHAR, N., LEI, N. Y., WANG, J., JABAJI, Z., TUNG, S. C., JOSHI, V., LEWIS, M., STELZNER, M., MARTIN, 
M. G. & DUNN, J. C. 2011. Intestinal subepithelial myofibroblasts support in vitro and in vivo 
growth of human small intestinal epithelium. PLoS One, 6, e26898. 
LAVER, T., HARRISON, J., O'NEILL, P. A., MOORE, K., FARBOS, A., PASZKIEWICZ, K. & STUDHOLME, D. 
J. 2015. Assessing the performance of the Oxford Nanopore Technologies MinION. Biomol 
Detect Quantif, 3, 1-8. 
LE PODER, S. 2011. Feline and canine coronaviruses: common genetic and pathobiological features. 
Adv Virol, 2011, 609465. 
LEGENDRE, A. M. & BARTGES, J. W. 2009. Effect of Polyprenyl Immunostimulant on the survival 
times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg, 11, 
624-6. 
LEGENDRE, A. M., KURITZ, T., GALYON, G., BAYLOR, V. M. & HEIDEL, R. E. 2017. Polyprenyl 
Immunostimulant Treatment of Cats with Presumptive Non-Effusive Feline Infectious 
Peritonitis In a Field Study. Front Vet Sci, 4, 7. 
164 
 
LEWIS, C. S., PORTER, E., MATTHEWS, D., KIPAR, A., TASKER, S., HELPS, C. R. & SIDDELL, S. G. 2015. 
Genotyping coronaviruses associated with feline infectious peritonitis. J Gen Virol, 96, 1358-
68. 
LI, C., LIU, Q., KONG, F., GUO, D., ZHAI, J., SU, M. & SUN, D. 2018. Circulation and Genetic Diversity of 
Feline Coronavirus Type I and II From Clinically Healthy and FIP-Suspected Cats in China. 
Transbound Emerg Dis. 
LI, F. 2015. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J 
Virol, 89, 1954-64. 
LI, F. 2016. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 
LICITRA, B. N., MILLET, J. K., REGAN, A. D., HAMILTON, B. S., RINALDI, V. D., DUHAMEL, G. E. & 
WHITTAKER, G. R. 2013. Mutation in spike protein cleavage site and pathogenesis of feline 
coronavirus. Emerg Infect Dis, 19, 1066-73. 
LIN, C. N., SU, B. L., WANG, C. H., HSIEH, M. W., CHUEH, T. J. & CHUEH, L. L. 2009. Genetic diversity 
and correlation with feline infectious peritonitis of feline coronavirus type I and II: a 5-year 
study in Taiwan. Vet Microbiol, 136, 233-9. 
LITSTER, A. L., POGRANICHNIY, R. & LIN, T. L. 2013. Diagnostic utility of a direct immunofluorescence 
test to detect feline coronavirus antigen in macrophages in effusive feline infectious 
peritonitis. Vet J, 198, 362-6. 
LONGSTAFF, L., PORTER, E., CROSSLEY, V. J., HAYHOW, S. E., HELPS, C. R. & TASKER, S. 2015. Feline 
coronavirus quantitative reverse transcriptase polymerase chain reaction on effusion 
samples in cats with and without feline infectious peritonitis. J Feline Med Surg. 
MAHE, M. M., AIHARA, E., SCHUMACHER, M. A., ZAVROS, Y., MONTROSE, M. H., HELMRATH, M. A., 
SATO, T. & SHROYER, N. F. 2013. Establishment of Gastrointestinal Epithelial Organoids. Curr 
Protoc Mouse Biol, 3, 217-40. 
MALBON, A. J., MELI, M. L., BARKER, E. N., DAVIDSON, A. D., TASKER, S. & KIPAR, A. 2019. 
Inflammatory Mediators in the Mesenteric Lymph Nodes, Site of a Possible Intermediate 
Phase in the Immune Response to Feline Coronavirus and the Pathogenesis of Feline 
Infectious Peritonitis? J Comp Pathol, 166, 69-86. 
MAYER, M. P. 2013. Hsp70 chaperone dynamics and molecular mechanism. Trends Biochem Sci, 38, 
507-14. 
MCBRIDE, R., VAN ZYL, M. & FIELDING, B. C. 2014. The coronavirus nucleocapsid is a multifunctional 
protein. Viruses, 6, 2991-3018. 
MEAZZI, S., STRANIERI, A., LAUZI, S., BONSEMBIANTE, F., FERRO, S., PALTRINIERI, S. & GIORDANO, A. 
2019. Feline gut microbiota composition in association with feline coronavirus infection: A 
pilot study. Res Vet Sci, 125, 272-278. 
MELI, M., KIPAR, A., MULLER, C., JENAL, K., GONCZI, E., BOREL, N., GUNN-MOORE, D., CHALMERS, S., 
LIN, F., REINACHER, M. & LUTZ, H. 2004. High viral loads despite absence of clinical and 
pathological findings in cats experimentally infected with feline coronavirus (FCoV) type I 
and in naturally FCoV-infected cats. J Feline Med Surg, 6, 69-81. 
MESZAROS, I., OLASZ, F., KADAR-HURKECZ, E., BALINT, A., HORNYAK, A., BELAK, S. & ZADORI, Z. 
2018. Cellular localisation of the proteins of region 3 of feline enteric coronavirus. Acta Vet 
Hung, 66, 493-508. 
MIGUEL, B., PHARR, G. T. & WANG, C. 2002. The role of feline aminopeptidase N as a receptor for 
infectious bronchitis virus. Brief review. Arch Virol, 147, 2047-56. 
MIYOSHI, H. & STAPPENBECK, T. S. 2013. In vitro expansion and genetic modification of 
gastrointestinal stem cells in spheroid culture. Nature Protocols, 8, 2471-2482. 
MURPHY, B. G., PERRON, M., MURAKAMI, E., BAUER, K., PARK, Y., ECKSTRAND, C., LIEPNIEKS, M. & 
PEDERSEN, N. C. 2018. The nucleoside analog GS-441524 strongly inhibits feline infectious 




MURPHY, K., TRAVERS, P., WALPORT, M. & JANEWAY, C. 2012. Janeway's immunobiology, London, 
Garland Science ; London : Taylor & Francis [distributor]. 
MUSTAFFA-KAMAL, F., LIU, H., PEDERSEN, N. C. & SPARGER, E. E. 2019. Characterization of antiviral T 
cell responses during primary and secondary challenge of laboratory cats with feline 
infectious peritonitis virus (FIPV). BMC Vet Res, 15, 165. 
NAMY, O., MORAN, S. J., STUART, D. I., GILBERT, R. J. & BRIERLEY, I. 2006. A mechanical explanation 
of RNA pseudoknot function in programmed ribosomal frameshifting. Nature, 441, 244-7. 
NEUMAN, B. W., CHAMBERLAIN, P., BOWDEN, F. & JOSEPH, J. 2014. Atlas of coronavirus replicase 
structure. Virus Res, 194, 49-66. 
NEUMAN, B. W., KISS, G., KUNDING, A. H., BHELLA, D., BAKSH, M. F., CONNELLY, S., DROESE, B., 
KLAUS, J. P., MAKINO, S., SAWICKI, S. G., SIDDELL, S. G., STAMOU, D. G., WILSON, I. A., KUHN, 
P. & BUCHMEIER, M. J. 2011. A structural analysis of M protein in coronavirus assembly and 
morphology. J Struct Biol, 174, 11-22. 
NORDONE, S. K., STEVENS, R., LAVOY, A. S. & DEAN, G. A. 2005. Feline cytokine ELISPOT: issues in 
assay development. Methods Mol Biol, 302, 167-78. 
NORRIS, J. M., BOSWARD, K. L., WHITE, J. D., BARAL, R. M., CATT, M. J. & MALIK, R. 2005. 
Clinicopathological findings associated with feline infectious peritonitis in Sydney, Australia: 
42 cases (1990-2002). Aust Vet J, 83, 666-73. 
OLSEN, C. W. 1993. A review of feline infectious peritonitis virus: molecular biology, 
immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol, 36, 1-37. 
OLSEN, C. W., CORAPI, W. V., NGICHABE, C. K., BAINES, J. D. & SCOTT, F. W. 1992. Monoclonal 
antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-
dependent enhancement of infection of feline macrophages. J Virol, 66, 956-65. 
OLYSLAEGERS, D. A., DEDEURWAERDER, A., DESMARETS, L. M., VERMEULEN, B. L., DEWERCHIN, H. L. 
& NAUWYNCK, H. J. 2013. Altered expression of adhesion molecules on peripheral blood 
leukocytes in feline infectious peritonitis. Vet Microbiol, 166, 438-49. 
ORTEGO, J., ESCORS, D., LAUDE, H. & ENJUANES, L. 2002. Generation of a replication-competent, 
propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus 
genome. J Virol, 76, 11518-29. 
OSUMI, T., MITSUI, I., LEUTENEGGER, C. M., OKABE, R., IDE, K. & NISHIFUJI, K. 2018. First 
identification of a single amino acid change in the spike protein region of feline coronavirus 
detected from a coronavirus-associated cutaneous nodule in a cat. JFMS Open Rep, 4, 
2055116918801385. 
OTSUKI, K., MAEDA, J., YAMAMOTO, H. & TSUBOKURA, M. 1979. Studies on avian infectious 
bronchitis virus (IBV). III. Interferon induction by and sensitivity to interferon of IBV. Arch 
Virol, 60, 249-55. 
PALTRINIERI, S., GIORDANO, A., TRANQUILLO, V. & GUAZZETTI, S. 2007. Critical assessment of the 
diagnostic value of feline alpha1-acid glycoprotein for feline infectious peritonitis using the 
likelihood ratios approach. J Vet Diagn Invest, 19, 266-72. 
PASSLACK, N., KOHN, B., DOHERR, M. G. & ZENTEK, J. 2017. Impact of Dietary Protein Concentration 
and Quality on Immune Function of Cats. PLoS One, 12, e0169822. 
PASTERNAK, A. O., SPAAN, W. J. & SNIJDER, E. J. 2006. Nidovirus transcription: how to make sense...? 
J Gen Virol, 87, 1403-21. 
PEDERSEN, N. C. 1987. Virologic and immunologic aspects of feline infectious peritonitis virus 
infection. Adv Exp Med Biol, 218, 529-50. 
PEDERSEN, N. C. 2009. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline 
Med Surg, 11, 225-58. 
PEDERSEN, N. C. 2014a. An update on feline infectious peritonitis: diagnostics and therapeutics. Vet 
J, 201, 133-41. 
PEDERSEN, N. C. 2014b. An update on feline infectious peritonitis: virology and 
immunopathogenesis. Vet J, 201, 123-32. 
166 
 
PEDERSEN, N. C., ALLEN, C. E. & LYONS, L. A. 2008. Pathogenesis of feline enteric coronavirus 
infection. J Feline Med Surg, 10, 529-41. 
PEDERSEN, N. C., ECKSTRAND, C., LIU, H., LEUTENEGGER, C. & MURPHY, B. 2015. Levels of feline 
infectious peritonitis virus in blood, effusions, and various tissues and the role of 
lymphopenia in disease outcome following experimental infection. Vet Microbiol, 175, 157-
66. 
PEDERSEN, N. C., KIM, Y., LIU, H., GALASITI KANKANAMALAGE, A. C., ECKSTRAND, C., GROUTAS, W. 
C., BANNASCH, M., MEADOWS, J. M. & CHANG, K. O. 2017. Efficacy of a 3C-like protease 
inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg, 
1098612X17729626. 
PEDERSEN, N. C., LIU, H., DURDEN, M. & LYONS, L. A. 2016. Natural resistance to experimental feline 
infectious peritonitis virus infection is decreased rather than increased by positive genetic 
selection. Vet Immunol Immunopathol, 171, 17-20. 
PEDERSEN, N. C., LIU, H., GANDOLFI, B. & LYONS, L. A. 2014. The influence of age and genetics on 
natural resistance to experimentally induced feline infectious peritonitis. Vet Immunol 
Immunopathol, 162, 33-40. 
PEDERSEN, N. C., LIU, H., SCARLETT, J., LEUTENEGGER, C. M., GOLOVKO, L., KENNEDY, H. & KAMAL, 
F. M. 2012. Feline infectious peritonitis: role of the feline coronavirus 3c gene in intestinal 
tropism and pathogenicity based upon isolates from resident and adopted shelter cats. Virus 
Res, 165, 17-28. 
PEDERSEN, N. C., PERRON, M., BANNASCH, M., MONTGOMERY, E., MURAKAMI, E., LIEPNIEKS, M. & 
LIU, H. 2019. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats 
with naturally occurring feline infectious peritonitis. J Feline Med Surg, 1098612X19825701. 
PEREZ-VARGAS, J., ROMERO, P., LOPEZ, S. & ARIAS, C. F. 2006. The peptide-binding and ATPase 
domains of recombinant hsc70 are required to interact with rotavirus and reduce its 
infectivity. J Virol, 80, 3322-31. 
PESTEANU-SOMOGYI, L. D., RADZAI, C. & PRESSLER, B. M. 2006. Prevalence of feline infectious 
peritonitis in specific cat breeds. J Feline Med Surg, 8, 1-5. 
PONCELET, L., COPPENS, A., PEETERS, D., BIANCHI, E., GRANT, C. K. & KADHIM, H. 2008. Detection of 
antigenic heterogeneity in feline coronavirus nucleocapsid in feline pyogranulomatous 
meningoencephalitis. Vet Pathol, 45, 140-53. 
PORTER, E., TASKER, S., DAY, M. J., HARLEY, R., KIPAR, A., SIDDELL, S. G. & HELPS, C. R. 2014. Amino 
acid changes in the spike protein of feline coronavirus correlate with systemic spread of 
virus from the intestine and not with feline infectious peritonitis. Vet Res, 45, 49. 
POWELL, R. H. & BEHNKE, M. S. 2017. WRN conditioned media is sufficient for in vitro propagation of 
intestinal organoids from large farm and small companion animals. Biology Open, 6, 698-
705. 
PUJHARI, S., BRUSTOLIN, M., MACIAS, V. M., NISSLY, R. H., NOMURA, M., KUCHIPUDI, S. V. & 
RASGON, J. L. 2019. Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and 
egress from host cells. Emerg Microbes Infect, 8, 8-16. 
QUIRKE, G. 2016. Coronavirus Entry Mechanisms. MRes, University of Bristol. 
R&D. 2016. Troubleshooting guide: ELISpot [Online]. Available: 
https://www.rndsystems.com/resources/technical/troubleshooting-guide-elispot [Accessed 
25 February 2016]. 
RAJ, V. S., MOU, H., SMITS, S. L., DEKKERS, D. H., MULLER, M. A., DIJKMAN, R., MUTH, D., DEMMERS, 
J. A., ZAKI, A., FOUCHIER, R. A., THIEL, V., DROSTEN, C., ROTTIER, P. J., OSTERHAUS, A. D., 
BOSCH, B. J. & HAAGMANS, B. L. 2013. Dipeptidyl peptidase 4 is a functional receptor for the 
emerging human coronavirus-EMC. Nature, 495, 251-4. 
RAMAN, S. & BRIAN, D. A. 2005. Stem-loop IV in the 5' untranslated region is a cis-acting element in 
bovine coronavirus defective interfering RNA replication. J Virol, 79, 12434-46. 
167 
 
RAMANI, S., CRAWFORD, S. E., BLUTT, S. E. & ESTES, M. K. 2018. Human organoid cultures: 
transformative new tools for human virus studies. Curr Opin Virol, 29, 79-86. 
REDFORD, T. & AL-DISSI, A. N. 2019. Feline infectious peritonitis in a cat presented because of 
papular skin lesions. Can Vet J, 60, 183-185. 
REGAN, A. D., OUSTEROUT, D. G. & WHITTAKER, G. R. 2010. Feline lectin activity is critical for the 
cellular entry of feline infectious peritonitis virus. J Virol, 84, 7917-21. 
REGAN, A. D., SHRAYBMAN, R., COHEN, R. D. & WHITTAKER, G. R. 2008. Differential role for low pH 
and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline 
coronaviruses. Vet Microbiol, 132, 235-48. 
REGAN, A. D. & WHITTAKER, G. R. 2008. Utilization of DC-SIGN for entry of feline coronaviruses into 
host cells. J Virol, 82, 11992-6. 
REYES-DEL VALLE, J., CHAVEZ-SALINAS, S., MEDINA, F. & DEL ANGEL, R. M. 2005. Heat shock protein 
90 and heat shock protein 70 are components of dengue virus receptor complex in human 
cells. J Virol, 79, 4557-67. 
RIEMER, F., KUEHNER, K. A., RITZ, S., SAUTER-LOUIS, C. & HARTMANN, K. 2015. Clinical and 
laboratory features of cats with feline infectious peritonitis - a retrospective study of 231 
confirmed cases (2000-2010). J Feline Med Surg. 
RITZ, S., EGBERINK, H. & HARTMANN, K. 2007. Effect of feline interferon-omega on the survival time 
and quality of life of cats with feline infectious peritonitis. J Vet Intern Med, 21, 1193-7. 
ROBERTS, J. D., THAPALIYA, A., MARTINEZ-LUMBRERAS, S., KRYSZTOFINSKA, E. M. & ISAACSON, R. L. 
2015. Structural and Functional Insights into Small, Glutamine-Rich, Tetratricopeptide 
Repeat Protein Alpha. Front Mol Biosci, 2, 71. 
ROHRBACH, B. W., LEGENDRE, A. M., BALDWIN, C. A., LEIN, D. H., REED, W. M. & WILSON, R. B. 2001. 
Epidemiology of feline infectious peritonitis among cats examined at veterinary medical 
teaching hospitals. J Am Vet Med Assoc, 218, 1111-5. 
ROTTIER, P. J. 1999. The molecular dynamics of feline coronaviruses. Vet Microbiol, 69, 117-25. 
ROTTIER, P. J., NAKAMURA, K., SCHELLEN, P., VOLDERS, H. & HAIJEMA, B. J. 2005. Acquisition of 
macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by 
mutations in the feline coronavirus spike protein. J Virol, 79, 14122-30. 
SABSHIN, S. J., LEVY, J. K., TUPLER, T., TUCKER, S. J., GREINER, E. C. & LEUTENEGGER, C. M. 2012. 
Enteropathogens identified in cats entering a Florida animal shelter with normal feces or 
diarrhea. J Am Vet Med Assoc, 241, 331-7. 
SANGL, L., MATIASEK, K., FELTEN, S., GRUNDL, S., BERGMANN, M., BALZER, H. J., PANTCHEV, N., 
LEUTENEGGER, C. M. & HARTMANN, K. 2018. Detection of feline coronavirus mutations in 
paraffin-embedded tissues in cats with feline infectious peritonitis and controls. J Feline Med 
Surg, 1098612X18762883. 
SATO, T., STANGE, D. E., FERRANTE, M., VRIES, R. G., VAN ES, J. H., VAN DEN BRINK, S., VAN HOUDT, 
W. J., PRONK, A., VAN GORP, J., SIERSEMA, P. D. & CLEVERS, H. 2011. Long-term expansion 
of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's 
epithelium. Gastroenterology, 141, 1762-72. 
SATO, T., VRIES, R. G., SNIPPERT, H. J., VAN DE WETERING, M., BARKER, N., STANGE, D. E., VAN ES, J. 
H., ABO, A., KUJALA, P., PETERS, P. J. & CLEVERS, H. 2009. Single Lgr5 stem cells build crypt-
villus structures in vitro without a mesenchymal niche. Nature, 459, 262-5. 
SATOH, R., FURUKAWA, T., KOTAKE, M., TAKANO, T., MOTOKAWA, K., GEMMA, T., WATANABE, R., 
ARAI, S. & HOHDATSU, T. 2011a. Screening and identification of T helper 1 and linear 
immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid 
protein of feline infectious peritonitis virus. Vaccine, 29, 1791-800. 
SATOH, R., KAKU, A., SATOMURA, M., KOHORI, M., NOURA, K., FURUKAWA, T., KOTAKE, M., 
TAKANO, T. & HOHDATSU, T. 2011b. Development of monoclonal antibodies (MAbs) to 
feline interferon (fIFN)-gamma as tools to evaluate cellular immune responses to feline 
infectious peritonitis virus (FIPV). J Feline Med Surg, 13, 427-35. 
168 
 
SATOH, R., KOBAYASHI, H., TAKANO, T., MOTOKAWA, K., KUSUHARA, H. & HOHDATSU, T. 2010. 
Characterization of T helper (Th)1- and Th2-type immune responses caused by baculovirus-
expressed protein derived from the S2 domain of feline infectious peritonitis virus, and 
exploration of the Th1 and Th2 epitopes in a mouse model. Microbiol Immunol, 54, 726-33. 
SAWICKI, S. G., SAWICKI, D. L. & SIDDELL, S. G. 2007. A contemporary view of coronavirus 
transcription. J Virol, 81, 20-9. 
SAXENA, K., BLUTT, S. E., ETTAYEBI, K., ZENG, X. L., BROUGHMAN, J. R., CRAWFORD, S. E., 
KARANDIKAR, U. C., SASTRI, N. P., CONNER, M. E., OPEKUN, A. R., GRAHAM, D. Y., QURESHI, 
W., SHERMAN, V., FOULKE-ABEL, J., IN, J., KOVBASNJUK, O., ZACHOS, N. C., DONOWITZ, M. & 
ESTES, M. K. 2016. Human Intestinal Enteroids: a New Model To Study Human Rotavirus 
Infection, Host Restriction, and Pathophysiology. J Virol, 90, 43-56. 
SCHMITTEL, A., KEILHOLZ, U., BAUER, S., KUHNE, U., STEVANOVIC, S., THIEL, E. & SCHEIBENBOGEN, 
C. 2001. Application of the IFN-gamma ELISPOT assay to quantify T cell responses against 
proteins. J Immunol Methods, 247, 17-24. 
SCHOEMAN, D. & FIELDING, B. C. 2019. Coronavirus envelope protein: current knowledge. Virol J, 16, 
69. 
SCHWEGMANN-WESSELS, C. & HERRLER, G. 2006. Sialic acids as receptor determinants for 
coronaviruses. Glycoconj J, 23, 51-8. 
SCOBEY, T., YOUNT, B. L., SIMS, A. C., DONALDSON, E. F., AGNIHOTHRAM, S. S., MENACHERY, V. D., 
GRAHAM, R. L., SWANSTROM, J., BOVE, P. F., KIM, J. D., GREGO, S., RANDELL, S. H. & BARIC, 
R. S. 2013. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory 
syndrome coronavirus. Proc Natl Acad Sci U S A, 110, 16157-62. 
SHARIFI TABAR, M., HESARAKI, M., ESFANDIARI, F., SAHRANESHIN SAMANI, F., VAKILIAN, H. & 
BAHARVAND, H. 2015. Evaluating Electroporation and Lipofectamine Approaches for 
Transient and Stable Transgene Expressions in Human Fibroblasts and Embryonic Stem Cells. 
Cell J, 17, 438-50. 
SHIBA, N., MAEDA, K., KATO, H., MOCHIZUKI, M. & IWATA, H. 2007. Differentiation of feline 
coronavirus type I and II infections by virus neutralization test. Vet Microbiol, 124, 348-52. 
SHIRATO, K., CHANG, H. W. & ROTTIER, P. J. M. 2018. Differential susceptibility of macrophages to 
serotype II feline coronaviruses correlates with differences in the viral spike protein. Virus 
Res. 
SIDDELL, S. 1995. The coronaviridae, New York ; London, Plenum Press. 
SLOTA, M., LIM, J. B., DANG, Y. & DISIS, M. L. 2011. ELISpot for measuring human immune responses 
to vaccines. Expert Rev Vaccines, 10, 299-306. 
SOLA, I., ALMAZAN, F., ZUNIGA, S. & ENJUANES, L. 2015. Continuous and Discontinuous RNA 
Synthesis in Coronaviruses. Annu Rev Virol, 2, 265-88. 
SOMA, T., SAITO, N., KAWAGUCHI, M. & SASAI, K. 2018. Feline coronavirus antibody titer in 
cerebrospinal fluid from cats with neurological signs. J Vet Med Sci, 80, 59-62. 
SPARKES, A. H., GRUFFYDD-JONES, T. J. & HARBOUR, D. A. 1991. Feline infectious peritonitis: a 
review of clinicopathological changes in 65 cases, and a critical assessment of their 
diagnostic value. Vet Rec, 129, 209-12. 
STOBART, C. C. & MOORE, M. L. 2014. RNA virus reverse genetics and vaccine design. Viruses, 6, 
2531-50. 
STOHLMAN, S. A., BARIC, R. S., NELSON, G. N., SOE, L. H., WELTER, L. M. & DEANS, R. J. 1988. Specific 
interaction between coronavirus leader RNA and nucleocapsid protein. J Virol, 62, 4288-95. 
STRANIERI, A., GIORDANO, A., PALTRINIERI, S., GIUDICE, C., CANNITO, V. & LAUZI, S. 2018. 
Comparison of the performance of laboratory tests in the diagnosis of feline infectious 
peritonitis. J Vet Diagn Invest, 1040638718756460. 
SZCZEPANSKI, A., OWCZAREK, K., BZOWSKA, M., GULA, K., DREBOT, I., OCHMAN, M., MAKSYM, B., 
RAJFUR, Z., MITCHELL, J. A. & PYRC, K. 2019. Canine Respiratory Coronavirus, Bovine 
Coronavirus, and Human Coronavirus OC43: Receptors and Attachment Factors. Viruses, 11. 
169 
 
TAKANO, T., AKIYAMA, M., DOKI, T. & HOHDATSU, T. 2019a. Antiviral activity of itraconazole against 
type I feline coronavirus infection. Vet Res, 50, 5. 
TAKANO, T., AZUMA, N., SATOH, M., TODA, A., HASHIDA, Y., SATOH, R. & HOHDATSU, T. 2009. 
Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in 
cats infected with feline infectious peritonitis virus contribute to the pathogenesis of 
granulomatous lesions. Arch Virol, 154, 775-81. 
TAKANO, T., HOHDATSU, T., HASHIDA, Y., KANEKO, Y., TANABE, M. & KOYAMA, H. 2007. A "possible" 
involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats 
with feline infectious peritonitis. Vet Microbiol, 119, 121-31. 
TAKANO, T., KATADA, Y., MORITOH, S., OGASAWARA, M., SATOH, K., SATOH, R., TANABE, M. & 
HOHDATSU, T. 2008a. Analysis of the mechanism of antibody-dependent enhancement of 
feline infectious peritonitis virus infection: aminopeptidase N is not important and a process 
of acidification of the endosome is necessary. J Gen Virol, 89, 1025-9. 
TAKANO, T., KATOH, Y., DOKI, T. & HOHDATSU, T. 2013. Effect of chloroquine on feline infectious 
peritonitis virus infection in vitro and in vivo. Antiviral Res, 99, 100-7. 
TAKANO, T., KAWAKAMI, C., YAMADA, S., SATOH, R. & HOHDATSU, T. 2008b. Antibody-dependent 
enhancement occurs upon re-infection with the identical serotype virus in feline infectious 
peritonitis virus infection. J Vet Med Sci, 70, 1315-21. 
TAKANO, T., MORIOKA, H., GOMI, K., TOMIZAWA, K., DOKI, T. & HOHDATSU, T. 2014. Screening and 
identification of T helper 1 and linear immunodominant antibody-binding epitopes in spike 1 
domain and membrane protein of feline infectious peritonitis virus. Vaccine, 32, 1834-40. 
TAKANO, T., YAMADA, S., DOKI, T. & HOHDATSU, T. 2019b. Pathogenesis of oral type I feline 
infectious peritonitis virus (FIPV) infection: antibody-dependent enhancement infection of 
cats with type I FIPV via the oral route. J Vet Med Sci. 
TANAKA, Y., SATO, Y. & SASAKI, T. 2013. Suppression of coronavirus replication by cyclophilin 
inhibitors. Viruses, 5, 1250-60. 
TASKER, S. 2018. Diagnosis of feline infectious peritonitis: Update on evidence supporting available 
tests. J Feline Med Surg, 20, 228-243. 
TEKES, G., HOFMANN-LEHMANN, R., BANK-WOLF, B., MAIER, R., THIEL, H. J. & THIEL, V. 2010. 
Chimeric feline coronaviruses that encode type II spike protein on type I genetic background 
display accelerated viral growth and altered receptor usage. J Virol, 84, 1326-33. 
TEKES, G., HOFMANN-LEHMANN, R., STALLKAMP, I., THIEL, V. & THIEL, H. J. 2008. Genome 
organization and reverse genetic analysis of a type I feline coronavirus. J Virol, 82, 1851-9. 
TEKES, G., SPIES, D., BANK-WOLF, B., THIEL, V. & THIEL, H. J. 2012. A reverse genetics approach to 
study feline infectious peritonitis. J Virol, 86, 6994-8. 
THERMO-FISHER. 2015. Transfection Reagent FAQs [Online]. Available: 
https://www.thermofisher.com/uk/en/home/life-science/cell-
culture/transfection/transfection-support/transfection-reagent-faqs.html#faq2 [Accessed 28 
July 2016]. 
THIEL, V., HEROLD, J., SCHELLE, B. & SIDDELL, S. G. 2001. Viral replicase gene products suffice for 
coronavirus discontinuous transcription. J Virol, 75, 6676-81. 
THIEL, V., THIEL, H. J. & TEKES, G. 2014. Tackling feline infectious peritonitis via reverse genetics. 
Bioengineered, 5, 396-400. 
TIAN, J., HU, X., LIU, D., WU, H. & QU, L. 2016. Identification of Inonotus obliquus polysaccharide 
with broad-spectrum antiviral activity against multi-feline viruses. Int J Biol Macromol. 
TRESNAN, D. B., LEVIS, R. & HOLMES, K. V. 1996. Feline aminopeptidase N serves as a receptor for 
feline, canine, porcine, and human coronaviruses in serogroup I. J Virol, 70, 8669-74. 
UCHIDA, R., SAITO, Y., NOGAMI, K., KAJIYAMA, Y., SUZUKI, Y., KAWASE, Y., NAKAOKA, T., 
MURAMATSU, T., KIMURA, M. & SAITO, H. 2019. Epigenetic silencing of Lgr5 induces 
senescence of intestinal epithelial organoids during the process of aging. NPJ Aging Mech 
Dis, 5, 1. 
170 
 
VAN DEN WORM, S. H., ERIKSSON, K. K., ZEVENHOVEN, J. C., WEBER, F., ZUST, R., KURI, T., DIJKMAN, 
R., CHANG, G., SIDDELL, S. G., SNIJDER, E. J., THIEL, V. & DAVIDSON, A. D. 2012. Reverse 
genetics of SARS-related coronavirus using vaccinia virus-based recombination. PLoS One, 7, 
e32857. 
VAN DER HEE, B., LOONEN, L. M. P., TAVERNE, N., TAVERNE-THIELE, J. J., SMIDT, H. & WELLS, J. M. 
2018. Optimized procedures for generating an enhanced, near physiological 2D culture 
system from porcine intestinal organoids. Stem Cell Res, 28, 165-171. 
VAN HAMME, E., DESMARETS, L., DEWERCHIN, H. L. & NAUWYNCK, H. J. 2011. Intriguing interplay 
between feline infectious peritonitis virus and its receptors during entry in primary feline 
monocytes. Virus Res, 160, 32-9. 
VAN HAMME, E., DEWERCHIN, H. L., CORNELISSEN, E. & NAUWYNCK, H. J. 2007. Attachment and 
internalization of feline infectious peritonitis virus in feline blood monocytes and Crandell 
feline kidney cells. J Gen Virol, 88, 2527-32. 
VENNEMA, H., DE GROOT, R. J., HARBOUR, D. A., DALDERUP, M., GRUFFYDD-JONES, T., HORZINEK, 
M. C. & SPAAN, W. J. 1990. Early death after feline infectious peritonitis virus challenge due 
to recombinant vaccinia virus immunization. J Virol, 64, 1407-9. 
VENNEMA, H., HEIJNEN, L., ROTTIER, P. J., HORZINEK, M. C. & SPAAN, W. J. 1992. A novel 
glycoprotein of feline infectious peritonitis coronavirus contains a KDEL-like endoplasmic 
reticulum retention signal. J Virol, 66, 4951-6. 
VENNEMA, H., POLAND, A., FOLEY, J. & PEDERSEN, N. C. 1998. Feline infectious peritonitis viruses 
arise by mutation from endemic feline enteric coronaviruses. Virology, 243, 150-7. 
VERMEULEN, B. L., DEVRIENDT, B., OLYSLAEGERS, D. A., DEDEURWAERDER, A., DESMARETS, L. M., 
FAVOREEL, H. W., DEWERCHIN, H. L. & NAUWYNCK, H. J. 2013. Suppression of NK cells and 
regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Vet 
Microbiol, 164, 46-59. 
VIEHWEGER, A., KRAUTWURST, S., LAMKIEWICZ, K., MADHUGIRI, R., ZIEBUHR, J., HOLZER, M. & 
MARZ, M. 2019. Direct RNA nanopore sequencing of full-length coronavirus genomes 
provides novel insights into structural variants and enables modification analysis. Genome 
Res, 29, 1545-1554. 
WANG, Y. T., HSIEH, L. E., DAI, Y. R. & CHUEH, L. L. 2014. Polymorphisms in the feline TNFA and 
CD209 genes are associated with the outcome of feline coronavirus infection. Vet Res, 45, 
123. 
WATANABE, R., ECKSTRAND, C., LIU, H. & PEDERSEN, N. C. 2018. Characterization of peritoneal cells 
from cats with experimentally-induced feline infectious peritonitis (FIP) using RNA-seq. Vet 
Res, 49, 81. 
WATARI, T., KANESHIMA, T., TSUJIMOTO, H., ONO, K. & HASEGAWA, A. 1998. Effect of thromboxane 
synthetase inhibitor on feline infectious peritonitis in cats. J Vet Med Sci, 60, 657-9. 
WEISS, R. C., COX, N. R. & MARTINEZ, M. L. 1993. Evaluation of free or liposome-encapsulated 
ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet 
Sci, 55, 162-72. 
WEISS, R. C., COX, N. R. & OOSTROM-RAM, T. 1990. Effect of interferon or Propionibacterium acnes 
on the course of experimentally induced feline infectious peritonitis in specific-pathogen-
free and random-source cats. Am J Vet Res, 51, 726-33. 
WIDAGDO, W., OKBA, N. M. A., LI, W., DE JONG, A., DE SWART, R. L., BEGEMAN, L., VAN DEN BRAND, 
J. M. A., BOSCH, B. J. & HAAGMANS, B. L. 2019. Species-Specific Colocalization of Middle East 
Respiratory Syndrome Coronavirus Attachment and Entry Receptors. J Virol, 93. 
WILLIAMS, R. K., JIANG, G. S. & HOLMES, K. V. 1991. Receptor for mouse hepatitis virus is a member 
of the carcinoembryonic antigen family of glycoproteins. Proc Natl Acad Sci U S A, 88, 5533-
6. 
WU, K., LI, W., PENG, G. & LI, F. 2009. Crystal structure of NL63 respiratory coronavirus receptor-
binding domain complexed with its human receptor. Proc Natl Acad Sci U S A, 106, 19970-4. 
171 
 
YEAGER, C. L., ASHMUN, R. A., WILLIAMS, R. K., CARDELLICHIO, C. B., SHAPIRO, L. H., LOOK, A. T. & 
HOLMES, K. V. 1992. Human aminopeptidase N is a receptor for human coronavirus 229E. 
Nature, 357, 420-2. 
YIP, C. W., HON, C. C., SHI, M., LAM, T. T., CHOW, K. Y., ZENG, F. & LEUNG, F. C. 2009. Phylogenetic 
perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. Infect 
Genet Evol, 9, 1185-96. 
YOUNT, B., CURTIS, K. M. & BARIC, R. S. 2000. Strategy for systematic assembly of large RNA and 
DNA genomes: transmissible gastroenteritis virus model. J Virol, 74, 10600-11. 
ZHANG, Z., YANG, X., XU, P., WU, X., ZHOU, L. & WANG, H. 2017. Heat shock protein 70 in lung and 
kidney of specific-pathogen-free chickens is a receptor-associated protein that interacts with 
the binding domain of the spike protein of infectious bronchitis virus. Arch Virol, 162, 1625-
1631. 
ZHU, Y. Z., CAO, M. M., WANG, W. B., WANG, W., REN, H., ZHAO, P. & QI, Z. T. 2012. Association of 
heat-shock protein 70 with lipid rafts is required for Japanese encephalitis virus infection in 
Huh7 cells. J Gen Virol, 93, 61-71. 




Appendix A: Synthetic DNA sequences 
Bait protein coding sequences 
NNNN FCoV S1 
NNNN Human IgG Fc 
NNNN Restriction site 
 




























































































Infectious clone cDNA fragments 
NNNN Intra-unit overlaps 
NNNN Fragment A/C overlaps (incorporating BsmBI site) 
NNNN XmaI site 
NNNN SalI site 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NNNN Feline HSPA1A coding sequence 
NNNN 3x FLAG Tag 


































Primers and oligonucleotides 
Primer name Sequence Use 
U1-1 AAATCGCCCGTACTGGAAATG Sequencing 
U1-2 TTGAAGGCGAATTGAACGAC Sequencing 
U1-3 ATTGTCATTGTAGGCGACATGG Sequencing 
U1-4 GTGACACAGCTCGTAAAGAC Sequencing 
U1-5 AAAGTGATTCTGATGCAAGCG Sequencing 
U1-6 AAGCGTGGAAGGTTCAGGTG Sequencing 
U1-7 TTCACAGGTGGTAAGTTGACG Sequencing 
U2-1 GAGTGGTGCAGATTACACAC Sequencing 
U2-1 Rev CTGCCTAGCAATCTTAGAACAAG Sequencing 
U2-2 TTAAGGCAGTTCTCGCACTTAAAC Sequencing 
U2-3 TGGCTGTTAATAACGCTCATAG Sequencing 
U2-4 TGGTAGATCCCTAGTGTTTGCG Sequencing 
U2-5 TTGGTGATTGTACTCTCCTAGTTG Sequencing 
U2-6 CCTAGACACGTCATTGCAAG Sequencing 
U2-7 TTTGGAGGACGCACTATACTC Sequencing 
U3-1 ATTGTGTTGGGCTGCATAATG Sequencing 
U3-2 TTGAACCTGACCTGGCCTTTG Sequencing 
U3-3 TTGTTCAAGTACCAACCGGC Sequencing 
U3-4 CGTGGAGAAAGGTTACATAGG Sequencing 
U3-5 CTTTGAGGAGGGATCTGAGTTG Sequencing 
U3-6 GCCTAATATGATACGAATGGCTTC Sequencing 
U3-7 ACCTTAATGTTGGACCACACG Sequencing 
U4-1 AACTATCCAAGGTCCTCCTG Sequencing 
U4-1 Rev ACAGAGAATACCAACCTTTGCTC Sequencing 
U4-2 ATCTCACCCTATAACAGTCAGAAC Sequencing 
U4-3 ACCACCGGGTGAGCAATTTG Sequencing 
U4-4 GATGTCTGGAGTATGATTACATGG Sequencing 
U4-5 CAAACTTGGACTCACACCTC Sequencing 
U4-6 GCATCTTCTTATATCACAAGTGCG Sequencing 
U4-7 ATGATATGAGGGATTACGTTTCCG Sequencing 
U5-1 CCAGTATTTCCTACCACTGGAAC Sequencing 
U5-2 ACTGTGCGAGAGTTTGCGTTTGGC Sequencing 
U5-3 TGTTAAATGGCGCACACAGTTTGC Sequencing 
U5-4 ACATTCAGATTCAAGTCAAACCCG Sequencing 
U5-5 ATGCCTTTAATAATGCCATCGG Sequencing 
U5-6 TTCCTACAGAATGGGAAGTAGTG Sequencing 
U6-1 TTGTGACAACAACTGTCTTAGC Sequencing 
U6-2 ATTAAGGCATATAATCCCGACG Sequencing 
U6-3 GTGGTCTTACCATCGAGCAC Sequencing 
U6-4 GGAACAATTCAAGGTCTGGTTCTC Sequencing 
U6-5 ATGACACACAGGTTGAGATGATTG Sequencing 
U6-6 AATCTCAGATTAGTTGGTGCTGTG Sequencing 
U6-6 II ACATCATTTGCTGTTGACCTTCC Sequencing 
202 
 
U5R-1 GCATGGACGAGCTGTACAAG Sequencing/Amp 6.2 PCR 
U6R-1 TTGTGACAACAACTGTCTTAGC Sequencing 
U6R-2 AGGAAACGGATGATAACTGGTC Sequencing 
U6R-3 TACGTGCAAGTGATGATTTACC Sequencing 
U6R-3 Rev TGGATTTAGAACGTGACCTTTG Sequencing 
U5T2-1 ACCAAGGTGTTTCTAACTTCAC Sequencing 
U5T2-2 TTGGACAATTGCTTACACATCG Sequencing 
U5T2-3 GTCTGTGCTACACCTAGACTCC Sequencing 
U5T2-4 CTTAAATTGGCATCTGTTGAGGC Sequencing 
U5T2-5 ATGCACAAGTTGATAGGCTG Sequencing 
U5T2-6 GTGCAGTTGACGTTGTTTCG Sequencing 
Twist For CCGCACGCATCTGGAATAAGG Sequencing/PCR (Twist vector) 
Twist Rev CATGCATCCACCATCGCAGAC Sequencing/PCR (Twist vector) 
M13-UC For CCCAGTCACGACGTTGTAAAACG Sequencing/PCR (pWSK29 vector) 
M13-UC Rev AGCGGATAACAATTTCACACAGG Sequencing/PCR (pWSK29 vector) 
Unit 4 For TAAGCAGCGGCCGCCGTCTCCTGATGTAACAAAAT
TG 
Unit 4 PCR 
Unit 4 Rev TGCTTAGTCGACCGTCTCTCATGGTGTGTTAAC Unit 4 PCR 
N gene For TAAGCAGTCGACTAATACGACTCACTATAGATGGC
CACACAGGGACAAC 
N gene PCR 
N gene Rev TGCTTATCTAGATTTTTTTTTTTTTTTTTTTTTTT
TTTTTAGTTCGTAACCTCATCAATC 
N gene PCR 
FL For GGCCCTAATACGACTCACTATAGAC Long range PCR 
FL Rev TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTGTA
TCAC 
Long range PCR 
F1 AAAGTTAAGTGAGTGTAGCGTGG Amp 1 PCR 
R1 GTGCGAGAACTGCCTTAA Amp 1 PCR 
F2 GATTGAACTCACGTGGTCATT Amp 2 PCR 
R2 GAGGTCTTCATCTGAACCCAC Amp 2 PCR 
F3 GCTAGTGTTAGAAATGTCTGTGTT Amp 3 PCR 
R3 AAAAGCTCTACTAACGTGGTC Amp 3 PCR 
F4 CATCCTGCAATTGATGGATTG Amp 4 PCR 
R4 TCCGGGTACATGTCTACGTTG Amp 4 PCR 
F5 GATTGGTCCATTGTGTACCC Amp 5 PCR 
R5 CACTTGTACAAAACACAGTCC Amp 5 PCR 
F6 GTATTAAGAAGATGGTTGCCAG Amp 6/6.1 PCR 
R6 ATAACCGCCTGAGAAAAGGCT Amp 6/6.2 PCR 
R6Rep TGAGGAAGAGTTCTTGCAGC Amp 6.1 PCR 
F7 CATTGGCATCTCTGTAGACG Amp 7 PCR 




Oligonucleotide adaptors for pWSK29 vector 
U1_F  TCGACACTTGGGCCCTAATACGACTCACTAGGATCCTTTAGCATTACAAAGGCTTGAGACGGC 
U1_R  GGCCGCCGTCTCAAGCCTTTGTAATGCTAAAGGATCCTAGTGAGTCGTATTAGGGCCCAAGTG 
 
U5_F   TCGACCGTCTCCCATGATACTATTGTTGGTGGATCCAAAGGTTCACATTCATTAAGAGACGGC  





















Appendix B: Thermocycler programmes 






























Step Temperature Time 
Denaturation 94 °C 30 seconds 
30 cycles 94 °C 30 seconds 
45-68 °C 1 minute 
68 °C 1 minute per kb 
Final extension 68 °C 5 minutes 
Hold 4 °C Infinite 
Step Temperature Time 
Denaturation 98 °C 30 seconds 
30 cycles 98 °C 10 seconds 
72 °C 30 seconds per kb 
Final extension 72 °C 10 minutes 
Hold 4 °C Infinite 
Step Temperature Time 
Denaturation 98 °C 30 seconds 
30 cycles 98 °C 10 seconds 
45-72 °C 30 seconds 
72 °C 30 seconds per kb 
Final extension 72 °C 10 minutes 
Hold 4 °C Infinite 
Step Temperature Time 
Denaturation 95 °C 2 minutes 
30 cycles 93 °C 20 seconds 
52 °C 30 seconds 
65 °C 1 minute per kb 
Final extension 72 °C 10 minutes 
Hold 4 °C Infinite 
Step Temperature Time 
Reverse 
transcription 
50 °C 10 minutes 
Denaturation 98 °C 2 minutes 
35 cycles 98 °C 10 seconds 
55-72 °C 10 seconds 
72 °C 30 seconds per kb 
Final extension 72 °C 5 minutes 
Hold 4 °C Infinite 
205 
 
Appendix C: ELISpot peptides 
































Appendix D: Proteomics 
A folder containing data from the proteomics experiments can be accessed at the following address: 
https://uob-
my.sharepoint.com/:f:/g/personal/ss15846_bristol_ac_uk/EiMLoDzWuaRAtq71ZazCw3wBPFiVffcZP4
ea9gbFE232Dg?e=VEnbAx  
